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ABSTRACT 
Complex diseases which affect a large proportion of our population today 
demand more strategic methods to produce significant association results. As 
it currently stands there are numerous disorders and diseases which are yet to 
be identified with a genetic causal variant despite evidence produced by 
research efforts which indicate the existence of high genetic concordance. 
Breast Cancer is one of the most prominent cancers in the female population 
with approximately 55K new cases each year in the UK and approximately 
11K deaths.  
The genetic component of Breast Cancer is a popular research area and has 
uncovered many genetic associations from high to low penetrance. The dataset 
used within this research is obtained from the DRIVE project, one of five 
introduced under the GAME-ON initiative. The general research use DRIVE 
dataset contains approximately 533K single-nucleotide polymorphisms 
(SNPs), with more than 280K sequenced with reference to the 5 most 
prominent cancers; colon, breast, ovarian, prostate and lung. SNP’s are 
sequenced for approximately 28K subjects, of which approximately 14K were 
diagnosed with one of three stages of Breast Cancer; unknown, in-situ and 
invasive.  
Epistasis is a progressive approach that complements the ‘common disease, 
common variant’ hypothesis that highlights the potential for connected 
networks of genetic variants collaborating to produce a phenotypic 
expression. Epistasis is commonly performed as a pairwise or limitless-arity 
capacity that considers variant networks as either variant vs variant or as high 
order interactions. This type of analysis extends the number of tests that were 
previously performed in a standard approach such as GWAS, in which FDR 
was already an issue, therefore by multiplying the number of tests up to a 
factorial rate also increases the issue of FDR.  
Further to this, epistasis introduces its own limitations of computational 
complexity that are generated based on the analysis performed; to consider the 
most intense approach, a multivariate analysis introduces a time complexity 
of ( !)O n . Throughout this thesis, approaches, methods and techniques for 
epistasis analysis and GWAS are discussed, as well as the limitations that exist 
and how to address these issues. 
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Proposed in this thesis is a novel methodology, methodology and methods for 
the detection of epistasis using interpretable methods and best practice to 
outline interactions through filtering processes. RaSaR refers to process of 
Random Sampling Regularisation which randomly splits and produces sample 
sets to conduct a voting system to regularise the significance and reliability of 
biological markers, SNPs. Parallel to this, the proposed methodology takes 
into consideration and adjusts for the common limitations of computational 
complexity and false discovery using filter selection and a novel method to 
association analysis.  
Preliminary results are promising, outlining a concise detection of interactions 
using benchmarking standard approaches that consider the common 
approaches to multiple testing. Results for the detection of epistasis, in the 
classification of breast cancer patients, indicated nine outlined risk candidate 
interactions from five variants and a singular candidate variant with high 
protective association.  
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GLOSSARY 
 
Allele A variant within a locus 
Chromosome 
The structure of DNA distributed across, most commonly, 23 
pairs of chromosomes. 
Computational 
Complexity 
The amount of resources required to run a task. 
DNA 
Contains the instructions required to produce the functional 
elements of an organism. 
False Discovery Rate The rate of type 1 and type 2 errors. 
Familywise Error 
Rate 
The probability of at least one type 1 error occurring. 
Gene 
Commonly contains the instructions for the production of a 
segment or full protein. 
Genotype  
Genetic material that corresponds to a physical expression/ 
phenotype. 
Haplotype A group of alleles that are inherited in blocks 
Heterozygous 
A genotype expression that contains different nucleotide 
expressions e.g. Aa 
Homozygous 
A genotype expression that contains the same nucleotide 
expression e.g. AA or aa 
Incidence The percentage of the sample population that have a SNP/s state. 
Linkage 
Disequilibrium 
The non-random correlation between nearby alleles within the 
same chromosome 
Locus The location of a variant/nucleotide 
Lymph nodes A component of the body’s immune system 
Major Allele The allele occurring most frequently in the sample population 
Minor Allele The allele occurring least frequently in the sample population 
Nucleotide 
A single building block of DNA; 1 molecule of sugar, 1 molecule 
of phosphoric acid and 1 pyrimidine/purine (Adenine, Guanine, 
Cytosine or Thymine). 
OR A measure of association between outcome and exposure. 
Penetrance 
The frequency of the population that are affected by the 
phenotype, who also carry the SNP/s state. 
Phenotype Physical expression of genotype 
Population 
Stratification/ 
Structure 
Systematic difference in allele frequencies that commonly occur 
between sub-populations due to effects such as ancestry. 
Protein 
Polypeptide chains of amino acid that are used for the structure 
function and regulation of the body’s organs and tissue. 
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RR 
The ratio of the probability of an outcome in an exposed group to 
the probability of an outcome in an unexposed group 
Single Nucleotide 
Polymorphism  
A common genetic variation in the human genome. 
Somatic cells A cell of an organism that is not a gamete (reproductive cell) 
Time Complexity The amount of time taken to run an algorithm 
Type 1 error False positive discoveries 
Type 2 error False negative discoveries 
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ACRONYMS 
 
A, G,C,T Adenine, Guanine, Cytosine, Thymine 
BP Base-Pair 
CHAID Chi-square Automatic Interaction Detector 
CI Confidence Interval 
DNA Deoxyribonucleic acid 
ER Oestrogen Receptor 
FDR False Discovery Rate 
FWER Familywise Error Rate 
GC Genomic Control 
GENO Genotype Call 
GWAS Genome-Wide Association Study 
HWE Hardy-Weinberg Equilibrium 
LD Linkage Disequilibrium 
MAF Minor Allele Frequency 
MIND Missingness in Individuals 
OR Odd’s Ratio 
PCA  Principle Component Analysis 
PPP Petal Plot Policy Confidence Scale 
QC Quality Control 
RaSaR Random Sampling Regularisation 
RNA Ribonucleic acid 
RR Risk Ratio 
SNP Single Nucleotide Polymorphism 
X2 Chi-Squared metric 
α Threshold 
µ Mean 
σ Standard Deviation 
1 
 
Chapter 1: INTRODUCTION 
The following chapter provides an overview of the thesis, considering the aims and influences 
that have inspired the work. Genomics and Bioinformatics are established fields that cater to 
exploring and solving some of the most prominent and timely research questions. Throughout this 
thesis, the focus is predominantly based on a bioinformatics approach for the analysis of genetic 
data. There are many approaches and methods that have been developed to analyse genetic data 
that consider the complex nature and representation of the data, incorporating techniques and 
adaptations that account for specific issues and bias that are exclusive to human genetics. The 
limitations of these approaches and methods open areas for improvement, while some issues are 
specific the methods, others are widespread. To outline one of the most modern approaches, 
epistasis responds to the phenomenon of systems or networks of genetic components 
interconnecting to produce a phenotypic response, this also coordinates with the hypothesis of 
‘common disease, common variant’ [1], a term applicable to the theory that interactions of 
common variants cause common disease.  
PROBLEM STATEMENT 
Breast cancer is a complex disease; multifactorial effects represent the phenotypic response of the 
subject. While there is currently an abundance of techniques for the analysis of genetic data, there 
is still a limited contribution of reproducible genetic signals that provide evidence of association 
with sporadic breast cancer, which is estimated to encompass 66% of breast cancer cases [2]. This 
study will investigate the interactions that exist in subjects associated to breast neoplasms in 
invasive breast cancer. By considering a representative set of SNPs from the genome, further 
analysis can be conducted from genome-wide analysis to suggest potential SNPs for interactions.  
Current efforts in breast cancer have led to early screening, with great successes in reducing the 
number of advanced cases [3][4]. Further to this, the introduction of genetic knowledge also 
outlines patients and their family for potential susceptibility to cancer through examples of the 
BRCA1 and BRCA2 gene [5][6]. These measures provide a preventative outlook for patient 
health, a leading direction to personalised medicine that will address patients on an individual 
basis taking into consideration factors such as genetic make-up[6]. The identification of these 
SNPs could lead to the classification of susceptible breast cancer patients and potentially the 
pharmacological or therapy treatments that are most suitable for these individuals[7].  
The focus phenotype of this research is breast cancer due to the outlined genetic link in previous 
research that suggests a broad association to genetic components; the focus phenotype can be 
further defined to sporadic breast cancer which concerns the development of breast cancer outside 
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of familial genetic causation [5][8][9]. Breast cancer is an internationally recognised issue that 
concludes one of the most prominent mortality rates for cancer in women for 2016 [10]. As such, 
research efforts for this disease have continually increased over the past decade, a focus of this 
on genetics, resulting in large datasets of information for large sample sizes. Particularly in this 
research, a dataset of ~28K (pre-qc) subjects and ~500K SNPs that incorporated genotyped data 
from not only a common backbone of SNP’s (~280K) but additionally a collection of variants 
that are specific to the 5 most prominent cancers; breast, ovarian, prostate, colon and lung[11].  
There are current issues in bioinformatics that can result in misinterpretation or misunderstanding 
due to ‘black box’ methods. Therefore, an additional consideration of this work will be influenced 
by methods that present interpretable options for processes throughout the methodology.  
Progressive approach, epistasis, invites new avenues of research[12]. The phenomenon that 
suggests combinations of biological material such as SNP variants are working as a system or 
network to produce the phenotypic outcome is becoming a favourable lead. Given the elusiveness 
of genetic causation in the face of high heritability, epistasis suggests an enigmatic genetic 
component is not being detected, as the signal for networks of SNPs are masking one another. 
Therefore, the research subject of epistasis invites a new problem area to explore. Current 
practices in epistasis detection range from pairwise to exhaustive search criteria; the limiting 
nature of pairwise detection could lead to loss of information by oversight however exhaustive 
search present their own problems with the demand for computational power [13]. 
Computational complexity encompasses the most problematic area of limitations for the limitless-
arity technique as these analyses can be conducted using linear or parallel threading. These 
approaches require extensive hardware to accommodate the requirements of the analysis, however 
this will still be time intensive. This introduces the approach of feature selection to limit the 
number of input features to the analysis; but raises a new question of what feature selection 
technique to use [13]. Genome-wide Association Study (GWAS) is a common approach that 
considers the effect of the whole genome based on the phenotypic response variable but is subject 
to high false discovery rate [14]. There are currently established methods that adjust for the 
inflated values that are present in false positives by using the output p-values from the association 
analysis [15]. As these methods reduce the inflated value monotonically, the impact of a false 
positive that shows high significance will still be one of the most significant values when adjusted 
by a multiple testing method. Unless the researcher is prepared to disregard the results entirely, 
these false positives will still be outlined for significance.  
Additionally, one of the main focuses of this work considers to role of False Discovery Rate 
(FDR) and the issue of replicability in genomic studies [16][17][18]. Replicability has plagued 
the field of genomics for decades and is often attributed to the metric values and study processes 
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that are used resulting in the development of correction methods for metrics [14][19], and 
processes for genetic specific adjustments such as population stratification [20] and linkage 
disequilibrium [21]. Given these efforts, the issue of replicability has improve significantly in 
recent years [22] however the introduction of epistasis presents its’ own challenges with 
established methods for univariate analysis unsuited for the processing of epistasis detection [23]. 
To summarise, in order to develop a novel methodology, the problem to be addressed was 
established using criteria to guide the decisions. To focus on interpretable methods, epistasis 
detection is a relatively untapped resource for sporadic breast cancer with limited publications. 
To conduct an epistasis approach, a multivariate method must be used which covers an approach 
of pairwise to limitless arity, with the latter exposing the most potential combinations. A limitless-
arity approach analyses every combination that is available from the input data to expose high-
order interactions and is commonly exposed to the time complexity ( !)O n , this method introduces 
the issue of computational complexity and intensity.  
Within this chapter, introduced are the aims & objectives, scope and contributions to knowledge. 
The last section provides an overview of the thesis chapters and a small description of the contents 
of each. 
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AIMS & OBJECTIVES 
Epistasis is a progressive approach to genomic analysis that considers the evolving hypothesis of 
system/ networking components of genetic material. While epistasis is not a new concept, the 
approaches that are available fall to limitations such as computational complexity and false 
discovery. The aim of this study is to develop a novel methodology, Random Sampling 
Regularisation (RaSaR), for the detection of epistasis (See Chapter 5:), using interpretable 
methods and best practice that will cater for the pitfalls of computational complexity and false 
discovery. Additionally, the methodology will be evaluated for effectiveness, which in this case 
refers to the proposed methodology’s false positive outcome, using a genetic dataset and to 
benchmark against standard methods (See Chapter 3: and 6.4 ) in genomic publications. The 
objectives of this thesis were identified as: 
 
Objective Description 
RO1: 
Best Practice Quality Control 
To adopt best practice when conducting quality control to 
remove bias and erroneous data, to ensure that quality of 
the data for the purpose of performing further analysis. 
RO2: 
False Positive Rate Reduction 
To overcome/ reduce the occurrence of false positive 
genetic signals. 
RO3: 
Feature Filtering 
To outline features for epistatic analysis, accommodating 
for the occurring weaker/masked signals that are 
hypothesised for epistasis while maintaining objective 
RO2. 
RO4: 
Hardware Limitations 
To explore and appoint a method, technique or software 
that can perform epistasis analysis without the requirement 
of High-Performance Computing (HPC). 
RO5: 
Outline Candidate Variants 
To identify and outline candidate variants and interactions 
using a genetic dataset. 
 
Throughout the thesis, the key elements of genomics and bioinformatics in reference to Epistasis 
will be explored to develop the proposed methodology and evaluate its viability through measures 
of reliability and replicability (See section 5.6 and Chapter 7:). 
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SCOPE 
The proposed methodology aims to increase robustness detection of significant SNPs and SNP 
interactions, by filtering candidate features using sampling and statistical methods. It should be 
considered as good practice in the first stage process of exploring SNP markers. The research is 
of relevance to complex diseases where interactions between SNPs may be important. The 
methodology will be focusing on several areas that concern the analysis of Single Nucleotide 
Polymorphisms (SNPs). These areas include quality control, association analysis, multiple testing 
for high-order interactions and statistical epistasis analysis. The research uses large sample sizes 
and variants sequenced in line with current research in the area of the focus phenotype. 
CONTRIBUTIONS TO KNOWLEDGE 
Condensing the pipeline of the methodology, the approach chosen as the area of focus in this 
thesis is Epistasis, of which two main methods are conducted to accomplish the tasks; pairwise 
and limitless arity. Of these two, the method that leads to the least information loss is limitless 
arity. Using prominent research from this approach, the two main techniques flourish in 
Multidimensional Reduction (MDR) and Itemset Mining. These techniques are commonly 
coupled with other approaches that aim to reduce the computational complexity of limitless arity 
by reducing the number of variants for analysis. This introduces the problem of how to reduce the 
number of variants without increasing the false positive rate, whether that be the commonly 
occurring or artificially incited rate. The purpose; to analyse the behaviour of variants in each 
subset to measure the deviating behaviour and to regularise the measure by using all outputs to 
produce one overall mean. As epistasis introduces the concept of ‘masking’ (variants present 
reduced signals due to the presence or regulation of another variant), there is expectation that 
variants will not show a strong association to the phenotype and as such relying on the mean of 
the value is not the main concern of this method, alternatively the standard deviation, σ, is also 
produced from the value which will be used conservatively while the mean threshold will be set 
leniently.  
The contributions of this research are layered and each address an identified problem. The 
processes outlined in this thesis aimed to produce a methodology for epistasis detection, using 
interpretable methods and best practice that also catered for the common pitfalls, computational 
complexity and false discovery. The novelty of this methodology exists in 3 areas: 
FALSE POSITIVE REDUCTION ANALYSIS 
A novel methodology for false positive reduction association analysis by cohort sampling (× 𝑘) 
followed by cross-validation (J-fold) resulting in a dataset of 9 p-values for each individual SNP, 
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to which feature selection can then be applied. This novelty refers to the objectives outlines in 
RO2 and RO3. To refer to the results obtained from this research. While a larger feature set size 
was outlined for analysis with the RaSaR method, interactions output from LAMPlink analysis 
resulted in only 4 SNP interaction combinations, as outlined in Table 1.1. All combinations that 
are greyed out in Table 1.1 did not yield a statistical association in this study. 
 
Incorporating the confidence of the PPP, only 3 viable options would be considered in a normal 
process of the methodology as the PPP confidence of 9q21.13-9q21.13 was 0.25, which is <0.5 
and would not be considered for further analysis. Therefore, all viable combinations outlined by 
RaSaR indicated a true association based on the sample population. Reduced false positive 
concludes an improved detection of epistasis, demonstrated by the results. Of the combinations 
outlined, the proposed method was able to detect all but one combination (the singular variant 
1p12 was identified by every method as the top result).  
REDUCTION IN HARDWARE REQUIREMENTS 
Due to the novel methods occurring in association analysis and feature filtering, the methodology 
can be performed without high performance computing equipment. The use of the feature filtering 
method is a main component in the methodology for reducing the hardware requirements. By 
outlining candidate variants using statistical filtering, the dataset can be downsized to adhere to 
the computational limitations of the researcher. Additionally, the use of open-source software 
LAMPlink allows for computationally efficient analysis of a reduced number of SNPs. This 
novelty refers to the objective RO4. During the process computational expense was limited, 
TABLE 1.1: RESULT OF COMBINATIONS OUTLINED FROM EACH METHOD 
Combination Optimum 
PPP Conf. 
C1 C2 C3 C4 
rs4602520-rs6910087-rs7246472 0.833 O O   
9q21.13-9q21.13 0.25 O    
rs4602520-rs4144827 0.5 O    
1q41-rs3924215 0.75  O  O 
rs6911024-rs12170250 0.75  O   
rs6852865-rs4602520 1  O   
rs6852865-rs4602520-rs6910087-rs7246472 0.375  O   
rs6852865-rs6910087-rs7246472 0.667  O   
rs3924215-rs6011609 0.5   O  
1p12-rs6011609 0.5   O  
rs4602520-rs6911024-rs7246472 0.5    O 
rs6911024-rs7246472 0.5    O 
rs4602520-rs7246472 0.5 O O  O 
rs4602520-rs6911024 0.5    O 
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analysis was performed without the requirement of extensive hardware with limitless-arity 
analysis in LAMPlink for all methods taking an average of 20.5s. 
IDENTIFICATION OF PREDICTIVE FEATURES 
The identification of predictive features comprising individual SNPs and interactions between 
SNPs using decision tree methods followed by rigorous statistical significance testing for 
classification of cases vs. controls. This novelty refers to the objective RO5. Table 6.17 provides 
the genomic characteristics of the outlined variants from the RaSaR method, with exception for 
SNP rs6852865 which was not identified by the RaSaR method. Already outlined in section 7.1 
are the limitations of the method which state the compromise of this method in its susceptibility 
to False Negative results. Given this, the method was still able to detect the remainder of the 
interactions, outlining 4 novel candidate variants and 1 variant that has already had various 
publication surrounding it’s link to breast cancer (See section 6.7 ). 
STRUCTURE OF THE THESIS 
Continuing from the previous chapter, the remainder of the thesis illustrates the considerations of 
this project within the scope of the problem statement. Chapter 2 provides an overview of the 
core information that builds the foundation of this thesis. Genetics is a complex area that requires 
explanation if unfamiliar, given the speciality terms and components that are used sparingly 
across this thesis. The study of genetics is based on one of the most impressive and complex 
systems that is currently known and therefore this chapter discusses a succinct section of this field 
that provides information solely on the context scope. To conclude the section, the focus disease 
is discussed, providing statistical information regarding incidence, mortality and associated 
factors contributing to the development of breast cancer. The chapter concludes with a discussion 
of the concepts that introduce the subject of this research and analyses the impact on the 
methodology going forward, while providing information about decisions that determine the 
direction. 
Chapter 3 moves the focus towards bioinformatics, discussing the techniques and methods that 
are used in the analysis of genetics data. To conclude the section, a summary of the information 
is provided which outlines the main points and outcomes of the section. Concluding the chapter, 
a discussion combines the information and outlines the outcomes of the chapter. 
Already discussed is the complexity and various structure forms of genetic data, Chapter 4 
provides a representative section that cannot be to guide understanding of the processes of the 
methodology. This section includes information of the various representations of data and further 
provides the binary transformations that are used throughout the methodology. Also explained is 
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the data as represented by PLINK to introduce the outputs and inputs of information before 
analysis and transformation are conducted. Finally, this section introduces the breast cancer 
dataset that will be used to evaluate the methodology. 
Within Chapter 5, the proposed novel methodology is described, stage by stage, introducing the 
methods and techniques that are used along with the purpose of use. Stage 1 introduces the 
important stage of quality control, removing erroneous data and provides threshold choices for 
each process. Stage 2 introduces one of the novel elements of the methodology compared with 
standard approaches. The purpose and inspiration of this choice is discussed and explained using 
a definition of how the process is conducted and how it effects the process thread. Stage 3 
introduces the stage of association analysis, utilising the deviated step in stage 2 to conclude the 
novel filtering method. Stage 4 provides information about the process of feature selection, using 
the output of the association analysis to explore the data and apply thresholds to extract 
informative features. Stage 5 uses the extracted features from the output of feature selection to 
perform epistasis analysis using pre-defined limitless-arity approach. Stage 6 is the most 
informative and uses the output of the multivariate analysis to explore the relationships and 
associations. This section describes the approaches, techniques and methods used to gain insight 
into the associated interaction within the sample population. This section is concluded by a 
summary that outlines the purpose of the methodology and the intended outcomes of its use.  
 Chapter 6 outlines the results from the execution of the proposed novel methodology alongside 
comparable standard methods. Processing the stages as defined in Chapter 5, plots and 
information indicates the input, output and conclusion of the section. Stage 4 outlines threshold 
methods applicable to standard case-control approaches to benchmark and evaluate the 
effectiveness of the proposed methodology. Each method is described, and the section concludes 
by providing the features selected from all methods. The chapter progresses using the input 
outlined from stage 4 and concludes the results in stage 6, with a discussion about the 
interpretation provided in the final section of the chapter. 
The concluding Chapter 7 discusses the effectiveness of the method, the outcome of information 
and also outlined the limitations of this methodology. Future work is proposed which discusses 
the evaluation of the methodology and the adaptation for optimisation dependent on the given 
data structure and study design. 
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Chapter 2: LITERATURE REVIEW 
The following chapter will discuss the areas of interest that motivate this work. As a cross-
disciplinary approach to the research, the three fields of biology, computer science and statistics 
will be combined to address the defined problem as outlined in Introduction. The intent of the 
following chapter is to introduce the origins of this research by discussing the fundamental 
knowledge base as a primer to the remaining chapters. 
Genomic studies pose a particularly difficult challenge in the navigation of genetic mutations that 
can either directly or indirectly effect a phenotypic expression in its host. While the most current 
studies use association analysis in a univariate capacity, it is becoming clearer, as the field 
develops, that singular mutations are unlikely to produce the severe expression that is common in 
many genetic disorders and disease [24].   
With the introduction of GWAS, too came the added complexities that are now commonly 
associated with diseases. GWAS highlighted the cross chromosome and gene associations that 
were present in relation to disease and disorders [25]. Due to the discoveries uncovered by GWAS 
which suggests that genetic causation is far ‘messier’ than previously considered, therefore using 
SNP-SNP Interaction to uncover SNPs that work cooperatively to produce the phenotypic 
expression of these disorders and diseases is a considered approach of this work. SNP-SNP 
interaction considers the possibility that SNP mutations may occur in the population but are not 
effective unless one or a group of SNPs present a particular status which aggravates or 
“malfunctions”, resulting in the disease and disorders that are common in the population but are 
yet to be associated with a genetic component [26]. While SNP-SNP Interaction would result in 
an exhaustive search mechanism that may indicate potential associations and interactive groups; 
the computational complexity of full genome scan would render most computers useless. 
While using a small number of SNP isn’t exactly computationally expensive, if we consider 500K 
SNPs using a bivariate analysis, a result of 125 billion possible SNP pairs are possible [27]; further 
to this, these calculations do not take into account the possible genotypic state. Considering that 
any regular genome wide analysis will include approx. 300,000 – 500,000 SNPs, we can now 
start to get a better understanding of why SNP-SNP Interaction is not an easy problem to approach 
[28]. 
One way of reducing the computational complexities of a SNP-SNP Interaction analysis is to 
reduce the number of SNPs. The decision as to which SNPs to include then becomes a problem 
as evidenced from previous studies [29][30], significantly associated SNPs may not be true 
positive associations. It is also noted that SNP mutations that cause phenotypic expression may 
not appear significant when a univariate analysis is used [31]. Therefore, we require a method 
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that can pick out SNPs that are likely to show significance in an interaction analysis regardless of 
their significance in an initial univariate analysis. 
Complex disease and disorders continue to be evasive in the underlying genetic component, this 
is likely due to effects other than genetic inheritance and/or mutation [28]. Given the prevalence 
across the world, the occurrence of these diseases displays different prevalence among countries, 
environments, diets and classes [32]. While it is difficult to determine an environmental-gene 
factor, given the number of environmental factors that could contribute to the phenotypic 
expression of a disease, we can consider the potential of SNP-SNP interactions that could indicate 
a potential environmental factor due to the pathophysiology of the gene it belongs to. Firstly, 
introduced in this chapter is the root subject that will guide and effect the decisions and approaches 
of this work. To introduce genetics to this thesis, discussions will focus on the central dogma 
process that guides the biological expression of the focus data type. 
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GENETICS  
Genetics as a field considers a whole range of biological 
structures, functions and physiology that are present in every 
living organism. For this research, we are concentrating on 
human genetics particularly concerning the variability that is 
present between humans. The following section provides 
information about the basics of genetics. We discuss the basic 
components that make up the human genome, the function, 
activity and the impact on the body regarding the reported 
research in this document.  
2.1.1 FUNDAMENTALS OF GENETICS 
Genetics are determinant of not only our hair and eye colour 
but our bodily functions, personality and desires [33]. Genetic 
make-up is referred to as genotypic information; genotypic 
information produces the traits in humans and the physical 
expression of that trait is referred to as a phenotype [33].  
 
Terms genome, gene and base-pair refer to size and area of 
the genetic make-up [34];  
Genome the total set of instructions for protein 
production of an organisms or the total 
amount of genetic material in a cell. 
Gene an area of the genome with instructions 
to produce a specific protein; (Note: not 
all of the genome is divided into genes) 
Base-Pair one pair of nucleotides. 
 
Phenotype
Trait: Eye Colour
A
G
T
G G
Genotype
Gene: Eye Colour  
FIGURE 2-1: DEMONSTRATION OF PHENOTYPE AND GENOTYPE 
 
FIGURE 2-2: CHROMOSOME 
Each cell in the human body contains 46 
chromosomes or 23 pairs of 
chromosomes. Chromosome pairs are 
passed to us in as haploid cells from both 
of our parents, each chromosome is then 
paired with its corresponding pair i.e. 
Chromosome 1. 
 
FIGURE 2-3: DNA 
The structure of our genetic information, 
consisting of a sugar-phosphate 
backbone and nucleotide base-pairs; 
Adenine, Guanine, Thymine and 
Cytosine. DNA is coiled around histones 
which have been linked to environmental 
interaction  [198]. 
 
FIGURE 2-4: RNA  
Produced during the transcription phase 
of the central dogma, RNA is a 
complementary copy of a specific DNA 
strand. It is used in the translation 
process to produce proteins; codons of 3 
nucleotide bases are used to indicate the 
sequence of amino acids which form a 
polypeptide chain [199]. 
 
FIGURE 2-5: PROTEIN 
Proteins are created from the polypeptide 
chains that are formed during the 
translation process. Proteins are required 
for the function, structure and regulation 
of the bodies tissue and organs  [200]. 
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Genes provide the areas of the genome that specifically produce proteins. Areas of the genome 
that are used in the production of proteins are referred to as exons, or coding regions, while areas 
that are not used for protein production are referred to as introns, or non-coding regions. Intron 
regions are found outside of genes, but can also be found within [35].  
The central dogma is the process that reads the DNA sequence of a gene and translates it into a 
protein which will form structure or function within the human body; this includes the phases 
transcription and translation [34]. Transcription refers to the process of unzipping the double-
helix structure of DNA to create a copy of the sequence via complementary nucleotides. 
Translation uses the new single strand of DNA, referred to as RNA, to build a protein; using a 
sequence of 3 nucleotides called codons, a protein is built from the amino acids that correspond 
to the recipe of the 3 codons, once complete the protein is folded and transformed to its functional 
state.  
The process leading up to the point of protein expression is complex and many issues may occur 
such as protein misfolding [36]; however the focus of this thesis concentrates on the building 
blocks of genetic information, nucleotides. 
2.1.2 GENETIC MUTATION  
Genetic mutations are changes in the base structure of DNA; this could be a single nucleotide 
base or could include a set of genes. These changes can be either hereditary or somatic; hereditary 
changes are passed down to offspring from their parents. However, in some cases, genetic 
mutations can occur in the egg or sperm cell which are not present in the parent’s DNA, these 
types of mutations could explain genetic disorders that affect people whose parents do not possess 
the mutation in their genes [37].  
Somatic mutations either occur during cell division when copying the DNA or by environmental 
factors such as exposure to UV rays. Mutations occurring in somatic cells cannot be passed down 
to offspring. Genetic Mutation occurs during meiosis (Sexual haploid division) and mitosis (Cell 
division used for growth, repair and asexual reproduction).  
There are three types of mutation that occur in small regions; insertion, deletion and variation 
[38]. Insertion and deletion can have serious consequences is they are located in coding regions 
of the genome. This type of mutation can shift the protein reading sequence, this can lead to an 
incorrect subsequent protein. Mutations normally occur in non-coding regions, but even 
mutations that occur in coding regions will have little to no effect [39]. Mutations that do affect 
the body can influence the protein produced, the amount produced and/or when and where it is 
produced; this can cause serious health problem in the affected individual. 
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Normally mutations that cause disease in individuals are uncommon in the general population, 
however there are mutations that are common throughout the population. Common mutations 
normally control the differences in the population e.g. eye colour, hair colour, height etc.  There 
are however common mutations that are associated with disease and disorders; this type of 
variation is one that this research is interested in investigating. Base-pair nucleotides in which a 
variation exists in more than 1% of the population are referred to as Single Nucleotides 
Polymorphisms (SNPs); the focus data type of this thesis. The next section will discuss SNPs and 
their biological impact. 
2.1.3 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) 
SNPs are single base-pair nucleotides that span DNA to provide the instructions for protein 
production. Only nucleotide base-pairs that show variation in >1% of the population are 
considered SNPs. SNPs are denoted by the letters A, C, G and T which correspond to their 
representative amino acid, Adenine, Cytosine, Guanine and Thymine. Across the span of 
approximately 3 billion nucleotides, SNPs occur around every 300 nucleotides which is 
approximately a total of 10 million SNPs [40].  
SNPs are made up of 2 alleles that can take one of 3 forms (Explained further in Chapter 4:). 
Dominant alleles present the phenotypic traits that are present in humans i.e. Brown eyes are a 
dominant gene. Recessive alleles are ‘overpowered’ by the presence of the dominant allele but 
may still present phenotypic traits due to the genotype present. 
 
There are 3 variations of genotype, if we represent the dominant allele as ‘A’ and the recessive 
allele as ‘a’. Homozygous dominant refers to a genotype which presents the same allele on either 
chromatin, with both alleles being the dominant variant, and is represented by ‘AA’. Homozygous 
Recessive refers to a genotype which presents the same allele on either chromatin, with both 
alleles being the recessive variants, and is represented by ‘aa’. The final genotype is Heterozygous 
which refers to a genotype that has both a dominant and recessive allele and can be represented 
by, ‘Aa’ or ‘aA’. If the genotype is known, variants of both mother and father can be used to 
 
FIGURE 2-6: SINGLE NUCLEOTIDE POLYMORPHISM; A VARIATION IN A 
SINGLE LOCUS WHICH IS PRESENT IN MORE THAN 1% OF THE POPULATION. 
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generate a probability on the traits that any offspring would have, such as eye colour as 
demonstrated in Figure 2-7. 
 
As the dominant allele, A, is brown eyes, whenever the dominant allele is present in the genotype 
combination, the phenotype expression of that trait will be present. So even in the case of a 
heterozygous genotype, the dominant allele is present and therefore the phenotypic expression 
will be based on the instructions of this allele. 
There are two types of SNPs: Linked and Causative. Linked SNPs are located outside of genes 
but can still affect the function of the body such as drug response and disease risk. Causative 
SNPs are affective mutations that are located within genes; causative SNPs further divide into 
coding and non-coding SNPs which correspond to their location within the gene. Mutations 
occurring in the non-coding region of the gene do not affect the protein production of the gene 
but can still effect the time, locations and level of gene expression [41]. Mutation occurring in the 
coding region of the gene can affect the amino acid sequence, directly effecting the protein 
produced. Having discussed the fundamentals of genetic in the context of the research in the 
current section, the next section discusses standard and progressive study approaches to genetic 
analysis. 
 
 
FIGURE 2-7: EXAMPLE OF TRAIT INHERITANCE 
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GENOMIC STUDY APPROACHES  
The following section introduces the approaches used when investigating genetic data. These 
approaches consider the size of the dataset, the selection of features and the cohort design. The 
aim of these approaches is to aid in discovering potential candidate genes that can be utilised in a 
clinical setting for the purposes of improved pharmacological solutions, diagnostic criteria, 
susceptibility and finally the potential to identify predisposition to a disorder.  
The analysis of genomic data is providing individuals with information and knowledge to take 
control of their health [6]; while still in its early stages, genomic analysis and its resulting 
outcomes can aid the healthcare sector, approaching the much debated subject of personalised 
medicine [6]. Personalised medicine caters for the needs of patients by considering their 
biological and epidemiological make-up. This will in future replace the current “one-size-fits-all” 
approach that is common in prescription medication; an individual’s biological make-up could 
provide information for the most appropriate treatment response, i.e. indicating the amount, 
variety and response to particular drugs [7]. This is important in complex diseases as treatment is 
often based on a necessary ‘trail-and-error’ period which may or may not provide relief from the 
symptoms [42]. Further to this, even treatment options that aid in reducing or eliminating the 
problematic symptoms of a disease or disorder, can also cause a variety of side effects that can 
still effect patients Quality of Life [43][44]. 
There are several approaches to genomic study which are commonly used to identify risk variants 
in common, complex diseases such Breast Cancer; GWAS (Genome-wide Association study), 
Candidate Gene and Familial studies. One of the most popular genetic feature inputted for study 
analysis are SNPs (Single Nucleotide Polymorphisms), these are variants in base pairs within the 
DNA sequence [45]. 
While a majority of these SNPs will have little to no impact on the biological systems, the 
consequential causal sequence can lead to imbalances in chemicals, misfolds in protein 
polypeptide chains and instability in mRNA transcripts [36]. The involvement of these SNPs in 
the genetic analysis for the purpose of finding risk variants is due to the abundance of variation 
throughout the genome; proving promising and successful in many determined diseases so far 
[46][47]. Although there are many other genetic and biological studies that are successfully 
undertaken, the following identified approaches utilise the SNP feature input for the analysis of 
correlation and susceptibility in subjects. As such, the following sections encompass the 
approaches to data analysis that consider the variability that exists in genomics due to the structure 
of genetic data and the subject specification. 
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2.2.1 GWAS (GENOME WIDE ASSOCIATION STUDY)  
GWAS provides a way in which the whole genome (genotyped SNPs) can be scanned to identify 
SNPs that confer risk for the identified and analysed phenotype. Presenting a hypothesis-free 
approach that has introduced an option for researchers to visualise whole genome effects for 
diseases. 
The most common approach in GWAS utilises a case-control set-up [48]; Cases refer to a cohort 
affected by the disease subject of the study and Control refers to a cohort who are unaffected by 
the disease. The proceedings of a GWAS aims to find the correlation results between the cohorts 
and the disease. In an ordinary case-control GWAS, the odds ratio is the first considered statistics 
in which an OR > 1 suggests the association of an allele is a risk for disease, the greater the 
difference from 1, the more indicative of an association and an OR < 1 suggests a protective 
association against a disease [48].  Performing a chi-squared test from the results will provide 
significance of the alleles association; that is, how likely it is that the result is truly associated 
with the disease.  
While GWAS presents a unique approach for analysis of genetic material, its requirements 
introduce both advantages and disadvantages. GWAS have also previously been acknowledged 
for their expense; however, this criticism is becoming obsolete as advances in technology are 
reducing the costly price [49]. This approach also outlines some disadvantages that effect the 
reliability of the study such including high false discovery rate and the overlooking of rare alleles 
which could potentially be important to the discovery of biomarkers [50]. As such, an important 
feature of GWAS are the requirements for a large sample size for reliability of result outcomes 
[51]. Unfortunately, this accommodation does not rectify the issues that are present with false 
discovery in GWAS and given the parameters that define the size of these studies, transfer 
learning is commonly adopted from methods that aim to reduce, rectify and eliminate the effects 
of bias and false discovery in ‘Big Data’. A common approach from big data techniques is to use 
multiple testing adjustments, as discussed later on in Methodology. Successes in GWAS have 
previously outlined viable SNPs in complex diseases such as Crohn’s Disease [52], Rheumatoid 
Arthritis [53] and Celiac Disease [54].  It has also previously been proposed that GWAS studies 
should be a first step in the genetic identification process [55]. 
Within the next section, the focus moves to an approach that contrasts with the whole-genome 
approach of GWAS to introduce an approach that focuses its efforts in areas of significance based 
on prior knowledge. 
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2.2.2 CANDIDATE GENE APPROACH  
In contrast to GWAS, the candidate gene approach focuses on a small selection of genes, SNPs 
and/or alleles that are chosen based on relevance in the role of the disease/phenotype in question 
[56]. While the most common approach is to use relevant markers to test association, the relevance 
of the gene can be based on prior knowledge of the biological, functional and physiological 
mechanisms that have an identified association to the disease/phenotype [57]. However, markers 
that have identified in previous studies for the focus phenotype can also be used[58]. 
The candidate gene approach presents a unique advantage in that it is quick and easy to determine 
the association between the disease and selected genes to determine the effect of genetic variants 
[56]. Issues that arise with this approach lie in the conservative choice of genetic information, by 
reducing the dataset and therefore the number of genetic association possibilities, variants that 
could arise in a genome scan are overlooked. This couples with the limitations of the research 
present to determine a candidate gene; with the speed at which genomics is evolving; the 
information to supply to this field can only indicate a limited amount of candidate genes [59].  
In contrast to GWAS, the candidate gene approach focuses on a small selection of genes, SNPs 
and/or alleles that are selected based on known disease pathology. Within the next section, another 
approach is introduced that focuses its effort on the subject specification. 
2.2.3 FAMILIAL STUDY APPROACH  
Familial studies approach contains numerous types of study design built upon the unique 
advantages that are present in the focus research of related subjects. The study types can generally 
be summarised into 3 categories: Twin, Linkage Analysis and Other. The following sections 
provide a summarised outline of the study approaches in family studies and the unique value that 
they provide.  
2.2.3.1. TWIN STUDIES 
Twin studies have made some of the most ground-breaking discoveries in risk variants for disease 
[60]; this is due to the extreme similarities in their genomes particularly when concentrating on 
identical twins. There is a dissection in the study types which are conducted as follows: 
Monozygous twins (Identical), Dizygous twins (Non-identical/ Fraternal), twins who are nurtured 
apart and twins who are adopted and nurtured by unrelated foster parents [27].  
Monozygous twins provide an almost identical genome from the point of birth that implies that 
in the majority of cases any phenotypic, epidemiological or genotypic variation is caused by 
environmental intrusions and influences [27]. Dizygous twins are used within studies to determine 
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the concordance in both Dizygous and Monozygous twins; if concordance is higher in 
Monozygous twins then genetic susceptibility is a risk [27]. The use of both, reared apart and 
reared apart with unrelated foster parents, is used to determine the environmental effects on the 
subject when faced with different nurturing techniques and environment e.g. Urban vs. Rural 
living [43]. This can help us to identify, or at least give us some indication as to the environmental 
factors that can affect our genetic architecture; these implications can be studied in non-related 
individuals but the advantage of twins studies lies in the genome similarities given the genetic 
implications are unlikely to be due to variants in the genome. While the advantages of twin studies 
are clear, a few issues hinder the progress and preservation of this approach. The attainment of 
twin data is relatively restricted given the limited cohort, focus on genotype can be skewed if 
subjects are exposed to different environments, gene expression on monozygous twins can differ 
and the twin unaffected by the disease is less willing to participate than the twin affected [44].  
2.2.3.2. LINKAGE ANALYSIS 
Linkage Analysis focuses on the probability of transmission of alleles at closely located positions 
on the genome as an intact force, commonly referred to as a haplotype [44]. Linkage Analysis is 
an approach not confined to the family studies branch but can be adapted to many different 
approaches e.g. GWAS, Candidate. However, as a common approach in family studies. it uses 
related individual’s data to map the genetic sites of a disease or disorder trait. In doing so, it 
provides a unique opportunity to explore the potential of susceptibility association to multiple loci 
[44]. This uses the recombination factor to produce values of variance that either indicate tightly 
linked (No Recombination) or unlinked; unlinked recombination factor will indicate a shift in loci 
over generations of families. Linkage Analysis is primary approach that identifies an initial cohort 
of variants and loci of potential genes for further analysis; this therefore provides our basis 
becoming a less commonly used approach once the initial studies are produced.  
2.2.3.3. OTHER  
Other family studies can include different approaches that can include the identification of risk in 
1st- 2nd- or 3rd degree relative, the risk in female relatives, the risk of inheritance between 
offspring and parentage [27]. The main basis, and therefore the origination of family studies stems 
from the research conducted by the famous Mendel [45], in which he used ‘sweet peas’ to track 
the trait inheritance based on the manifested phenotype of the parentage. The most common 
approach in family studies is that of the case-control study type [45]; this uses affected subjects 
compared to unaffected subjects, therefore aiming to provide insight into the genetic differences 
that are present between the two cohorts essentially the identification of causal SNPs for the focus 
disease or disorder. Again, the issue with family studies lies in both the attainment of data and the 
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limits in application to society, as the results cannot indicate and are not generalised to the public 
it only provides heritability and susceptibility risk for the cohort included in the study e.g. risk 
variant for offspring of 2 parents affected by Schizophrenia [45]. The next section introduces the 
final study approach of this chapter, a progressive approach that responds to continuing research. 
2.2.4 EPISTASIS  
Epistasis refers to the interaction between genes, but more commonly encompasses the 
interactions between genetic components. Epistasis covers three major categories; functional, 
compositional and statistical epistasis [26]. Functional epistasis addresses the interactions that 
occur between proteins, this is less adopted use of the term epistasis but covers the functional 
consequences within genetic pathways. Compositional epistasis describes the phenomenon of the 
blocking of one allelic effect by an allele at another locus [26]. This category considers the 
composition of the genotype, and as such, the discovery of such interactions relies on a 
substitution process to realise the effects of the ‘masking’ or ‘aggravating’ loci. Statistical 
epistasis is the analysis of the effect of combinations of alleles at different loci over all present 
genotypes within a population. This approach presents the most flexible but consuming option 
that measure the average deviation given multiple states, combinations and locations.  
Epistasis benefits from an exhaustive technique that not only considers genetic components as 
singular entities but in combinatorial components. Genetic pathways already indicate a level of 
interaction as evidenced by the interactions that occur for regulation of gene expression, signal 
transduction and biochemical pathways [61].  
While epistasis extends a potentially untapped source of information in genetic pathways and 
disease penetrance, its current successes are limited. This may be due to the limitation of the 
approach; computational complexity refers to the amount of resource required to perform the 
algorithm. Commonly in GWAS, the number of SNPs that are tested extends past 300,000, as 
demonstrated in Figure 2-8, the computational complexity, 3𝑛, of epistasis increases 
exponentially with every additional feature that is included. At 10 features, more than 50000 
interactions are possible. 
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Epistasis is an approach fast emerging in genome studies [26]; its potential in inviting possible 
successes for diseases and disorders that show little to no genetic signal particularly concerning 
complex disease whose phenotypic presence can vary from individual to individual. Complex 
diseases present a particularly difficult challenge in their expression; with varying phenotypic 
expression that show strong association to environmental factors, the genetic composition remains 
ambiguous for many of these diseases. Epistasis may be able to shed some light on the genetic 
components causing the phenotypic expression of these diseases. 
2.2.1 BIOINFORMATIC PROJECTS 
We use SNP information for a variety of purposes including pattern recognition for classification, 
prediction and susceptibility. The following section introduces pinnacle projects in bioinformatics 
that have advanced the field and introduces the focus area of bioinformatics that influence the 
statistical components of the work. Bioinformatics can be categorised into two fields; 
representation and inference. While representation encompasses bioinformatics methods and 
techniques that aim to define the way in which genomic information is interpreted e.g. DNA 
structure, categorisation of coding regions, inference measures the associations within the 
structure e.g. relationships between phenotype and genotype, pathways that interconnect gene by 
functional expression or regulation. The field of genomics and bioinformatics is constantly 
expanding and improving as evidenced by the international projects that have rocketed the field 
into a new era: 
The Human Genome Project (HGP) was an international effort that pooled resources and skilled 
minds to fully sequence and map all the genes in human genome. Completed between 1990-2003, 
its distinguished contribution has encouraged and strengthened the field of genomics by providing 
 
FIGURE 2-8: DEMONSTRATION OF THE INCREASE OF COMPUTATION COMPLEXITY WITH EACH ADDITIONAL 
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a reference map for researchers to improve their research [62]. The HGP outlined approximately 
20,000-25,000 genes in the human genome.  
The HapMap Project defined what is now referred to as ‘tag-SNPs’, these SNPs allow researchers 
to reduce their SNP feature set from the original 10 million to a set of SNPs that are representative 
of a haplotype. A haplotype is a set of SNPs that are in high LD with each other, therefore can be 
represented as a group of SNPs with just 1 SNP that will provide the same results [63]. This 
project successfully aided researchers by reducing analysis from exhaustive to the necessary 
components. 
The 1000 Genome Project focused on genetic variants with frequency >1% in populations studies 
to create the world’s largest public catalogue of human variation and genotype data [64]. This 
provided references for the variations being studied by researchers.  
Each of these projects has had a significant effect on the genomic and bioinformatics community, 
giving rise to the development of more sophisticated software and techniques that ease the 
analysis process for researchers making the field of bioinformatics more accessible for geneticists. 
Within this research, the focus of our efforts is dedicated to the inference category of 
bioinformatics, considering the utilisation, adaptation and development of inference models and 
methodologies that can aid in producing robust and efficient results. The methods and techniques 
of inference bioinformatics, both standard and state-of-the-art, are later discussed in the next 
chapter. Given the bioinformatics approach, further considerations are required to incorporate the 
genetic component of the project in considering biological pathways, expression and participant 
specification. The next section discusses the focus phenotype used within this research. 
2.2.2 STUDY APPROACHES SUMMARY 
Having explored the various study approaches applicable in genomic studies it is clear that each 
approach has its own advantages and limitations. Firstly, considered is the feature space approach 
that heavily contrasts between GWAS and candidate studies; the advantages of candidate studies 
draw their benefit from specialised knowledge of the phenotype/ trait that in itself is also a 
disadvantage. Prior knowledge of the phenotype/ trait results in limitations of the analysis and 
while genetics is still advancing there are many concepts and functionalities that are ambiguous 
and unknown. GWAS presents a solution to this limitation but at the cost of a high FDR, 
overlooking rare alleles and the requirements of a large sample [24]. GWAS is better suited to 
complex and common diseases that are hypothesised to lend their causality to 'common disease, 
common variant', referring to the phenomena that common diseases will be caused by a large 
number of common alleles [65]. 
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To consider the subject specification, again there is a vast difference between the familial studies 
and GWAS. Familial studies can be used in conjunction with candidate studies depending the 
phenotype and study design and GWAS can be used in conjunction with Familial studies but is 
commonly performed using case-control unrelated subject cohorts. Familial studies introduce an 
approach that responds to fundamental genetic information that suggests that mutations are 
inherited from parentage. This study type has proved very significant in the genomics community 
and generally guides the research of the disease depending on the results. The limitations of this 
study approach lie within the fundamental requirements, the subjects. Common approaches in 
familial studies use either twins (monozygous or dizygous), trios (mother, father, offspring) or 
full-sisters, of which the genetic similarity is highest; this restricts the participant recruitment 
stage as if one of the duo/trio are not willing to participate, all participants must be removed. This 
also provides a very specific overview of a limited participation and does not apply to the general 
population. 
Epistasis is an emerging field that has seen a rise in interest as prevalent evidence points to 
systems or networks of functional variants interacting to produce a phenotypic response. 
However, given the lack of success for clinical incorporation, there is some scepticism around the 
area [66]. Having discussed the approaches of genomics the thesis now introduces the 
technological impacts that have influenced and advanced the field. 
  
23 
 
BREAST CANCER 
Cancer is a global concern, with prominent mortality rates across the board demonstrated by its 
current position as second leading cause of death in the United States, 2016 [67]. Cancer covers 
a range of related diseases which initiate in different areas of the body, most commonly 
originating in the breast, prostate, colon and rectum [68]. The pathology of cancer is caused by 
‘defects’ in the function of Apoptosis, also commonly referred to as Programmed Cell Death 
(PCD) [69]. Apoptosis refers to a process in which cells are instructed to deconstruct themselves; 
a necessary function of the body which particularly concerns the gastrointestinal tract, immune 
system and skin [70]. Excessive PCD can lead to diseases and disorders such as 
neurodegeneration and ischemia, while a lack of PCD can lead to diseases concerning the 
autoimmune system, famously, cancer. As the most frequently occurring cancer in women, breast 
cancer is a major health concern in our current society. On a global scale, breast cancer represents 
a broad spectrum which appears to be more prevalent in developed countries [71].   
In 2016, 11,563  deaths were reported due to Breast Cancer,  with increasing incidence rates that 
resulted in approx. 55,000 new cases in 2015, for England alone [10].  The current survival rate 
for Breast Cancer in England is 78%, however this is highly related to screening practices that are 
in place for quick diagnosis, ensuring treatment is started as soon as possible [10]. The symptoms 
of breast cancer vary, and quite often are due to common occurrences in the body that are 
unrelated to the development of cancerous cells. Current campaigns urge women to regularly 
check the size, shape and feel of breasts to be aware of changes that are associated with breast 
cancer. Lumps, breast pain, changes in skin colour and texture, abnormal discharge and inverted 
or sunken nipples encompass the most common symptoms associated with Breast Cancer [72].  
Breast cancer is most curable in its early stages which emphasises the importance of the screening 
processes that are in place.  Diagnosis of breast cancer is most commonly conducted using 
imaging techniques including mammograms and ultrasound [73]. Diagnosis of breast cancer 
normally adheres to a ‘two-week wait’ protocol that insists that suspected cancer patients are first 
seen by a specialist within 2-weeks [74]. With this protocol in place, ~90% of cases with known 
stage are diagnosed with early stage breast cancer (Stage 1 & 2, discussed later) [10].  
Breast Cancer is divided in to 4 stages that are based upon the TNM staging system. The TNM 
system uses information about the tumour size, node spread and metastasis status to assign a stage 
to a case. Tumour size refers to the size of the tumour present in the patient. Node spread considers 
the presences of cancer cells in lymph nodes in the surrounding area of the cancer site. Metastasis 
refers to status at which the cancer has developed in other areas of the body. Table 2.1 outlines 
the staging system for breast cancer [10]. Stages assigned to breast cancer cases are based on the 
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varying status of TNM. Table 2.2 outlines the breakdown of the breast cancer stages with 
reference to the TNM staging system [10]. 
 
Taking into consideration the stages outlines for breast cancer, it should also be noted that there 
are 2 types of breast cancer which refer to the status and spread of cancer cells in the breast.  
‘Ductal carcinoma in situ’ refers to the state of breast cancer when cancer cells have not yet spread 
beyond the lining of the duct or lobules [32].  In contrast, invasive breast cancer is the state in 
which the cancer cells have spread to the surrounding area; this type of cancer encompasses the 
majority of breast cancer stages and primarily concerns breast cancer states that have developed 
a tumour status [32]. 
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 FIGURE 2-9: OCCURRENCE OF 'IN SITU' AND 'INVASIVE' BREAST CANCER WITHIN THE LOBULES.  
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TABLE 2.1: TNM STAGING CLASSIFICATION CRITERION 
TNM Description 
Tumour How big is the primary tumour and where is it located? 
T0 No Evidence of Cancer in the breast 
Tis Carcinoma In-Situ. Cancer is confined to ducts and/or lobules. 
T1 x < 20mm 
T2 20mm > x < 50mm 
T3 x > 50mmm 
T4 Tumour has spread into the chest wall and/or skin, or is inflammatory breast 
cancer 
Nodes Is there evidence of cancer in any lymph nodes? If so, how many and where? 
N0 No cancer found or areas of cancer < 0.2mm 
N1 Cancer has spread to between 1 and 3 axillary lymph nodes and/or the internal 
mammary lymph nodes. 
N2 Cancer has spread to between 4 and 9 axillary lymph nodes or the internal 
mammary lymph nodes but no axillary lymph nodes. 
N3 Cancer has spread to 10 or more axillary lymph nodes. Or it has spready to 
lymph nodes located under the clavicle/ collarbone, it may have also spread to 
internal mammary lymph nodes. 
Metastasis Has cancer spread to other parts of the body? If so, how much and where? 
M0 Cancer has not metastasized  
M1 The is evidence of cancer in other areas/ organs of the body. 
 
 
 
 
TABLE 2.2: DIAGNOSIS OF BREAST USING TNM STAGING SYSTEM 
 T N M Cancer Type 
Stage 0 Tis N0 M0 Non-invasive(in-situ) 
Stage 1a T1 N0 M0 Invasive 
Stage 1b T0/T1 N1 M0 Invasive 
Stage 2a T0 N1 M0 Invasive 
 T1 N1 M0 Invasive 
 T2 N0 M0 Invasive 
Stage 2b T2 N1 M0 Invasive 
 T3 N0 M0 Invasive 
Stage 3a T0/1/2/3 N2 M0 Invasive 
 T3 N1 M0 Invasive 
Stage 3b T4 N0/1/2 M0 Invasive 
Stage 3c T(All) N3 M0 Invasive 
Stage 4 T(All) N(All) M1 Invasive 
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CONTRIBUTING FACTORS TO BREAST CANCER 
Disease prevention, progression and diagnosis rely on further contributing information that have 
been highlighted in research for their association and relationship with Breast Cancer. The 
majority of risk factors related to breast cancer are previously established in research from as 
early as 1970’s [8]; with the focus of research changing direction to embrace the advances of 
molecular and genetic impact. The following sections outline associated factors of Breast Cancer.  
2.3.1.1. AGE  
Incidence rates in breast cancer are highly associated to the age of the patient. The probability of 
developing Breast Cancer within the next 10 years increases as women age with the median age 
at ~61 [75]. Figure 2-10 provides an overview of the increase in probability of developing cancer 
over a period of 10 years, based on age [75]. However, this factor likely a covariate to the 
remaining factors that relate to the reproductive, growth and hormone production.  
 
2.3.1.2. AGE AT MENARCHE & MENOPAUSE 
Concerning menstruation, early start and late menopause are associated with an increased risk in 
Breast Cancer. Early age-at-menarche is associated with hormone receptor positive (HR+) cancer 
(explained later) [76]; high risk established in women whose menstruation starts before the age 
of 11 with a relative risk of 3 [67]. Natural menopause after the age of 55 presents a 2-fold risk 
than women whose natural menopause start before the age of 45 [77]. Further to this, women who 
undergo  bilateral oophorectomy before the age of 35 have a decreased risk of developing breast 
cancer than their peers who experience natural menopause [77].  
 
FIGURE 2-10: INCREASE OF PROBABILITY IN DEVELOPING BREAST CANCER OVER 10 YEARS BASED ON AGE 
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2.3.1.3. PARITY FACTORS 
In earlier years, focus of risk factors in breast cancer were associated with the relationship status 
of women, single or married [8]. This was later overshadowed by risk increase being associated 
with nulliparity (no pregnancies), or women whose first birth was at a late age [78]. Women who 
have their first child after the age of 30 are twice as likely to develop breast cancer as women who 
have their first child before the age of 20 [77]. A ratio risk (RR) of 3 is associated with women 
who have their first child past the of age 40, putting them in a high risk category [77].  
2.3.1.4. HORMONE-RELATED FACTORS 
Due to the sparse nature of cancer, and with that breast cancer itself, one occurrence of breast 
cancer may present differently to another due to molecular, histology or morphological tumour 
characteristics [32]. A prominent subtyping category for breast tumours is hormone expression 
pertaining to Oestrogen Receptors (ER), Progesterone Receptors (PR) and Human Epidermal 
Receptor 2 (HER2). Subtypes are guided by the presence of ER and HER2. ER positive (ER+) 
tumours are more common than ER negative (ER-) tumours, occurring in 30-70% of cases [32]. 
ER+ tumour present less aggressively than ER- tumours, with smaller tumours, low grade and 
lymph node negative. Major subtypes include Luminal A, Luminal B, Her2 and basal-like. 
Luminal A is the least aggressive form of cancerous tumour and presents the best prognosis while 
the remaining subtypes presents a worse prognosis that can include further complication such as 
cancerous cells in lymph nodes. Table 2.3 outlines the characteristics of each subtype [79].  
 
2.3.1.5. FAMILY HISTORY 
A commonly utilised factor for diagnosis and risk in patients is family history. This factor presents 
a link between breast cancer and genetic predisposition resulting from inherited genes from 
TABLE 2.3: CHARACTERISTICS OF TUMOUR SUBTYPES 
Subtype ER+/- HER2+/- Characteristics 
Luminal A + - 
Low levels of protein Ki-67a 
Tumour grade 1 or 2 
Slow growing tumour 
Best Prognosis 
Luminal B + +/- 
High levels of protein Ki-67 
Slightly faster growing than Luminal A 
Slightly worse prognosis than Luminal A 
Basal-like - - Common in women with BRCA1 mutation 
Common among young and African American women 
HER2 enriched - + 
More treatable with anti-HER2 drugs 
Lymph Node + 
Poorer tumour grade 
a A protein that helps to control how fast cancer cells grow 
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parents. Women with a first degree relative that has been diagnosed with breast cancer at a young 
age (before 50) are at high risk of developing breast cancer as well; this results in a risk of 2-fold 
or more of developing the disease [32].   
2.3.1.6. GENETICS 
Genetic predisposition to breast cancer is fast becoming a common practice in aiding both the 
diagnostic and preventative measures for Breast Cancer[80], [81]. One of the most commonly 
associated but rare genetic associations in breast cancer is the BRCA1 and BRCA2 genes; these 
are inherited genes that express a predisposition to breast cancer in 15% of familial cases; 
presenting a 50-85% increased risk in women. BRCA1 an BRCA2 presents the highest penetrance 
in familial cases of breast cancer, however several genes have been indicated to present a 
percentage of penetrance for familial breast cancer but does not explain all [5].  
2.3.1.7. OTHER RELATED FACTORS 
Additional factors relating to breast cancer include lifestyle factors such as diet, alcohol 
consumption, exposure to radiation, oral contraceptive use, hormone replacement therapy, 
smoking and geographical variation [77]. However, these factors do not present as much risk and 
are disputed in further studies [77]. 
Contributing factors for breast cancer range from environmental to demographics factors, 
however the most prominent focus for breast cancer is currently in the genetic association that 
highlights the underlying pathology of cancer. Genetic predisposition and classification of breast 
cancer is currently a focus given the increased survival rate and better prognosis associated with 
early diagnosis; therefore, the following sections focus on genetics and highlight the current 
research in the area of breast cancer.  
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GENETICS OF BREAST CANCER 
Familial studies encompass the vast majority of successful genetic discoveries in breast cancer 
with emphasis being placed in the now well-known BRCA1 and BRCA2 genes. There are 
currently three established categories of mutations defined as high penetrance, moderate-risk and 
low-risk. These categories currently include a number of genes indicated in research including 
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, FANCM, MLH1, MRE11A, MSH2, 
MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, STK11 and TP53 
genes [5]. 
As a high penetrance mutation, the BRCA1 gene was first localised in 1990 by Hall et al. [76] 
who utilised logarithm of the likelihood ratio for linkage, or better known as ‘Lod’, to ascertain a 
likelihood ratio ranging from 2000:1 and 1.4×106:1 among the 23 tested families within the study 
[76]. From this, further studies were performed, leading to the discovering of the BRCA2 gene 
by Wooster et al. [82], using similar techniques. Table 2.4 provides approximate estimates for 
penetrance and relative risk of high and moderate penetrance SNPs [5]. 
 
Given the advancements in technology and techniques in the area of genomics and bioinformatics, 
full genome scans are being utilised in studies to outline associations in breast cancer that are 
represented by much larger cohorts. While previous investigations have presented successes in 
the area of breast cancer, the limitations to the study are within the cohort size and therefore 
statistical power. Overall, there are further limitations that exist in the predictive power of Breast 
Cancer; the main concern being the diagnosis of Breast Cancer in patients whose case would not 
have become clinically evident [83]. This transpires to cases of diagnosis in patients whose 
tumours or abnormal cell growth deemed clinically relevant when advanced occurrence would 
TABLE 2.4: PENETRANCE LEVEL OF ESTABLISHED SNPS ASSOCIATED WITH BREAST CANCER  
High Penetrance Gene Incidence 
 BRCA1 82% lifetime risk 
 BRCA2 82% lifetime risk 
 PTEN 85% lifetime risk 
 TP53 25% by age 74 
 CDH1 39% lifetime risk of lobular breast cancer 
 STK11 32% by age 60 
   
Moderate Risk Gene Risk in Females (RR)a 
 CHEK2 1.7 
 BRIP1 2.0 
 ATM 2.37 
 PALB2 2.3 
a RR; Relative Risk   
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not have resulted in a cancerous presence. The following sections discuss two types of GWAS 
commonly conducted in Breast Cancer. 
2.4.1 FAMILIAL-BASED GWAS 
Familial GWAS extends the techniques of Genome-wide studies to family-based populations; 
with the aim focused on breast cancer associated genetic components that are present as inherited 
biological occurrences. These techniques allow for larger cohorts and SNP samples in analysis. 
Further SNPs and genes are outlined for their association with breast cancer due to these large 
analyses. The FGFR2 gene has been outlined in multiple studies [84], [85] during which further 
genes, LSP1 and TRNRC9 and MAP3K1 were also outlined [85].  These genes have also been 
replicated in further studies [86], [87] with further evidence found in other populations [88].   
Familial-based GWAS are at a disadvantage to familial-linkage studies as they use a feature of 
Family History Score to indicate the familial risk rather than analysing the relatives and the 
inherited haplotypes that are present in both parents and offspring. This restricts the study, as 
genetic susceptibility could not be measured based on the occurrence of genetic components in 
both parents and offspring.  The largest current familial study undertaken in breast cancer was 
conducted by Easton et al, in which ~44,000 subjects were included using Family History Score 
> 2 that indicates the number of and degree of family members with cases of breast cancer [85]. 
The main advantage of Familial GWAS as opposed to linkage studies is the ability to obtain larger 
cohorts for analysis, improving the statistical power of the investigation.  
2.4.2 POPULATION-BASED GWAS  
While many studies have been conducted in the area of familial occurrences of Breast Cancer, 
research into the sporadic occurrences of breast cancer in the general population remains less 
successful. Sporadic occurrences of breast cancer concern the development of the disease outside 
of the commonly associated inheritance from familial lines. A majority of Breast cancer cases 
(~66%) are considered to be sporadic occurrences [2]; these cases, while not affected by the 
established familial genetic mutations such BRCA1 and BRCA2, still adheres to the risk 
associations such as age and hormone-related factors. Further research has been conducted into 
sporadic occurrence of the disease in BRCA1 carriers, with promising results (~67% AUC) when 
utilising the blood signatures of white and peripheral blood cells with serum DNA. Thomas et al 
[89] produced a multi-stage study for population-based sporadic occurrence of breast cancer that 
outlined novel risk alleles in chromosomes 1 and 14. Focus of breast cancer in GWAS has been 
limited with the majority of studies concentrating on the pathology of breast cancer for suggestive 
genes and SNPs in candidate gene studies or the familial links that are prominent in breast cancer.  
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2.4.3 EPISTASIS STUDIES 
Previously mentioned, epistasis association is a developing technique that investigates the role of 
multiple genetic signatures in respect to the disease, suggesting the interacting components 
produce the phenotypic expression commonly associated with the disease. Breast cancer has 
received a lot of attention using the epistasis technique within the past 10 years. However, having 
been subject to the limitations of epistasis, studies have been focusing their effort on smaller sets 
of biologically related gene or prior knowledge from previous studies [90].  
The limitations of this study type result in many epistasis studies focusing on a dramatically 
reduced set of SNPs or using a limited 2-way interaction model that only considers the interactions 
of 2 SNPs in relation to the phenotype. A large-scale analysis of ~89,000 subjects and 75,380 
SNPs previously identified via 9 GWAS studies encompassing 10,052 cases and 12575 controls 
was conducted using two-way SNP interactions [91]. This study yielded few SNPs that exceeded 
the genome-wide threshold of 1×10-8 but concluded more SNPs with 1×10-6. Further studies have 
been conducted in association with Breast Cancer, using reduction parameters for SNP dimension 
such as pathway analysis. Pathway analysis considers the pathology of the disease and uses these 
genetic signatures to conduct an epistasis study. Using DNA repair, modification and metabolism 
related pathways, Sapkota et al [92] identified 2-way SNP interactions that yielded a result of 
<7.3×10-3, however this again uses a two-way interaction model which may not confer the risk 
that is associated with a group of interacting SNPs across genes or chromosomes. 
2.4.4 GENETICS OF BREAST CANCER SUMMARY 
The development of breast cancer in patients is still mostly undetermined, considering the most 
promising genes of high penetrance only explain ~5-20% of familial cases (~33%).  Sporadic 
occurrences of breast cancer form the majority of diagnosed cases; therefore, they present a 
unique challenge as opposed to the familial occurrence of breast cancer. Breast cancer is defined 
as a complex disease, which suggests that there are multiple factors effecting the development of 
the disease in subjects; this may relate to factors such as environmental that result in mutations in 
genetic components. Environmental factors present a challenge in themselves, as it is a difficult 
task to identify/ measure the significance of association to factors in the environment that may 
seem related, but aren’t, or may seem unrelated, but are.  
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DISCUSSION 
Explored in this chapter were the fundamental basis of knowledge that build the core aspects of 
this thesis. The fundamentals of genetics introduce and concentrate on the chain of events that 
lead to phenotypic expression; providing a summary as to the importance of the chosen biological 
material for analysis in this thesis. The choice of phenotype is due to the expanse of publications 
that indicate a genetic component to Breast Cancer; the purpose of this thesis is in validating a 
methodology therefore choosing a phenotype that has a genetic importance. An additional reason 
for the use of Breast Cancer is its prominence in media and research, which as a result has led to 
many studies in the area increasing the choice of data and the sample size. 
Study approaches concern the study design and influence the intention of the analysis. Previously 
discussed in 2.2 are the limitations and advantages of each approach. Incorporating the chosen 
phenotype directs the choice of approach; sporadic cancer concerns the development of the 
phenotype outside of familial relatedness therefore excluding the familial study approach. To 
consider the approaches GWAS and Candidate that approach a problem similarly but contrast in 
the inclusivity of features, a gap in publications that concern GWAS with sporadic cancer provide 
an area of interest for this thesis. Further to this, the restrictive nature of the candidate study 
approach does not complement the second approach of Epistasis. Epistasis is a progressive 
approach that has been developed in response to the hypothesised phenomena of genetic 
interactions, a core subject of this thesis. With the combination of GWAS and Epistasis, the 
limitations of epistasis are complemented by the process of GWAS. The computational 
complexity of Epistasis is a drawback of the approach that forces a range of solutions to be 
considered, one of the most common and best performing solutions is feature filtering for 
dimensionality reduction. Performing dimensionality reduction with the GWAS approach reduces 
the feature set to significant features and therefore significantly reduces the dimensionality of the 
data. However, there are still limitations that need to be addressed including a high false discovery 
rate and SNP selection, this is discussed throughout the remaining chapters. 
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Chapter 3: TECHNIQUES & METHODS 
In the previous chapter, the core aspects of the thesis were discussed and outlined the study design. 
To summarise this, with a focus on sporadic occurrences of Breast Cancer using a chained GWAS 
to Epistasis approach, presented is an advantageous combination that are complementary. Given 
the methodology built from the research so far, three general topics of analysis need to be 
addressed: Quality Control, Association Analysis and Inference Methods.  
 
Bioinformatics is a substantial field that has been benefitted by continuously advancing 
techniques and adaptations that suit a variety of biological material including SNP's; this results 
in an abundance of techniques and methods that are applicable to the current study design. A 
factor that is critical in this methodology, is the use of techniques and methods that are 
interpretable and therefore will be a demanding aspect to drive the decisions of this chapter. 
  
Quality Control
Association Analysis
Inference Analysis
RO1
RO2/3/4
RO5
 
FIGURE 3-1: DEPICTION OF THE SECTIONS OF TECHNIQUES AND METHODS DISCUSSED WITHIN THIS 
CHAPTER ALONG WITH THE RESEARCH OBJECTIVES BEING NAVIGATED. 
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QUALITY CONTROL 
The following section supports RO1; outlining the standard processes that are considered and 
applied in data quality control for genetic material, with focus on SNP data. Methods and 
techniques outlined in this section are standard practice techniques that are used to remove both 
subjects and SNP features that can cause bias, obstruct or mask signals, or produce false positive 
results [93].  
3.1.1 HETEROZYGOSITY 
Heterozygosity is a parameter often measured in the early stages of genetic variation studies 
[94][95][96]. This measure is used in this capacity as an indication for inbreeding or severe effects 
in populations to ensure that individuals with reduced or excessive rate of heterozygous genotypes 
are identified for removal [97]. The presence of these individuals could indicate contamination, 
inbreeding, outbreeding or poor genotype calling in the sample. Plots in Figure 3-2 are produce 
using the number of non-missing genotype (NNM) and the observed number of homozygotes 
(OHOM).  
 
Heterozygosity = 
NM HOM
NM
N O
N
−
 
EQ. 3-1 
 
Plotting this, the x-axis represents the proportion of missing genotypes for an individual while the 
y-axis represents the observed heterozygosity. ‘Rule of thumb’ indicates that individuals that 
deviate outside of 3σ are excluded from further analysis [97]; however, this threshold will be 
dependent on study factors, such as cohort size and focus disease. 
 
 
FIGURE 3-2: HETEROZYGOSITY × MISSINGNESS IN GENOTYPE PLOTS 
Example heterozygosity rate plots for removing outlier subjects (a) original data (b) outliers removed. Threshold lines on 
x-axis indicate the maximum level of missingness for genotypes in individuals, while the y-axis shows the outlier threshold 
for heterozygosity rate separated by 3σ from average. 
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3.1.2 SEX INCONSISTENCIES 
Sex inconsistencies is common method adopted in GWAS [98][99][46] that refers to a 
discrepancy between the recorded sex of a subject and the heterozygosity rate of X chromosome 
[97]. There are distinct differences between the genetics of males and females, in reference to the 
sex chromosomes (XX/ XY), leading to an evaluation method which considers the heterozygosity 
in the X chromosome, indicating a heterozygosity rate of >0.8 for males and <0.2 for females 
[97][93]. Therefore, subjects whose heterozygosity rate falls with the threshold of 0.2 < x > 0.8 
will be excluded from further analysis. The heterozygosity rate of individuals, in respect to the X 
chromosome, is analysed using fixation indices, or more commonly known as F-statistics, a 
statistical analysis to measure the expected level of heterozygosity against the observed level 
using the following equation [100]: 
X Chromsome Heterozygosity
Homozygosity Rate
=  
2 2
1
n
i
p q
n
=
+
 
EQ. 3-2 
As seen in Heterozygosity, a coefficient result of <0.2 is expected for females while males are 
expected to have a coefficient of 1, however leniency is adopted to account for genotyping error 
discrepancies [93]. For individuals that are flagged for issues between the recorded sex and F 
coefficient, the coefficient should be scrutinised to ensure that an error has not been made during 
the record of information. While sex checks are only essential to the analysis process when basing 
features or control on the sex of the individuals, they also provide a unique processing control 
that considers issues that exist in gametes such as Turner and Kleinfelter syndrome or mosaic 
individuals [101]; sex chromosome anomalies that while present normal phenotypically, the 
genotypic presence is abnormal. 
3.1.3 RELATEDNESS & DUPLICATES IN SUBJECTS 
Generally in clinical studies, the relatedness of individuals will be recorded and noted for research 
purpose [97]; however in cases where either subjects are unaware of attending related subjects in 
the study or are unaware of their relation status to other subjects in the study; subjects are excluded 
to avoid a bias analysis. Similarly, any duplicate cases, case in which the genetic material of a 
person is included in the same more than once, will be removed. Using case-control cohort, as 
demonstrated in this study, measures must be put in place to ensure that individuals included in 
the study are unrelated. When testing for relatedness in individuals, pairwise identity-by-descent 
(IBD) is used [102] to tests pairs of subjects to compare the reported relatedness of individuals 
against the proportion of loci with which two individuals share one, two or zero alleles. As 
provided in Table 3.1, relatedness in subjects is measured by the number of matching allele states 
i.e. Z score = 2 when individuals both show the same homozygous state, AA. 
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Calculated during IBD in PLINK is the PI_HAT value; a value that can be demonstrated as [102]: 
1
_ ( 2) ( 1)
2
PI HAT P IBD P IBD= = + =  EQ. 3-3 
This value provides an overall estimate of the relatedness of 2 individuals and as such can be used 
as exclusion criteria using the following thresholds [93]: 
 
Applying an upper threshold of 0.125 will exclude outlier subjects that appear to have relations 
up to and including 3rd Degree (Cousins) within the cohort.  
3.1.4 DIVERGENT ANCESTRY 
Diverging Ancestry is another problem that occurs in case-control data; individuals report their 
ancestry and are analysed based on these clustered groups. Ancestry in genomic analysis is 
important given the bias that can occur and false positive association which arise due to spurious 
associations that are a result of differences in ancestry rather than case-control [103]. It is 
established that the susceptibility to immune-related disease varies wildly between populations 
[104]. These differences can cause health disparities due to phenotypic diversity pertaining to the 
genetic differences that are evident between populations. Therefore, the exclusion of individuals 
that deviate from the population cluster can aid in creating a representative set of features and 
observations for further analysis. As a standard practice element of genetic analysis studies 
[98][46] ancestry divergence is commonly performed using a Principle Component Analysis 
(PCA) technique as outlined below. 
For this study, PCA based approach is used with the HapMap3 reference panel for YRI, CEU and 
CHB+JPT referring to and using tools outlined in [93]. Figure 3-3 provides a visualisation of the 
initial PCA model which is represented by YRI (Yoruba, Ibadan, Nigeria) (Green), CHB (Hans 
TABLE 3.1: REPRESENTATION OF RELATEDNESS MEASURED BY IBS 
Subject-1 Subject-2 IBS State/ Z 
AA AA 2 
AA Aa 1 
AA aa 0 
 
TABLE 3.2: RELATEDNESS PI_HAT SCORE WITH REFERENCE TO DEGREE OF RELATION 
Relatedness PI_HAT Value 
1st Degree (Siblings) 0.5 
2nd Degree (Half Siblings) 0.25 
3rd Degree (Cousins) 0.125 
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Chinese, Beijing, China) + JPT (Japanese, Tokyo, Japan) (Purple) and CEU (Utah residents with 
Northern & Western Europeans ancestry from CEPH collection) (Red), case and control subjects 
from the acquired data cohort are represented as black and blue, respectively. 
 
Figure 3-3 shows the acquired data clusters centrally in the plot indicating its separation from the 
outlined populations. The second plot provides a zoom view of the population plot to inspect the 
distribution, which shows there is a minor spread that extends outwards. Threshold are set to 
remove these outliers to improve the cohort reliability. 
3.1.5 LINKAGE DISEQUILIBRIUM PRUNING 
Linkage Disequilibrium (LD) pruning refers to a process that removes SNPs based on the 
correlative effect between two loci. The purpose of LD relates to the genomic population 
structure, considering the evolution of the genetics within. The genome is separated into 
Chromosomes (although the initial use of LD was analysed cross Chromosomes, this is no longer 
necessary as it is considered that associative haplotypes are inherited via chromosome blocks). 
Within the chromosome, each pair of loci are analysed using varying parameters of window size, 
step size and correlation threshold [21]. From here, any loci that present a LD greater than a 
(a)
(b)
(c)
YRI
Cases
Controls
JTP + CHB
CEU
Cases
Controls
Cases
Controls
 
FIGURE 3-3: ANCESTRY DIVERGENCE PCA PLOT EXAMPLE SHOWING THE DISTRIBUTION OF INDIVIDUALS IN 
RESPECT TO PCA1&2. 
(a) Overall distribution in relation to populations JPT+CHB, CEU and YRI. (b) Zoom view of the distribution with 
threshold lines associated to the x and y axis (c) Distribution after outliers have been removed. 
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specified threshold are eliminated. Commonly the process of LD adheres to the following 
equation [21]: 
AB AB A BD P P P= −  EQ. 3-4 
Where PA refers to the proportion of allele A, PB refers to the proportion of allele B and PAB refers 
to the proportion of allele A and allele B occurring together. Linkage Disequilibrium is in 
occurrence if: 
0D   EQ. 3-5 
The very basics of an LD pruning analysis will concern a window size, a step size and a threshold 
[102]. The window size refers to the number of SNPs considered at one time for analysis, while 
the step size indicates the number of SNPs that are used to shift a window of focus SNPs for 
analysis. In this motion, the analyses will advance across the chromosome until the full length of 
SNPs within the chromosome have been analysed. The threshold is a given measurable quantity 
with which the LD between two loci will exceed if exclusion is necessary; this threshold can use 
various correlation equations to determine the basis of LD including D’, r 2 and Variance Inflation 
Factor (VIF)[102]. At this point, we will be focusing on the standard approaches, r2 and VIF, most 
commonly applied in literature. The following equations outline the details of r2 and VIF [21]: 
2
2
(1 ) (1 )A A B B
D
r
P P P P
=
− −
 
 
EQ. 3-6 
2
1
1
i
i
VIF
R
=
−
 
where i = 1…n 
 
EQ. 3-7 
The threshold r2 provides an analysis in terms of the pairwise genotypic correlation while VIF 
focus on the variance dependent on the collinearity found between the loci [102]. Each of these 
candidates rely on different threshold inputs ranging from 0-1 (r2) [21]  or 1 and above (VIF) 
[105], depending on the stringency of the analysis. Of course, the more stringent the threshold, 
the more SNPs will be excluded, while this would leave the remaining candidate dataset with 
predominantly independent loci, this may also exclude SNPs that are highly associated with the 
disease. In essence, the use of LD within an analysis concerns the evolutionary path of human 
genomics and the effects on the genotyping information within [106]. We want to eliminate any 
genetic data that may present itself as ‘noise’ within our dataset and as such aim to provide the 
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most promising and prominent genotypes associated with the focus disorder. A common threshold 
of r2 < 0.6, or r2 < 0.8 are applied in studies [95][98]. 
3.1.6 GENOTYPE IMPUTATION 
Genotype Imputation is currently considered common practice in GWA analysis. Imputation is 
an applied method that will enrich a genotype dataset with the most similar genotype information 
given in the reference sample set [107]. Firstly, it is important to note that in common applications 
of imputation; missing values are imputed based on given values already present. Genetic 
imputation uses the values present in the data to impute new columns of data; that is, the 
imputation of data into genomic datasets will add new SNPs that were not present previously 
[107]. Given the introduction of data that is imputed using probabilistic methods for ‘new’ data, 
it is important that the accuracy of these methods be fully explored, not only for the accuracy of 
the data being imputed but also for its necessity in the methodology proposed. Due to this, 
required sizes of cohort for statistical power in genomic studies when sequencing the genetic data 
are expensive, so in order to reduce this cost and allow a more feasible genomic analysis, 
researchers adopt the imputation technique.  
The imputation process considers the genome within Chromosomes (Chromosome 1, 
Chromosome 2, etc), from there haplotypes are generated from tag-SNPs located within the 
genotype information provided [107]. Haplotypes are set genetic determinants located on a 
Chromosome, simply put this is a group of genes that are inherited together from a single parent. 
This could be a pair or set of genes that have been inherited together. From here, this information 
is used to impute genotypes for an individual based on the most similar reference haplotype(s) to 
insert markers/ alleles from the corresponding reference haplotype into the sample Haplotypes 
[108].  
While imputation introduces an inexpensive and quick way of populating genomic feature sets, 
there are implications and disadvantages to the method. The samples included in reference 
datasets are not known, however they are presumed to be predominantly healthy individuals, 
which introduces questions such as; how accurately these reference sets can predict the missing 
genotypic information for an affected disorder genotype set? Imputation is only as good as the 
provided sample set; this refers to the imputation of markers based on the current data that is 
already sequenced within the dataset. Therefore, there are a few considerations that should be 
explored in order to determine whether imputation would beneficial to the study; these 
considerations include the current sequenced information, the reference dataset being used and 
the sequencing chip that the genotypes were sequenced with [109]. 
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The provided dataset for imputation will only provide further genotype information based on the 
correlative tag-SNPs already available, therefore if there are tag-SNPs missing within a haplotype, 
imputation cannot be performed in that haplotype e.g. the APOE locus associated with Alzheimer 
Disease cannot be imputed from the Affy 500k chip [110]. This introduces the issues that concern 
sequencing chip options; while it is not always possible to choose which chip is used for the 
sequencing of data, there are advantages and disadvantages between them; the main and most 
significant difference is the outcome of sequenced information that differs between them.  
Finally, the reference dataset is a consideration that is most likely to affect the results of the data. 
Various datasets can be utilised dependent on the software in use. For example, PLINK utilises 
the HapMap reference dataset [102]. The datasets each provide a different sample of individuals 
however, some are shared e.g. HapMap reference and 1000 genomes share some individuals 
[110]. 
Another consideration concerning the process of imputation is the software that is used to perform 
the imputation. There are many open source options readily available for use however; we are 
considering the main open source options for imputation. MACH [111], IMPUTE2 [112] and 
BEAGLE [113] are in competition; each proving advantages and disadvantages when compared 
using criteria such as the memory consumption, runtime, prediction quality and error handling. 
The use of this software should be considered based several factors such as dataset format and 
size, reference panel for imputation, operating system used for analysis and the output from each 
software for association analysis. As demonstrated in [114], imputation’s correct rate reaches 
>95% when using many different software’s, of which the previously mentioned are some of the 
best performers. 
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3.1.7 THRESHOLD MEASURES 
Threshold Measures are standard practice applied as a base or final control process that removes 
individuals and SNP features. These quality control measures are important and are performed as 
a standard practice in any genomic study that utilises SNP or related data [99][89][96]. Figure 3-4 
provides a visual representation of the analysis of the below threshold measures. 
3.1.7.1. MISSINGNESS IN INDIVIDUALS (MIND) 
This threshold considers the missingness per individual for genotypic data. When we analyse the 
data further, we need to include individuals whose data is mostly, to entirely complete [115]. This 
threshold will remove any individuals whose data has a missing rate higher than the provided 
threshold. For this threshold we used a measure of 0.01, when ensures that every individual 
included in the dataset has at least 99% of their genotypic data. 
3.1.7.2. HARDY-WEINBERG EQUILIBRIUM (HWE) 
The Hardy-Weinberg Equilibrium is a simple equation that is used to discover the probable 
frequency of genotype in a given population and track the evolutionary changes from generation-
to-generation. When performing an association analysis or further testing in a genetic cohort, a 
control group is used as a representative sample of the given population and therefore if there are 
evolutionary migrations in the set, it could cause bias or incorrect results in the next stage. The 
Hardy-Weinberg equation is demonstrated as: 
 
2 2
1
2
1
2
2 1
p AA Aa
q aa Aa
p pq q
= +
= +
+ + =  
 
EQ. 3-8 
 
Standard approaches will use thresholds that range from 10-5 to 10-6 in case-control studies [115]. 
This process identifies issues that can relate to cryptic relatedness, genotyping error or population 
admixture and more [115].  
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3.1.7.3. GENOTYPE CALL RATE (GENO) 
Genotype rate (Geno) threshold concerns the marker genotyping efficiency relating to the SNP 
assays performance rate; in particular, this considers the percentage across all individuals 
pertaining to the missingness of SNP information [115]. This may reduce the marker set but will 
also improve the reliability of the results. Standard practice employs a threshold between 0.01 to 
0.05 lower limit that will exclude any markers that have more than 1-5% missing information, 
less than 99-95% call rate confidence.  
3.1.7.4. MINOR ALLELE FREQUENCY (MAF) 
Minor Allele Frequency considers the alleles of each SNP across all subjects; if this SNP is 
present in less than the specified threshold, then it is removed [97]. When we use the MAF 
threshold, we consider the presence of the minor allele as the potential risk and therefore we 
would like to reduce dimensionality by removing any SNPs that are unlikely to yield results. e.g. 
a MAF of r2 = 0.01 in a dataset of 500 subjects would result in SNPs whose minor allele is not 
present in more than 1% of the cohort, 5 people, being removed from set.  
 
SNP1    SNP2    SNP3    SNP4
A1
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G
G
G
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G
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Subject 4
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G
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A
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G
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C
C
C
T
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G
G
G
G
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G
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G
G
MAF
Col SNP1 A1
G       A     Total
5       1        6
MAF =       = 0.167
1
6
HWE
Col SNP2
  2                          2p  (CC)  pq(CT)  q  (TT)
 0.5      0.34   0.167
HWE = 0.5+0.34+0.167 = 1
GENO
Col SNP4 A1
Missing     Total
2             6
GENO =       = 0.334
2
6
MIND
Row Subject 1
Missing     Total
1             4
MIND =       = 0.25
1
4
MAF HWE
MIND
GENO
 
FIGURE 3-4: VISUAL REPRESENTATION OF ANALYSIS CONDUCTED FOR THRESHOLD MEASURES A 
 
A Column highlighted in yellow provide the input for MAF calculations. Columns highlighted in pink provide the 
input for HWE, with p2 referring to genotype CC (3/6), pq referring to genotype CT or TC (2/6) and q2 referring to 
genotype TT (1/6). Columns high in green provide the input for GENO. Columns highlighted in green provide the 
input for MIND. 
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3.1.8  QUALITY CONTROL SUMMARY 
Quality control is an essential process that can reduce bias, improve signal strength, reduce false 
positive signals but more importantly, it addresses issues that prove to be prominent pitfalls when 
analysing and processing data. Quality Control processes Heterozygosity rate, Sex 
Inconsistencies, Relatedness and Duplicates in Subjects, Divergent Ancestry and Threshold 
Measure all provide advantageous effects for utilisation in the proposed methodology. By 
removing individuals and SNPs that do not surpass the standards set by these methods, the dataset 
is being reduced to a representative set of SNP features and subject cohort that are more likely to 
present underlying genetic signals in association with the phenotype.  
Techniques that have not been adopted into the proposed methodology are Imputation. With the 
advantages that benefit a GWAS study primarily associated with the increase in feature set, the 
expansion of this dataset directly effects the primary objective analysis, epistasis. By increasing 
the number of SNPs included in the analysis, not only would the computational complexity be 
increased but also the time taken to perform the analysis. Further to this, imputation imputes 
features directly linked to tag SNPs already established in the dataset; these features are unlikely 
to produce signal effects that differ dramatically from their original source but would introduce 
more ‘noise’. Therefore, for the current methodology, imputation would cause more issues than 
would introduce benefits. The choice of methods and techniques to process the feature dataset are 
selected to produce a feature set optimised concerning reliability and robustness for further 
analysis in the proposed methodology. 
ASSOCIATION ANALYSIS 
Association analysis is a very broad term that encompasses a variety of approaches from statistical 
filtering to relationship modelling using univariate and multivariate data. In the context of these 
research, the following section outlines a variety of methods that perform association analysis in 
relation to genomic data with reference to RO2, RO3 and RO4. Further to this, discussed are 
techniques and methods that are used for correction in analysis for limitations and issues that arise 
in particular from the application of such methods to large datasets, such as genomic data. 
3.2.1 UNIVARIATE ANALYSIS 
Univariate analysis encompasses methods that measure associations between variable X and 
response Y, in the context of the research an example would be to measure the association of one 
genetic variant to the expressed phenotype. As previously mentioned, the analysis of the 
association is not a definitive answer to a question and therefore is commonly used as a supporting 
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method to either statistically filter data or to indicate potential relationships for further analysis. 
This section outlined methods and techniques for the exploration of RO2. 
To discuss one of the most prominent univariate methods, standard GWAS is a widely used 
approach that has been indicated as a powerful alternative to traditional linkage-studies [112]. 
GWAS has previously been discussed in 2.2.1 and at this point it is important to outline that 
GWAS approaches vary between studies and in order to outline techniques that are related to the 
current approach, the scope of GWAS is defined as the following: 
A genome-wide association study is an approach that involves rapidly 
scanning markers across the complete sets of DNA, or genomes, of many 
people to find genetic variations associated with a particular disease.  
- National Human Genome Research Institute [116]  
 
In standard practice GWAS as is commonly conducted, a univariate analysis of the data will be 
performed using a permutation test on a 2x2 or 2x3 contingency table (refer to Table 3.53.2.1.1. 
) that transforms the data to manipulate the focus. This will commonly be performed by fisher’s 
exact test, chi-squared [13][102] or logistic regression [84]. Further adaptations of the GWAS 
approach include simulation techniques to deduce empirical statistics of causal variants based on 
control haplotype frequencies [117][118] and incorporating multiple traits [119]. Further to this, 
due to the release of datasets and information, access to this information is much more accessible 
and has given rise to a GWAS adaptation called ‘meta-analysis’ that use data from multiple 
studies to gain insight, particularly in complex diseases [120].  
3.2.1.1. GENETIC MODELS 
The following section discusses the association models that are commonly utilised during 
univariate analysis. Due to the nature of SNP data we must consider the variable presence of 
features in both allele and genotype form, further explained in 0. Due to the different combinations 
that are available for testing purposes, there are a number of models that can be used. An Additive 
model is used to determine the disease penetrance of a given SNP, that is, the risk of disease in 
subjects carrying a given genotype. This is assessed using code 0, 1 and 2, which corresponds to 
the γ-fold risk increase with each additional genotype presence. Table 3.3 presents the assigned 
risk codes and corresponding genotypes.  Similarly, the dominant model also measures the 
disease penetrance of a given SNP but rather than using the genotype states separately, it 
combines Aa and aa to produce a model which assesses the risk of genotypes that do not contain 
a dominant allele. The recessive model again measures the disease penetrance as demonstrated 
by the dominant model, but rather than measuring the disease penetrance of the SNP in subjects 
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that do not hold a dominant homozygous genotype, the focus is instead on recessive homozygous 
genotype status. 
 
Allelic model uses an OR calculation and utilises the allele form of the SNP by measuring the 
‘Odds of Disease’. The ‘Odds of disease’ is the probability that a disease is present compared to 
the probability that a disease is absent; while this cannot be directly measured, the ‘Odds of 
Exposure’ can be; this uses the frequencies of exposure in case and control. The allelic model 
measures the association between the Odds of Disease in subjects with dominant allele A over 
the odds of disease of subjects with the recessive allele a. This is represented in Table 3.4 to Table 
3.5 where a, b, c, d and T refer to the values within the table. 
 
 
The Multiplicative Model produces an OR similar to the allelic model, assuming that the 
genotypes represent in increasing risk with each additional minor allele [121]. Similar to the 
additive model and commonly referred to as the log-additive model, the multiplicative model 
assumes a greater risk from risk homozygotes as demonstrated by the n2 risk increase. It should 
also be noted that there are some inconsistencies in the literature regarding the disease penetrance 
models [122], the above mentioned disease penetrance models are chosen to optimise the 
investigation of risk alleles [123]. Further to the above-mentioned models is the commonly used 
logistic regression that builds upon the additive model. Logistic Regression is explained further 
in the next section. 
TABLE 3.3: DATA TRANSFORMATIONS FOR DISEASE PENETRANCE MODELS 
 Penetrance 
 AA Aa aa 
Additive 0 γ 2 γ 
Dominant 0 γ γ 
Recessive 0 0 γ 
Multiplicative 0 γ γ 2 
 
TABLE 3.4: ALLELIC MODEL CODE REPRESENTATION 
Allele 1 Allele 2 
A a A A 
1 0 1 0 
 
TABLE 3.5: ALLELIC MODEL OR  
 Allele 1 Allele 2  
Case a b a + b 
Control c d c + d 
 a + c b + d T 
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3.2.1.2. LOGISTIC REGRESSION 
The logistic regression model is a renowned statistical method that commonly utilises binary 
predictors to estimate the parameters of a model, in simple terms, it provides a co-efficient that 
indicates, based on the inputted data, that the presence of a risk factor increases the odds of a 
given outcome by factor 𝑥. 
The logistic regression curve is given as: 
 
EQ. (3-9) 
To give us probability, P, with coefficients βi using predictors, 𝑥𝑖. 
The logistic regression model can be utilised to produce coefficient values for a variety of data 
types including categorised (multinomial logistic regression), ordinal (Ordinal Logistic 
Regression) and continuous (Linear Regression), the use of these models depends on the 
dependent variable data type. Further varieties of data types can also be used within the analysis 
using logistic regression by employing adjusted log-odds ratios e.g. Binary with continuous 
feature. The logit model produces the coefficients, 𝛽. Each coefficient is generated from one 
feature across all observations. In this instance, the following derivations produce 𝛽 coefficients 
based on binary features.  
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 EQ. (3-10) 
 
Log-Odds is used to estimate the value of 𝛽 (See 3.3.1 for more information on Odds Ratio). 
log ( (1)) log ( (0))
(1) (0)
log log
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EQ. 3-11 
For this, we firstly generate 𝛼 by using ‘unexposed’ binary observations. This is the proceeded 
with 𝛽 using the ‘exposed’ binary observations which provide a nominal factor value of how 
much the odds of given outcome are increased by the presence of this risk factor. Where x = 0, β 
coefficients are not produced, providing a value for the intercept, the expected mean value of Y. 
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1 1 2 2
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+
47 
 
0( ), ( (0)) (0)
1( ), ( (1)) (1)
x unexposed logit p
x exposed logit p
  
   
= = + =
= = + = +
 
EQ. 3-12 
Logistic regression presents an option to geneticists to incorporate the effects of covariates such 
as gender, smoking, lifestyle and age. This controls for any bias that these covariates may have 
on the data particularly when concerning complex traits. 
3.2.1.3. GENOMIC THRESHOLDS 
Within genomics there is a constant debate surrounding the threshold measures of significance 
[124],[125],[14]. These thresholds are advisable in genetic analysis studies, particularly SNP 
studies, to outlined significant results however the debate discusses the issues that are present 
with a threshold that is too conservative and those that are present with a threshold that is too 
lenient. A standard process in GWAS is to use the genome-wide significance threshold that is 
based on Bonferroni correction [19] under the assumption of a feature set of 1 million SNPs. As 
a result of plentiful publications claiming significance in genetic markers; the genome-wide 
significance threshold was set to 1 x 10-8 [125]. This ensured that any studies undertaken would 
adhere to the threshold and only results that showed a significantly high genetic variant would 
prove reliable for further study and replication.  
However, with many studies this does not prove to be the most effective solution. [125] introduces 
research which explores the p-values of genotype-phenotype associations of previous studies 
investigating the potential of replication between the widely-accepted threshold of 1 x 10-8 and 
the borderline threshold of 1 x 10-7[19]. Associations falling within these thresholds are deemed 
to be borderline associations. Depending on the study, borderline associations may be included 
in the final set of candidate variants as research suggests that variants that fall into the borderline 
category may also show significance to the phenotypic trait [125]. The results of this study 
suggested that borderline associations can prove significantly replicable for numerous 
phenotypes.  
Many papers [126][19][127] have also suggested that the restriction of the genome-wide 
significance threshold could lead to the suspension of research concerning genetic associations to 
demonstrate true significance with a given phenotype. However, this claim is also disputed in 
numerous papers which suggest that lower thresholds do not produce significant associations 
[125]. Publications discussing the threshold of significant associations review the threshold based 
on the empirical measure of p-values. This paper explores the potential for true association in 
genetic variants when adopting various threshold measures for the genome-wide significance line. 
Considering the controversy around the subject in relation to p-values [128], [129], further 
thresholds are explored in relation to multiple testing in section 3.2.3 . 
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3.2.2 MULTIVARIATE ANALYSIS 
Multivariate analysis refers to the statistical analysis of features X1, X2, X3, … Xn and their 
combined effect on response Y e.g. to measure the statistical significance of an age, height and a 
particular genetic variant in reference to an expressed phenotype.  Multivariate analyses pose a 
particularly challenging problem when using large datasets as the number of features that are 
included can become very computationally expensive. Multivariate analysis encompasses a 
variety of approaches that consider hypothesis regarding covariates, environmental factors and 
interactions. In order to remain within the scope of this research, the following section focuses on 
the multivariate analysis approaches that can and are used for interactions, pattern detection and 
relationships between features. This section outlined methods and techniques for the exploration 
of RO4. 
Epistasis as previously discussed, is an increasing presence in genomic studies. The potential of 
combinatorial genetic signals as significant features is also more likely in complex diseases given 
the varying phenotypic expression of symptoms in these diseases. Many complex diseases are 
deemed ‘umbrella’ terms that cluster the most common symptoms into one disease while the 
varying of additional symptoms suggests potential interaction among the underlying genetic 
aetiology. The complexity of performing an epistasis study lies in the combination arrays required 
to test all possible combinations, an exponential increase in computation complexity and time. 
The following sections discusses the two main approaches to perform epistasis; Pairwise-
Interactions detection and limitless-arity. 
3.2.2.1. PAIRWISE SNP INTERACTION DETECTION 
Due to the prominent issue of computational complexity in epistasis approaches, a solution that 
is presented for many techniques to consider the interactions within the genome is to instead use 
a pairwise interaction method. Using this, an exhaustive approach can be successfully performed 
without high performance computing hardware, which analyses and measures probability of 
association to phenotype between every pair combination within the input features as visualised 
in Figure 3-5 considering 4 SNPs, analysis for interactions with SNP 1.  
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FIGURE 3-5: PAIRWISE INTERACTION ANALYSIS REPRESENTATION 
 
While the computational complexity of the model is significantly reduced by limiting the 
combination factors to 2, the problem still exists given the size and required representations of 
the data. There are numerous solutions that exist to approach this problem. 
PLINK employs a logistic regression model that corrects and adjusts for multiple testing using 
the Bonferroni multiple-test correction. While this method adjusts for the errors introduced from 
high dimensional data, the consequence is the reduction of type 1 errors and the increase in type 
2 errors given the conservative approach of the Bonferroni. Further to this, this method is costly 
in time and therefore the logistic regression model has been denoted for its unsuitability in 
handling genome-wide datasets [13]. While logistic regression has been outlined as inappropriate 
for use in genome-wide datasets, variations on the model have been employed successfully in 
Least Absolute Shrinkage and Selection Operator (LASSO) [130]. 
Boolean Operation-based testing and screening (BOOST) transforms the data into binary 
representation to improve time and space efficiency by using language that is closer to machine 
code [131]. The operational measures are conducted using contingency tables and applying 
Fisher’s exact test and using a non-iterative approximation of the log-likelihood ratio, Kirkwood 
superposition approximation (KSA) [13].  
3.2.2.2. LIMITLESS ARITY DETECTION 
Multifactor Dimensional Reduction (MDR) is a non-parametric and genetic-model free data 
mining strategy used with discrete data for the prediction of discrete outcomes. This machine 
learning model approaches the area of epistasis using feature extraction to define a new attribute 
through a process called ‘constructive induction’ by pooling (combining SNPs as genotypes). 
Using Multi-locus genotypes, it produces a ratio of case and controls for each genotype and 
compares this to the overall ratio of case and controls, assigning a status of either high, G1, or low 
risk, G0, depending on whether the defined ratio of the genotype exceeds that of the overall ratio. 
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MDR relies on the transformation of the representation space for easier classification using ML 
models to detect attribute dependencies [132][2]. Since its introduction in 2001, the MDR method 
has been further developed to incorporate additional techniques and models [133] to improve 
robustness [134], data flexibility[135] and adaptations to concede to various data imperfections 
such as missing data and status imbalances [136].  
While there has been a vast contributing community for the improvement and development of 
MDR techniques, limitations still exist. In its native form, the consistent issue in epistasis of 
computational complexity is still present. While MDR provides a method for non-parametric and 
genetic-model free performance, the computational intensity still performs at an exponential time 
expense [13] and further to this, the arduous task of performing MDR on more than 2 SNPs 
requires the steps to be repeated for each model size [13].  
 
FIGURE 3-6: LIMITLESS-ARITY INTERACTION ANALYSIS REPRESENTATION 
 
While association rule-mining (ARM) is a widely used method in ‘market-basket’ research, the 
fundamental applications are transferrable to genomic data, and in particular SNP data. The 
original application of these algorithms was to detect frequent patterns in purchased items [137]. 
ARM is based on the ‘apriori’ algorithm that identifies frequent ‘itemsets’ that are then used to 
generate rules. ARM is used in a variety of field including the automated detection of unusual soil 
moisture probe response patterns [138], and darknet big data [137]. There are also adaptations 
such as the frequent pattern growth algorithm using a prefix tree that recursively eliminates 
branches of itemsets to store minimum supports that generate the association rules [137]. Further 
to this, ARM has previously been used in a genomic capacity to complement and modify the 
GWAS process [139]. While ARM presents a method to perform an exhaustive search for 
interactions in genomic data, computational expense and the fundamental practice of 
unsupervised learning can create issues in both the analysis and result interpretation. 
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Software program LAMPlink [140] derives its name from methods employed, 'Limitless Arity 
Multiple-testing Procedure'. This developed algorithm provides a method of detecting significant 
associations using a limitless number of features. The benefit of this method is the vast reduction 
in computational complexities by using ‘itemset mining’ to remove redundant SNP combinations 
before an exhaustive search is performed. For further information on the techniques in LAMPlink, 
refer to section 5.5.1 . The limitations of LAMPlink exist in the requirements of using limited 
genetic models, dominant and recessive. This contrasts with the benefits provided by the MDR 
technique but is superior in addressing the prominent issue of computational complexities. 
As previously mentioned, and utilised in the above software, ‘itemset mining’ is a limitless arity 
option that falls within the area of association rule learning for data mining. Previously designed 
for market basket analysis, its uses have extended into many fields, including genetics [141]. 
‘Itemset mining’ approaches the problem using an unsupervised machine learning which benefits 
from a hypothesis-free and assumption-free method. Additionally, it also provides a method in 
which all combinations of SNPs can be investigated, but as previously mentioned, this is at the 
cost of computational complexity and further to this, unsupervised learning methods are used to 
analyse and extract patterns of information from the data; this results in all patterns being 
investigated which may not always be associated to the phenotype.  
3.2.3 CORRECTION METHODS 
Due to the nature of genomic data, with large datasets with variability in the representation, there 
are problems that arise when analysing information such as this. Within this section, some of the 
most prominent issues in association analysis for genomics are discussed and correction methods 
that are produced to modify or adapt the analysis results to better represent the true nature of the 
results. This section outlined methods and techniques for the exploration of RO3 and RO1. 
3.2.3.1. MULTIPLE TESTING PROBLEM 
Univariate association analysis considers a feature, X, against a response, Y. This analysis 
provides a value of measure to indicate the probability that a feature, X, deviates from the null 
hypothesis. The null hypothesis in the case of given example is ‘SNP A’ is not significant to the 
occurrence of breast cancer in the given cohort’; therefore anything that deviates from a p-value 
of 1 (less than 1) implies that there is an increased occurrence of ‘SNP A’ in response to subjects 
status, case and control. During common data analysis investigations, a p-value of 0.05 (5%) 
suggests that feature, X, is very significant to response, Y; however, when investigating genomic 
data, a more conservative threshold is considered due to the vast number of features that are tested.  
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In standard GWAS, the number of SNP features considered are commonly in the range of 300,000 
to 500,000. In order to put this into context, if the number of features to be tested is 8 the following 
calculation provides an approximate estimation for the probability of observing at least one 
significant result (S) by chance: 
8
( 1| ) 1 ( 0)
( 1| 8) 1 (1 0.05)
( 1| 8) ~ 0.34
P S N P S
P S
P S
 = − =
 = − −

 
EQ. 3-13 
So, even with only 8 features there is a 34% chance of observing a least one significant result, S. 
Using the common 300,000 features that are consistently used or exceeded during genomic 
studies, an estimated probability of 1 signifies that at least one false positive result will present 
itself. This is known as the multiple testing problem as the more features that are included in the 
test, the greater the probability of observing at least one significant result and with this, are likely 
to observe what is referred to as ‘type 1’ and ‘type 2’ errors. 
FAMILY WISE ERROR RATE (FWER) AND FALSE DISCOVERY RATE (FDR) 
When analysing data, results consist of a set of p-values that are calculated probabilities based on 
a null hypothesis. These p-value results will provide a value between 0 and 1 that denote the 
significance of the feature; values closest to 0 are considered very significant results with the most 
common threshold being applied at 0.05, in other words, a 5% chance of false positive result.   
'FDR is the rate that significant features are truly null'[1] 
The FDR is statistical measure that aims to correct or reduce the effects of Type 1 and Type 2 
errors [142]. FWER refers to the probability of making at least one Type 1 error [143]. Type 1 
errors occur when false positive results are present and type 2 errors occur when there are false 
negative results present; in other words, results with no significance are deemed significant and 
results with significance are not considered when they should be. Table 3.6 demonstrates the 
variables considered in FWER and FDR. While FWER refers to the control of V where a test that 
is truly null has been labelled significant, FDR refers to the control of V and T, where V remains 
the same and T refers to tests that reject the null hypothesis but are labelled non-significant. 
TABLE 3.6: TYPE 1 AND TYPE 2 ERRORS DEMONSTRATION 
 Null True (H0) Alternative True (H1) Total 
Declared Significant V S V+S 
Declared Non-significant U T U+T 
Total V + U S+T N 
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p-values produce results based on a false positive rate; however, it has been heavily discredited 
for its lenient measurements which lead to a large number of type 1 errors. There have been 
numerous techniques which attempt to correct the issue by making adjustments to the resulting 
p-values of a given statistical test such as Bonferroni Correction [144], Local False Discovery 
Rate [145] and q-value [51].  
BONFERRONI CORRECTION 
Bonferroni Correction is a technique that adjusts the significance threshold in response to the 
number of features in the test [19]. Therefore, 
1
( ) (1 )
;
nf x
where
n



= −
=
 
EQ. 3-14 
However, this adjustment technique is very conservative; while it corrects for the number of type 
2 errors, it is at a disadvantage to type 1 errors that increase dramatically depending on the number 
of features [146]. While we may be ensuring a reduction in the number of false positive results, 
type 2 errors have also disregarded in X amount of results that contain genuine results and effects 
for the given hypothesis. The Bonferroni method can also extended the Bonferroni inequality, or 
Boole’s law which suggests that the probability of at one event happening is either equal to or 
less than the sum of the probability of the individual events [147]. 
Q VALUE 
The q-values [14] consider the level of uniform distribution in the given set of results to correct 
and adjustment the probability measurements based on threshold, t.  
0
ˆ
( )
areaunder
FDR t
total area

=  
0
ˆ proportionof features that aretruly null =  
EQ. 3-15 
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Threshold  ?̂?𝑜 is demonstrated by the red line in Figure 3-7. This provides a more realistic 
measurement for FDR and as such balancing the potential of type 1 and type 2 errors. In 
comparison, performing 1000 tests using a threshold of 0.05, p-values would yield a likely result 
of approx. 100 false positives. In contrast, q-values would only yield approx. 5% false positive 
from the significant results; so, if 100 significant results were found, the number of likely false 
positive is reduced to 5. With q-values, each estimated q-value is either greater than or equal to 
its actual value; this approach is more conservative (but not overly so) which is desirable when 
choosing features for further analysis [14][148].  
3.2.3.2. POPULATION STRATIFICATION 
Genomic control (GC) is an adjustment method for population stratification that controls for the 
presence of population structure. Population stratification is used to control for the presence of 
systematic difference that exist in a population based on the allele frequencies that suggest there 
exists sub-populations within the cohort [115]. As previously mentioned, the majority of 
association models used within genomic studies use the chi-squared statistical measure to produce 
a p-value measure. GC utilises the chi-squared results (X2) and assumes that a constant inflation 
factor (λ) is in effect across the population, therefore each results is adjusted using [15]; 
2
2 2 2
1 2( , ,..., , )
0.456
L
X
GC
median X X X


=
=
 
EQ. 3-16 
 
 
FIGURE 3-7: REPRESENTATION OF THE Q-VALUE THRESHOLD 
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eq. 3-16 [115] produces the genomic inflation factor, where L represents the number of null 
results. Using the median of L, null X2 feature results to adjust by the expected median that when 
based on 1df is 0.456. This inflation is then used as a constant to adjust the total results. 
One of the visual tools for quality control that is commonly used is Quantile-Quantile plot, or 
more commonly referred to as, Q-Q plot. This visual tool plots the observed values of p against 
the expected values (null hypothesis) where it is expected that no deviation exists toward the left-
side of the plot, while minor deviation exists at the right-side. Genomic control is most notable in 
its adjustment difference when visualised using Q-Q plots, as demonstrated below; 
As can be seen from Figure 3-8, GC adjusts the results so that the deviation from the null 
hypothesis is corrected. 
 
As the demand for genetic material is becoming more prevalent in the field of genomics, with 
larger cohort sizes required for analysis to improve the statistical power of results, this can, and 
normally does, result in anomaly cohort clusters. There are as a result of differences due a number 
of factors, primarily, environmental exposure that can include lifestyle choices, urban or rural 
habitation, weather exposure, etc. This is due to the increasing distance required to obtain subjects 
for studies across multiple sites, states and even countries particularly concerning rare diseases 
and even complex diseases which require larger cohorts to compensate for the vast phenotypic 
differences that can be present. Reliance on control for ancestry alone will not control for sub-
population occurrence therefore GC performs the necessary adjustments to control for this. 
Without Genomic Control  With Genomic Control 
(A)  (B) 
FIGURE 3-8: DEMONSTRATION OF THE EFFECT OF NO GENOMIC CONTROL (A) AS OPPOSED TO USING THE 
CORRECTION METHOD GENOMIC CONTROL (B). 
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3.2.4 ASSOCIATION ANALYSIS SUMMARY 
Association analysis is used to determine a p-value estimate for each feature. However, due to the 
structure of SNPs, the interpretation of these values can be evaluated using a variety of models as 
outlined in section 3.2.1 . 
Apparent in Figure 3-9 is the lack of diversity between the allelic and logistic models, the -log10 
p-values presented in these plots vary slightly however the overall structure of the data remains 
similar among the models. Logistic regression provides a less optimistic results but does not have 
the added advantages of increased statistical power, however, when approaching genetic data as 
a singular process, this method provides the most realistic results. 
 
DOMINANT, RECESSIVE AND GENOTYPIC METHOD DEMONSTRATED IN  
Figure 3-10 present similar results to allelic and logistic with the majority of the structure 
remaining the same, but differences in the p-values show the effect the model choice can make. 
Although all these models produce an estimate based on a different approach, only two of these 
models can utilise genomic control. Genomic Control is standard practice in current genomic 
studies given the increasing cohort sizes that are available and demanded to produce reliable 
results that effectively represent the population. Therefore, there is an increased probability of 
(A) 
 (B) 
FIGURE 3-9: COMPARISON OF GENETIC MODELS (A) ADDITIVE (LOGISTIC) (B) ALLELIC 
57 
 
sub-populations existing with the data; as previously discussed, these sub-populations can present 
themselves due to environmental factors that commonly differ between countries, states and 
classes of individuals. It is not always possible to obtain all data to control for these 
subpopulations, therefore genomic control provides a control estimate for the differences that 
exist in the data. 
 
 
The adopted association model used within this methodology is allelic analysis as it increases 
statistical power over genotypic models [48], this is an important quality that will be beneficial to 
the feature extraction phase. The use of the allelic model, while beneficial, is at the expense of 
analysing the genotypic presence of genotypes, however, throughout the remainder of the 
(A) 
(B) 
(C) 
 
FIGURE 3-10: COMPARISON OF GENETIC MODELS (A) DOMINANT (B) RECESSIVE (C) GENOTYPIC 
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methodology the genotype state is the primary format used to analyse the statistical significance 
of genetic features. 
Within this research, a combination of univariate and multivariate approaches is used within 
stages for feature filtering and analysis. During this research, the use of multiple testing is 
explored, and further demonstration is provided in section 3.2.3 . Genomic control presents a 
particularly advantageous adjustment method that is an accepted standard in current studies in 
order to adjust for the issues that population structure can cause as demonstrated in Figure 3-8. 
Multivariate analysis is a particularly important aspect of this research given that one of the most 
challenging aspect of an epistasis approach is the computational constraints and hardware 
demands. While there are several solutions to epistasis, the restraints prove particularly restrictive. 
To adhere to the requirements of the research, the multivariate analysis considers a limitation in 
hardware specifications with the need for a timely return, preferably using an exhaustive search. 
As previously outlined, the stages of the methodology utilise a combination of univariate and 
multivariate analysis in order to reduce the representative dataset to the most prominent SNPs. 
This leads to an improvement in time performance and increases the selection of software that 
can be considered, particularly concerning limitless-arity choices as this takes into consideration 
the possibility of interactions between SNP that extend beyond a pair-wise nature. To compare 
the multivariate limitless-arity methods, the limitations of the MDR method exist in the 
computation time expense and the continuous iterative process that it demands for more than 2 
SNPs. The limitations of the ARM method exist in the unsupervised approach that takes no 
guidance from the classification labels; this could lead to outlined interactions that are unrelated 
to the phenotype. The limitations of the LAMPlink software exists in the number of SNPs that 
can be input as the computation time expense exponentially increases. Given the above methods 
and their limitations, the choice of multivariate analysis technique that would be best suited to the 
current research is LAMPlink as the limitations of the method are complemented by previous 
stages of using univariate analysis and further to this the implemented ‘itemset mining’, an ARM 
technique, systematically reduces the number of combinations to be tested, overall providing a 
faster option. 
INFERENCE ANALYSIS METHODS 
The analysis of SNPs is an important process that not only aims to analyse and produce an 
estimated measure of associative significance but to also represent that information in an 
interpretable form that can be used to outline relationships and association that exist in real-world 
terms. Through this stage it is appreciated that there are a substantial number of techniques, 
models and approaches to apply to the current data type [149]–[151]. In order to scale the 
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literature to within the scope of our project and in particular for the purposes required the 
following section targets analysis techniques that are used in context of computing the probability 
that a variant and/or combination is truly associated with the phenotype [1] and measure of 
association. Further to this, one of the most demanding requirements in the health field currently, 
with the rise in techniques and technology, is classification, particularly for the inclusion of 
decision support systems (DSS) [152]–[154]. This section outlined methods and techniques for 
the exploration of RO4 and RO5. 
3.3.1 STATISTICAL TECHNIQUES 
Statistical techniques are used throughout genomics, therefore, to reduce the scope of this section, 
the statistical techniques that are considered for this are those that represent the relationship in 
terms of association or the measure of associations. To consider first statistical techniques that 
test for association, the considered techniques are frequently used within the broad term of data 
analysis with confirmed applications in genetic analysis. The second considers the relationship 
that exists and provides a measure for how associated one variable has to another. 
3.3.1.1. TEST OF ASSOCIATION 
Tests of association are commonly conducted using contingency tables, taking a variety of 
approaches in how to analyse the data. This then presents a choice of test depending on how the 
data is represented within each approach. The following tests are standard practice in data analysis 
and are also commonly applied in genomics. 
FISHER’S EXACT TEST 
The Fisher’s exact test is a commonly used tool to assess the statistical significance between 
variants in the capacity of GWAS [103], epistasis [30] and is also adopted as a permutation test 
in standard software for genetic analysis [102]. Fisher’s exact test identifies the exact difference 
between the null and alternative hypothesis [155]. Fisher’s exact test is recommended for sample 
sizes < 1000 while the technique introduced next is recommended for sample sizes > 1000, 
however, fisher’s exact test is applicable in both cases [155]. Refer to Table 3.8 in regard to Eq. 
3.16. 
[ ]![ ]![ ]![ ]!
[ ]! ! ! ! !
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PEARSON’S CHI-SQUARED TEST OF INDEPENDENCE 
The Chi-Squared test (X2) is an approximation method [155]. This technique models and 
measures the departure from independence in a non-parametric test making no assumptions about 
normality or homogeneity of variance [156]. The X2 test is a transparent and interpretable method 
that has previously been used in studies to assess heterogeneity [47] , QC [101], GWAS [51] and 
for statistical association [47]. These tests are noted to have considerable power [157] but they 
are limited given their inability to consider covariates and as such are susceptible to population 
stratification. 
2
2 ( )X i i
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E
−
=  EQ. 3-18 
The main difference that exists between the Fisher’s exact test and X2 test is due to the approaches. 
While fisher’s exact test will give an exact difference between null and alternative hypothesis, the 
X2 will provide an approximation. As only an approximation relies on the assumption that the 
probability of observed binomial frequencies can be approximated by the continuous X2 
distribution, which is not always correct and creates some error. 
 
Under circumstances that it is required, an adaptation of the X2 test is the Yate’s correction for 
continuity [158]. To prevent overestimation of statistical significance when analysis small data 
(cells of contingency table contain small values), Yates’ suggested a -0.5 correction between the 
observed and expected values in the contingency table, therefore reducing the chi-squared value 
and increasing the p-value. 
COCHRAN-ARMITAGE (CA) TREND TEST 
An adaptation of the infamous X2, CA introduces a robust directional adjustment that focuses on 
the suspected result [12] and can be used without the pre-processing of HWE [159].  
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FIGURE 3-11: X2 DISTRIBUTION (2DF) 
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TABLE 3.7: CA EXAMPLE 3X2 CONTINGENCY TABLE 
 NN NM MM Total 
Exposed r0 (p10) r1 (p11) r2 (p12) r (p1.) 
Not Exposed s0 (p20) s1 (p21) s2 (p22) s (p2.) 
Total n0 (p.0) n1 (p.1) n2 (p.2) n (1.0) 
 
referring to Table 3.6, which can be derived as [160]; 
 
1 2 1 2
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with reference to a 2x2 contingency table as provided in Table 3.7. 
The limitations of this method exist in the nature of the approach, as an adaptation that aimed to 
focus on the alternative hypothesis, the test can overlook associations that exist outside of the 
null and alternative hypothesis. 
3.3.1.2. RELATIVE RISK 
Measures of association apply a value to an association which suggests the relationship that exists 
between them e.g. in the presence of genotype A there is 1:1.2 risk that subject A will have the 
disease. The following section explores the common measures of association in genomic studies 
referred to as the relative risk. 
ODDS RATIO (OR) 
The odds ratio is a common method that is widely used across many if not all fields that require 
statistical analysis. It is also a method that is commonly used in genetics [47] to outline the 
measure of association for a variety of conclusions particularly in case-control studies to measure, 
for example, the risk presented for a genotype in a sample population present for a phenotypic 
trait [161]. 
 
odds of disease among exposed (1) / (1 (1))
odds of disease among unexposed (0) / (1 (0))
p p
OR
p p
−
= =
−
 
 
a d
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b c

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  
EQ. 3-21 
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eq. 3-21 shows the equation of the odds ratio in relation to a contingency table, for demonstration 
in Table 3.8. 
 
While the odds ratio is a simple interpretable test that is devoid of bias, there are still limitations 
as with any method. The prevalence ratio is not approximated which can result in misleading 
assumptions of the information [162] and information is hidden when analysing dichotomized 
continuous measure, leading the reduce statistical power and amplification of the measurement 
error [163]. 
RISK RATIO (RR) 
Complementary to odds ratio, the risk ratio provides the multiple of risk of the outcome in one 
group compared to another[164]. This is in contrast to odds ratio that provides an estimate of the 
odds of disease between exposed and non-exposed individuals which can yield much higher 
values that the risk ratio e.g. in cases with an incidence rate of 20%, an OR of 10 corresponds to 
a RR of <4 [163].  
 
/
/
prevalence a a b
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incidence c c d
+
= =
+
 EQ. 3-22 
In reference to case-control studies, the incidence rate is not measurable given that the study is 
split (normally evenly) into exposed and unexposed individuals, however the OR can be 
transformed into RR. 
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3.3.2 CLASSIFICATION TECHNIQUES 
Classification techniques are advancing as more data becomes available and more focus is drawn 
to these methods. Machine learning is a technique that uses algorithms and statistical techniques 
to produce a model which can 'learn' information about a given set of data to provide us with the 
resulting correlations (or otherwise)[165]. ML can be used in a variety of capacities including for 
feature selection, extraction, classification and regression [166]. There are several methods of 
machine learning which can be applied to various types of data, however choosing the correct ML 
TABLE 3.8: OR EXAMPLE 2X2 CONTINGENCY TABLE 
 Case Control 
Exposed a b 
Not Exposed c d 
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method is key to discovering valuable information from the given data. There are a number of 
desired outcome features that are normally used to select the most appropriate Machine Learning 
method; classification and regression provide a focus for machine learning methods for 
classifying data etc. In terms of machine learning methods, there are two main areas which are 
supervised and unsupervised learning. 
3.3.2.1. SUPERVISED LEARNING 
Supervised Learning uses previous information, demonstration or what would primarily be 
training data to produce a basic framework which can be used in a number of circumstances: 
Classification and Regression [167]. This type of learning can be explained using a simple 
example: 
A child is given a pile of sweets and is told to identify the different classes; either chocolate or 
gummy. The child will firstly take a selection of the sweets and eat them to find out whether or 
not they are chocolate or gummy. Based on their physical appearance and the previous knowledge 
of which appearance corresponds to which class of sweet they will then divide them between the 
two classes.  
3.3.2.2. UNSUPERVISED LEARNING 
Unsupervised Learning does not use any previous information to produce a framework of 
information. In cases where unsupervised learning is used, the researcher will likely be looking 
for patterns of information in the data that are not lead by any given classification bias [168][169]. 
An example of unsupervised learning: 
A museum would like to introduce events on different floors of the museum. They would however 
like to address their target audience. The museum has collected a list of attendants to the museum 
with a large amount of variable data e.g. age, sex, group attendance (e.g. family, couple), exhibits 
visited, exhibits enjoyed, clothing worn, hair colour, eye colour, gift shop purchases, etc. Using 
this data, they want to identify if there is a pattern among the visitations of the varying types of 
people.  
Associations will be drawn from the data which could either lead to successful or unsuccessful 
decisions of events on the each of the floors. The data could produce an association that families 
that are attending are more likely to both visit and enjoy the insect and bug section of the museum 
which could indicate an event associated with this exhibit advertised towards children could 
produce increased attendance. However, an association could also be made between the dinosaur 
exhibit and people with blue eyes; a dinosaur event advertised towards people with blue is less 
likely to be a success. This method produces results free of any bias; however, they can also result 
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in a lot of false positive results. Unsupervised learning can be detrimental to the findings of 
genetic association studies as with such a large dataset with a large set of features there are bound 
to be false positive associations frequently[170]. The following methods use different techniques 
to apply ML analysis which include feed-forward, back-propagation, cost/loss functions, risk 
minimisation, feature selection etc. These methods will address classification of case/ control 
subject data to produce a best accuracy estimation based on the given features in the data.  
3.3.2.3. DECISION TREES 
Tree methods can be applied to both classification and regression-based problems. Most if not all 
decision tree models derive from logic and statistics and generally provide interpretable models 
for inductive reasoning using supervised learning. 
 
The Random Forests (RF) algorithm [171], or Random Decision Forest, works as a large 
collection of de-correlated trees. It is an ensemble approach and a type of ‘bagging’ technique. 
An ensemble approach combines a group of ‘weak learners’ to produce a ‘strong learner’; the 
effect of this aims to improve performance by reducing noise in the set. Bagging techniques 
normally have low variance, and therefore, as previously noted, are less prone to influence of 
‘noise’. The RF method starts with the initial tree, 𝑆, which is the randomly split into several 
subsets of the tree, 𝑆1, 𝑆2  ⋯ 𝑆𝑛, including feature 𝐴𝑛 ⋯ 𝑛𝑛, depending on the number of features 
in the given set, as demonstrated in (10). From here the RF classifier uses the results from each 
of the subset trees, acting a ‘voting system’ to give an overall predictive estimate of the results. 
Chi-Squared Automatic Interaction Detection (CHAID) is one of the most popular statistical 
decision tree methods. It is a multivariable algorithm, based on Pearson’s Chi-square statistic that 
identifies the strongest interaction association to the dependent variable (Phenotype). The 
dependent variable of a CHAID tree is required to be categorical but the independent variable can 
be categorical or metric data types [172]. The rules are generated using X2 test for categorical 
 
FIGURE 3-12: REPRESENTATION OF DECISION TREES 
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variables and F-test statistics for continuous variables and Bonferroni is used to adjust the p-value. 
CHAID is suited for large datasets and commonly used in marketing. 
Classification and Regression Trees (CART) is a technique very similar to CHAID with the 
main difference being that CART use binary splits, while CHAID uses multiway splits. While 
there has been some discussion around the area, authors of the CART method argue that the binary 
split are preferred as they improve predictive performance [173]. This predictive performance 
however may be at the cost of ease in interpretability as trees can grow large with predictors used 
many times.  
3.3.2.4. NEURAL NETWORKS 
Neural Networks encompass a collection of algorithms that base their systems on biologically 
inspired networks, in particular, the brain. It is composed of a large network of interconnecting 
edges that work together to produce a response from input variables. This can be used for 
classification or regression. 
 
Multi-layer Perceptron (MLPs) is a type of Neural Network which is based on the biological 
axons of the brain. If we consider a single Perceptron, we can use this to model linearly separable 
problems; this occurs when data can be separated by one single threshold or a line if we consider 
a graph. However, a lot of problems are not linearly separable, as is the case with the current 
study; in these cases, Multi-layered Perceptron model can be used which builds numerous 
Perceptrons to classify and interpret inputted data that could not be processed by a single neuro. 
Stacked Autoencoder (SAE) is a deep learning method that builds upon the standard neural 
network framework to produce a larger system to analyse complex data structures. SAE builds 
itself using a series of Autoencoders that are simplified versions of an MLP, one hidden layer and 
one output layer, that have an equal number of output layers to input layers. Each hidden layer of 
the autoencoder, ‘encodes’ the information and forms the input layer of the consecutive 
autoencoder to build the stacked autoencoders.  The purpose of this model is to ‘recreate’ the 
 
FIGURE 3-13: REPRESENTATION OF A NEURAL NETWORK 
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information from the input layer in the output layer using compressed values as the hidden layer 
will force this when smaller [174]. While stacked autoencoders have predominantly focused 
efforts in the area of market basket analysis, its uses have recently been extended to pattern 
recognition for epistasis [175]. 
3.3.2.5. SUPPORT VECTOR MACHINES (SVM) 
SVM’s are a firm favourite in the machine learning community and while this category stems 
from one main algorithm, the adaptations that have been developed categorise and extenuate its 
uses beyond linearly separable data structures.  
 
Linear SVM’s consider data structures with a linear approach. The aim to find the ‘maximum 
margin hyperplane’, that is using two hyperplanes to bound the categories or clustered regions 
with the largest distance between them, the maximum margin hyperplane then lie halfway 
between them as demonstrated in Figure 3-14. If the input data is linearly separable, a ‘hard 
margin’ will be used that supports the hyperplanes based on the most outer coordinates which 
then determine the margin hyperplane that differentiates the two. If the input is not linearly 
separable due to outliers, then Linear SVM’s can still be used, the hyperplanes will allow for 
some noise, but this will come at a cost for misclassification.  
(a) (b) 
FIGURE 3-14: VISUALISATION OF LINEAR SVM (A) HARD MARGIN (B) SOFT MARGIN 
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Non-linear SVM’s considers data structures that not linearly separable, in this instant they will 
use a ‘kernel trick’ that will use a small dimensional space and transform it into a large to infinite 
dimensional space using a function called a ‘kernel’. There are a few kernels that can be used 
including linear, polynomial linear, radial based function that use varying functions to instantiate 
the process. 
SVM’s are strong candidates in many complex problems concerning data classification and 
regression due to their flexibility towards a variety of data structures. Further to this, it holds a 
particular advantage when the researcher is unaware of the data structure. However, SVM’s are 
mathematically complex and computationally expensive [176], which is a limitation in small 
dimensional data.  
3.3.3 INFERENCE METHODS SUMMARY 
Inference methods are split into two categories, the statistical and classification approaches. To 
assess the inference methods, there are number of criteria that need to be fulfilled; the test of 
association, measure of association and classification. The techniques outlined for test of 
association are standard techniques that are widely used in not only the genomics field but overall 
in data analysis; the limitations of these methods present a minor challenge that by using multiple, 
verification is introduced with a variety of approaches. The choice of methods is chi-squared and 
fisher's exact test, both of these methods are standard, and it is expected that they should reach 
similar conclusions to significance of association, under circumstances where they are not, further 
investigation can be flagged. Additionally, the use of Yate's continuity correction will be adopted 
for tests of association that require it combat the issues that can be apparent in Chi-Squared. The 
exclusion of CA trend test is due to the specific nature of focusing on the alternative hypothesis, 
the benefits of this technique can be recreated in a similar fashion with the chosen techniques. 
 
FIGURE 3-15: VISUALISATION OF NON-LINEAR SVM 
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Measure of association provides a value to indicate the relevance of the relationship. Outlined are 
two methods that represent this information however only one method can be use under the study 
design. The OR is a standard method that is again widely applied across all areas of data analysis, 
however its disadvantages in this field are due to misinterpretation. The RR technique addresses 
this but cannot be directly calculated from case-control data but can be calculated from the OR, 
therefore in order to provide a measure that better represents the information, the RR is also 
adopted. 
Classification of data is a wide field that is continually receiving updates, adaptations and new 
methods and techniques to perform the analysis. Each method uses its own approach to data; 
previously discussed are some of the most prominent categories of machine learning. Previously 
outlined was the critical factor of interpretability, previous methods demonstrate this factor, but 
it becomes a defining factor in classification. Neural network and SVM methods are strong 
candidates in classification due to their successes when being applied to many different data types. 
While the successes of these methods are well documented, the interpretability is lacking, the 
advantages of interpretation lie in the ability to outline areas of adjustment, correction and interest 
that cannot be identified through the output of a model. Therefore, the most interpretable approach 
is decision trees, such as CHAID and CART. As the most interpretable methods outlined, the 
differences between these two define their approach. CHAID method uses multi-split chi-squared 
technique while CART uses binary splits that can obstruct the interpretation by outputting large 
trees that can be difficult to navigate and outlined areas of interest. 
The methods and techniques outlined in this section encompass the 'belly' of the methodology and 
are chosen in response to the study design and a crucial factor of interpretability. The next section 
summarises the findings of this chapter. 
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DISCUSSION 
Within this chapter, various methods and techniques have been discussed that service and analyse 
the dataset to improve and gain insight from the information available. Chosen quality control 
procedures are chosen in response to the study design and perform a necessary service that 
improve the representation of the dataset by removing bias and erroneous data. 
Univariate association analysis again introduces a variety of approaches to genetic data that 
concern the transformation and processing of the data taking into consideration the specific 
relevance of genetic information in the form of allelic and genotypic formats. An allelic model 
has been outlined as the model of choice given the increase in statistical power. Multivariate 
analysis outlined the choice of software LAMPlink that complements the study design and also 
incorporates techniques that address the main concern of multivariate analysis in the context of 
genomics, computational complexity. 
While each method has its advantages, there are always limitations. Previously discussed are the 
limitations of GWAS due to the large feature set used in analysis; this opens up the method to 
issue of False Discovery Rate which incorporates False Positives and Negatives. In order to 
combat this, there are a number of techniques that can be used. A specialised technique for 
genomics is genomic control, this specifically controls for population structure in the dataset 
which is addressed during the association analysis to reduce inflated values as a result of existing 
population structure. Further to this, to address value inflation due to large feature sets, a common 
approach is to use multiple testing techniques.  
Within this research, one of the issues that is prevalent is the use multiple testing; this is applicable 
once the association analysis has been performed to adjust the values to provide a realistic 
representation of the information. While many techniques have been introduced that range from 
lenient to conservative, a concern of this thesis is the adjustment of these values after they have 
already inflated. The concept of probability suggests that out of the features analysed there is 
likely to be at least 1 false positive, and in the size of data used in genomics, this is likely to be 
far more. Therefore, adjusting the values will control for inflation of features that represent their 
true significance to the phenotype, while features that are inflated due to a biased representation 
of the data will retain significance. Therefore, the problem needs to be addressed before the 
association analysis is conducted to reduce the presence of these biased features. This is discussed 
further in section 3.2.3 . 
Inference methods are used to provide an evaluation of the relationships and significant of features 
within the given sample population. Previously discussed is the importance of interpretability 
which has influenced the choice of techniques and methods in this section. Multiple methods are 
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chosen for test of association and measure of association in order to validate, verify and improve 
representation of the information. Chi-Squared and Fishers' exact approach data analysis from 
different perspectives, this can lead to a small margin of error that can skew the results and 
therefore by using both, they can verify the result of the other. Further to this, the choice of OR 
and RR will lead to better interpretation of the resulting information. Defined previously are 
classification methods, the use of these methods is aimed at statistical feature selection by 
outlining best performing combinations of features. As a result, the most qualified methods that 
also adheres to the interpretability requirement are decision trees, in particular, the CHAID 
analysis, explained in section 5.6 . 
These outlined methods are the working engine of the proposed methodology and as such are 
important considerations to a successful application. The complexity of genomic data and the 
transformations required to better represent the data based on the techniques being used can lead 
to some confusion. To better understand and describe this, the next chapter will discuss the 
representation of the data and to describe the dataset used to evaluate the method. 
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Chapter 4: DATA DESCRIPTION 
Due to the complexity of genetic data, there are many representations and transformations that 
can be used to approach the data based on different hypothesis e.g. the presence of a recessive 
allele will increase the risk of the variant. Further to this, in order to represent the varying 
approaches, the data can be transformed in a variety of ways; this is further explained during this 
chapter. This chapter is provided for use as a reference going forward to the next chapters. This 
chapter contains descriptions and examples of the data based on genetic form and representation 
during analysis. This includes the genetic representation, binary transformation and the format of 
the PLINK input data that are used to perform the association analysis. Additionally, during this 
chapter the DRIVE dataset for breast cancer subjects is outlined and described including 
characteristics of the data and the available information. 
GAME-ON: DRIVE: DATA DESCRIPTION 
Subject genotypes were attained from repository platform, Database of Genotypes and 
Phenotypes (DBGaP). Data was collected under the Genetic Associations and Mechanisms in 
Oncology (GAME-ON) initiative that funded 5 projects, one of which was the Discovery, 
Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) [11] project that focused its 
efforts in breast cancer for the systematic discovery and replication of additional common genetic 
variants. These variants were assessed for their biological significance and from this, developed 
evidence-based assessments of the clinical validity of prediction algorithms in practice. 
Genotyping was conducted by the Center for Inherited Disease Research (CIDR), Centre for 
Cancer Genetic Epidemiology, University of Cambridge, and the National Cancer Institute. The 
following studies contributed germline DNA from breast cancer cases and controls:  
Study Inc. Ref 
Breast Oncology Galicia Network (BREOGAN)  [177] 
Cancer Prevention Study 2 (CPSII) X [178] 
Copenhagen General Population Study (CGPS) X [179] 
Melbourne Collaborative Cohort Study (MCCS) X [180] 
Multiethnic Cohort (MEC) X [181] 
Nashville Breast Health Study (NBHS)  [182] 
Nurses Health Study (NHS) X [183] 
Nurses Health Study 2 (NHS2) X [183] 
Polish Breast Cancer Study (PBCS)  [184] 
Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO)  [185] 
Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH)  [186] 
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Swedish Mammographic Cohort (SMC)  [187] 
The European Prospective Investigation into Cancer and Nutrition (EPIC)  [188] 
The Sister Study (SISTER)  [189] 
The Two Sister Study (2SISTER)  [189] 
Women's Health Initiative (WHI) X [190] 
Women of African Ancestry Breast Cancer Study (WAABCS)  -- 
 
After quality control was conducted, genotype information remained from 7 combined studies, 
more information is provided below for each: 
Cancer Prevention Study 2 (CPSII): The Cancer Prevention Study II (CPS-II) is a 
prospective mortality study of approximately 1.2 million American men and women [178]. 
Copenhagen General Population Study (CGPS): Initiated in 2003, participants from 
Copenhagen were randomly invited using the Danish Civil Registration System. Participants 
completed a questionnaire, a physical examination and provide blood samples for DNA 
extraction. Statistical analyses of cancer risk were determined from the Danish Civil Registration 
System. All participants gave written informed consent. The study was approved by the Herlev 
and Gentofte Hospital and by a Danish ethical committee (H-KF-01-144/01) and was conducted 
according to the Declaration of Helsinki. Since 1987, is has been compulsory for all physicians 
by law to register cancer diagnoses in Denmark in the national Danish Cancer Registry which 
records approximately 98% of all cancers in Denmark [190]. Diagnoses of invasive cancer were 
made using the seventh or tenth editions of the WHO International Classification of Diseases 
[191]. 
Melbourne Collaborative Cohort Study (MCCS): A cohort of 41,500 subjects were 
collected between 1990 and 1994, aged 40-69. Cases of cancer were identified by matching to 
cancer registries and death indices [192]. 
Multiethnic Cohort (MEC): The Multiethnic Cohort Study of Diet and Cancer (MEC) was 
funded by the National Cancer Institute (NCI) in 1993. The cohort is comprised of more than 
215,000 men and women primarily of African American, Japanese, Latino, Native Hawaiian and 
Caucasian origin. The study focused on examining lifestyle risk factors, including genetic 
susceptibility in relation to causation of cancer. Each member completed a 26-page questionnaire 
as well as biological specimens (blood or urine). Cancer status was confirmed using cancer 
registries established by state statute in Hawai`i and California [181].  
Nurses Health Study (NHS): The Nurses' Health Study (NHS) was established in 1976. The 
focus of this study was to investigate the potential long-term consequences of oral contraceptives. 
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Nurses were used for subjects given their knowledge about public health assuming their ability to 
provide complete and accurate information regarding diseases. The study was carried out across 
the following states of USA: California, Connecticut, Florida, Maryland, Massachusetts, 
Michigan, New Jersey, New York, Ohio, Pennsylvania, and Texas. Biological specimens 
consisted of blood and urine samples. [183] 
Nurses Health Study 2 (NHS2): Established in 1989, a continuation from the previous study 
to included younger nurses that has started using oral contraceptives during adolescence (a 
maximal exposure during early reproductive life). The study was carried out in the following 
states: California, Connecticut, Indiana, Iowa, Kentucky, Massachusetts, Michigan, Missouri, 
New York, North Carolina, Ohio, Pennsylvania, South Carolina, and Texas. Biological specimens 
consisted of blood and urine samples. [183] 
Women's Health Initiative (WHI): The WHI entered postmenopausal women into four 
clinical trials (n = 68 132) and an observational study (n = 93 176) at 40 US clinical centers. 
Participants were aged between 50 and 79 years and had anticipated 3-year survival. Exclusion 
criteria of prior hysterectomy or breast cancer. Participants were required to have a mammogram 
not suspicious for breast cancer less than 2 years before entry was required and should also be 
taking oestrogen plus progesterone or no hormone therapy [190]. 
The genotype sequencing chip used to sequence the data for the subjects from the above studies 
was the OncoArray Illumina Chip that was designed with a GWAS backbone of ~250K SNPs for 
the Illumina HumanCore, with a total of ~533K. The remaining SNPs outside of the GWAS 
backbone were focused on variant findings and pathways indicated for the 5 most prominent 
cancers; breast, ovarian, prostate, colon and lung [193]. 
Table 4.3 provides demographic information regarding the country in which the study was 
conducted. Further information regarding demographic information in regards to the final set of 
participants used and clinical information pertaining to the dataset acquired is available in Table 
4.1 and Table 4.2.  
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With Breast Cancer incidence rates primarily effecting the female population, the study cohort is 
made up entirely of female participants (n = 28,281). Of these participants 14,435 subjects were 
cases and 13,846 were controls. Age ranged from 20 to 98 (µ = 63) based on a sample of 27,585 
with age ranging from 20 to 92 (µ = 65). Estrogen Receptor Status has not been utilised in this 
study (See 2.3.1.4. for more information on Oestrogen Receptors). Cases were split into 3 
histology types, invasive (12,412), in-situ (1,506) and unknown (517) of which, individuals of 
interest in this research are invasive histology type. Invasive breast cancer status regards cancer 
cells that have at least ‘spread’ to the surrounding breast tissue. 
TABLE 4.1: CLINICAL VARIABLES AVAILABLE WITH THE DATASET 
Variable Variable Description 
Subject ID Unique identification number for each individual 
Study Name Acronym identifier for study 
Study Country  Country of the study 
Status  Case-Control category 
Sex Gender of Participant 
Age Age at Interview 
Age of Diagnosis Age at Diagnosis 
ER Status Estrogen Receptor status of tumour 
ER Status Source Source of ER Status 
Sex by Genotype Identified sex by genotype 
 
TABLE 4.2: ADDITIONAL EXCLUSION CRITERIA 
Exclusion Criteria Reason 
Individuals with AA ancestry To reduce population structure bias 
Individuals aged <40  To remove early onset breast cancer 
Individuals without category 
invasive breast cancer 
To include only individuals with confirmed 
breast cancer status 
 
TABLE 4.3: DEMOGRAPHIC FEATURES BY STUDY 
    Australia Cameroon Denmark Nigeria Uganda USA 
CGPS - - 2140 - - - 
CPSII - - - - - 6103 
MCCS 1693 - - - - - 
MEC - - - - - 1169 
NHS - - - - - 3404 
NHS2 - - - - - 3525 
WAABCS - 125 - 442 62 - 
WHI - - - - - 9618 
 
TABLE 4.4: OESTROGEN RECEPTOR (ER) STATUS BY STUDY (EXCLUDING CONTROLS) 
                   Negative ER Positive ER 
  CGPS 172 1029 
  CPSII 102 2044 
  MCCS 189 662 
  MEC 24 483 
  NHS 205 935 
  NHS2 225 1063 
  WAABCS 63 21 
  WHI 670 3918 
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DATA REPRESENTATION 
The following section outlines the representation of genetic data and the binary transformations 
used having converted information into a format for statistical manipulation. Firstly, consider the 
structure of bi-allelic SNPs that are used within this study; these SNPs can either be represented 
as alleles, their primary format, or genotypes, the combined state of the alleles, as presented in 
Table 4.5 and Table 4.6. 
 
Further to this, SNPs also contain dominant and recessive alleles, or can also be commonly 
referred to as major and minor alleles, respectively, as represented in Table 4.7. This describes 
the genotypic expression found within the focus population; therefore, a dominant or major allele 
will describe an allele that is present in the majority of the population. However, it should be 
noted that while the dominant allele will commonly be expressed in the majority of the population, 
the main purpose of this term is to describe the effect that the allele has on the phenotypic 
expression. A dominant allele will generally mask the contribution of the recessive allele. 
 
Combined these alleles form one of three genotype states as demonstrated in Table 4.6, that can 
also be described in terms of a noted state as represented in Table 4.8 
• When both alleles are dominant (AA), this is referred to as dominant homozygous,  
• When both alleles are recessive (aa), this is referred to as homozygous recessive.  
• In the case, allele 1 is dominant and allele 2 is recessive (Aa), this is referred to as 
heterozygous  
 
These states and terms are used throughout the remainder of the methodology. 
TABLE 4.5: ALLELE REPRESENTATION 
SNP X 
Allele 1 Allele 2 
 
TABLE 4.6: GENOTYPE REPRESENTATION 
SNP X 
AA Aa aa 
 
TABLE 4.7: DOMINANT AND RECESSIVE ALLELE REPRESENTATION 
SNP X 
Allele 1 Allele 2 
Dominant Recessive Dominant Recessive 
A a A a 
 
TABLE 4.8: HOMOZYGOUS AND HETEROZYGOUS GENOTYPE REPRESENTATION 
SNP X 
Dominant Homozygous Heterozygous Recessive Homozygous 
AA Aa aa 
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BINARY TRANSFORMATION 
When transforming data to a binary or ordinal state, we take the approach that a recessive allele 
presents as the risk allele and therefore each additional recessive is additional risk. The following 
tables show the numerical representation of genotypic states in regard to the varying models that 
are commonly adopted in genetic studies, and further to this, are used throughout the proposed 
methodology. 
Table 4.9 assumes that in the presence of 1 recessive allele, the risk increase 1-fold as is 
represented in a Heterozygous state (Aa). Further to this, a genotype state with a presence of 2 
recessive allele, Homozygous Recessive state, the risk increases 2-fold. 
 
Table 4.10 presents the assumption that any presence of a recessive allele will increase the risk 
1-fold which also results in Heterozygous and Homozygous Recessives states being combined 
when conducting analysis such as permutation tests. 
 
Table 4.11 presents the assumption that only state, Homozygous Recessive which contains 2 
recessive alleles, results in a 1-fold risk. Similar to the dominant model, the recessive model 
will normally combine Homozygous Dominant and Heterozygous states in analysis such as 
permutation tests. 
 
Lastly, Table 4.12 presents the allelic model that considers the genetic information in an allelic 
state rather than genotypic as can be observed from the difference in representation between 
Table 4.5 and Table 4.6. For this model, the assumption presents a binary transformation 
between dominant and recessive allele states, similar to previous models, the recessive allele 
will be regarded as the risk allele and therefore will be assigned as 1. 
TABLE 4.9: ADDITIVE MODEL CODE REPRESENTATION 
AA Aa aa 
0 1 2 
 
TABLE 4.10: DOMINANT MODEL CODE REPRESENTATION 
AA Aa aa 
0 1 1 
 
TABLE 4.11: RECESSIVE MODEL CODE REPRESENTATION 
AA Aa aa 
0 0 1 
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The above models do not encompass all of the utilised genetic models in the literature but do 
represent the models that are adopted throughout the methodology. For further information 
regarding other genetic models, see 3.2.1  
PLINK DATA FORMAT 
The following section provides representation of the PLINK binary files that are input into PLINK 
to perform statistical analysis. There are 3 files associated with a cohort set: .bim, .bed, .fam. The 
.fam file provides information about subject characteristics and identity codes as presented in 
Table 4.14 and Table 4.13. 
 
 
The .bim file provide information about SNP characteristics that are used to consider the location, 
assigned reference/ name of the SNP and allele representation. 
TABLE 4.12: ALLELIC MODEL CODE REPRESENTATION 
Allele 1 Allele 2 
A a A a 
0 1 0 1 
 
TABLE 4.13: FORMAT DESCRIPTION OF .FAM FILE 
Column Name Description 
IID  Individual ID 
FID Family ID indicates if individual belongs to a family set. 
PID Paternal ID indicates the IID of the individual’s father. 
MID Maternal ID indicates the IID of the individual’s mother. 
SEX The recorded sex of the individual  
(1=male, 2=female) 
Phenotype The case status of the individual  
(-9/0 = missing, 1= unaffected, 2 = affected) 
 
TABLE 4.14: FORMAT OF .FAM FILE 
IID FID PID MID Sex Phenotype 
Sub123 Fam01 Sub124 Sub125 2 2 
Sub124 Fam01 0 0 1 1 
Sub125 Fam01 0 0 2 2 
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The .bed file is represented in machine language that unfriendly for readability in humans but 
contains a readable format of 8-bit codes that correspond to genotype code, further to this it also 
maps the information between the .fam and .bim files. 
 
DISCUSSION 
During this chapter, data representations and transformations were described for reference in 
further chapters when analysing data due to the complex variation of data hypothesis. Further to 
this, the breast cancer DRIVE dataset was discussed outlined ~28K subjects for analysis from a 
multitude of originating countries, and a wide range of age. Already discussed are some exclusion 
criteria including age < 40 and individuals of African American ancestry. At this point, the focus 
of the analysis is not considering the tumour histology in order to retain a larger subject sample 
size. Also outlined, the criteria of invasive breast cancer histology; participants that have 
confirmed cancers cells that have spread to the surrounding breast tissue. This ensures that the 
patients are under the influence of a developed cancer that is more likely to show a genetic link. 
The next chapter introduces the proposed methodology, describing the steps of the process as well 
as indicating the reasons for each decision. 
  
TABLE 4.15: FORMAT DESCRIPTION OF .BIM FILE 
Column Name Description 
Chrom  Chromosome of marker 
Var ID Variant ID 
Pos Position in morgans or centimorgans 
BP Base-pair coordinate (Refer to 2.1.1  
Allele 1 Corresponding to clear bits in .bed; usually minor 
Allele 2 Corresponding to set bits in .bed; usually major 
 
TABLE 4.16: FORMAT OF .BIM FILE 
Chrom Var ID Pos BP Allele 1 Allele 2 
2 rs1045485 0 202149589 A G 
13 rs1799944 0 32911463 C T 
17 rs28897696 0 41215920 G A 
 
TABLE 4.17: FORMAT DESCRIPTION OF GENOTYPE DATA IN .BED FILE 
Genotype Code Description 
00 Homozygous for first allele 
01 Missing genotype 
10 Heterozygous 
11 Homozygous for second allele 
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Chapter 5: PROPOSED METHODOLOGY: RASAR 
Random Sampling Regularisation (RaSaR) is a proposed methodology that aims to improve 
selection criterion for epistasis, reduce false discovery and cater for non-intensive computational 
requirements by prefiltering features using regularisation (See 5.4 ). The following selection 
outlines the stages of the methodology and explains the processes involved, the reason for their 
selection, how they benefit the method and what input and output is provided for each stage.  
Cascading processes rely on information from the previous process in order to perform their 
function, therefore introducing the first stage, Quality Control that prepares the data for further 
analysis to remove bias and erroneous data. Cohort Extraction and Association analysis provide 
the details for the main deviation of this methodology from standard case-control. Feature 
selection introduces the threshold choice and the regularisation technique that presents a main 
part in false positive reduction objective (RO2). for this research and explains how the success of 
the previous stages is presented in this stage. Having prepared and selected the most promising 
features according to this methodology, the epistasis stage will outline relationships that pass a 
significance threshold. Finally, inference analysis will expand, analyse and represent the 
information to infer the relationships that exist in the outlined combination within this sample 
population. To demonstrate the methodology Figure 5-1 provides a visualisation that 
encompasses the stages of the methodology and shows the transfer of data and information during 
the process.
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FIGURE 5-1: VISUALISATION OF THE PROPOSED METHODOLOGY 
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STAGE 1: QUALITY CONTROL (QC) 
QC is a pre-processing stage to remove erroneous data and information that may cause bias in the study. 
This stage is standard practice in the genomic research and can vary among studies. The proposed 
methodology adheres to standard practices in GWAS [115][93][97]; adopted in many studies [136][52] 
employing standard processes; ancestry divergence, sex inconsistencies, heterozygosity, relatedness and 
duplicates in subjects, LD pruning and common threshold measures, MAF, GENO, MIND and HWE. 
Conservative threshold measures are applied to create a reliable dataset that is devoid of missing values 
and information that could cause errors later.  
 
 
The processes in Table 5.1 vary in threshold leniency in order to accommodate for the epistasis 
approach. While sex inconsistencies along with relatedness and duplicates in subjects adheres to the 
standard thresholds, the remaining processes are variable and should respond to data structure and study 
design. Heterozygosity is commonly confirmed based on visual and/or statistical output; for this 
particular threshold, the measure was based on the observed structure to streamline results, refer to 6.1 
for further evidence. Similarly, ancestry divergence is based on the visual representation and thresholds 
are decided in response to this, refer to 6.1 for further evidence. LD pruning was processed using a 
lenient threshold in order to retain a representative SNP dataset while removing features to reduce noise. 
Threshold specified for MAF is lenient given that only 1% of minor alleles need to be present to retain 
the feature; this decision was in response to the study design, as these processes will be dependents for 
an Epistasis approach both common and rare alleles could present as interactions. Further to this, the 
remainder of the threshold measure are based on standard practice methods [93].  For more information 
regarding the processes involved in the QC stages, refer to section 3.1 . 
 
TABLE 5.1: QUALITY CONTROL PROCESS THRESHOLDS 
Process Threshold 
Ancestry Divergence 0.6  
Sex Inconsistencies 0.2 < x > 0.8 
Heterozygosity ?̅? + 2σ  
Relatedness and duplicates in subjects x < 0.125 
LD Pruning x < 0.8 
MAF x > 1% 
GENO x > 99% 
MIND x < 1% 
HWE x < 1 x 10-4 
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STAGE 2: RANDOM COHORT SAMPLING 
To respond to the common issues that are present in GWAS, the cohort extraction is a preliminary stage 
in RaSaR to extract random cohorts of individuals that can represent a real-world sample cohort for 
analysis. Using this method, the data is prepared to explore in later stages if a constant effect is common 
across significant SNPs (which it should be if it is truly associated). Further to this, the effect of 
population structure is evident in many studies; this is a difficult problem to solve unless the study data 
has been obtained from a purpose-built clinical study. Therefore, the randomisation of the data can 
disperse the effect of the population structure among the cohort to reduce the effects.  
Having performed QC, excluding any outlier subjects and/or SNPs, in a standard GWAS the remaining 
subjects are used to perform an association analysis to provide a resulting set of SNPs with their 
corresponding p-values to indicate the probability of significance to the phenotype. However, in order 
to consider the varying presence of the SNPs across clusters of individuals, the following step produces 
sets of subjects that consider both the potential effects of separating the cohort and randomising the 
subjects within. 
The first stage is to randomise the subjects by phenotype status and split the dataset into n sections 
depending on the number of desired folds used to perform the analysis, i.e. n = 3. The training cohort is 
split into 3 subsets of randomised individuals with proportionate levels of cases and controls. This is 
then repeated 2 more times, resulting in a total of 9 subsets of which all derive from the original training 
cohort but contain varied subjects for further analysis in the next stage. By varying to subjects randomly, 
the probability of obtaining a false positive across all subsets of the training cohort is dramatically 
reduced. 
 
 
FIGURE 5-2: REPRESENTATION OF RANDOM COHORT SAMPLING 
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This stage introduces the initial deviation from the standard methods employed in GWAS. Standard 
methods input the full set of observations and features into association analysis to evaluate the 
probability of significance between feature X and response Y; however even in large datasets, bias is 
likely to occur given the size of the feature set. Some GWAS are utilising multiple datasets to validate 
results however this can cause additional problems such as differences in population structure 
established in the initial study as well as difficulty in attaining a further dataset particularly for disease 
or disorders that are difficult to genotype large cohorts in case status. Therefore, this stage produces 
cohort sets for a method that in inspired by the ‘weak learners to strong learners’ [166] approach as seen 
in machine learning algorithms such as Random Forests. The main purpose of this approach is to use a 
number of weak models to produce a strong model using a ‘voting system’. To elaborate further, 9 p-
values produced for one feature will dramatically reduce the chances of producing false positives as all 
cohorts must be constructed in such a way that by chance a bias has occurred in each sample, while not 
impossible, it significantly reduces the probability. During this stage, a sample size is defined depending 
on the size of the dataset and the number of folds being analysed. From here, the phenotype is 
established, and random permutations are used to generate cohorts of the size defined which adhere and 
retain the phenotype distribution. 
STAGE 3: ASSOCIATION ANALYSIS 
Association analysis models vary in the outcome information, this puts importance on choosing the most 
appropriate model for the approach. As further analysis is used to investigate the information beyond 
this point, there is affordance to use the allelic model analysis and gain the benefits of the increased 
statistical power. During this stage, multiple testing is not utilised but will be addressed in later stages, 
however genomic control is used to control for population structure. 
STAGE 4: FEATURE SELECTION 
This stage uses the results of the association analysis to produce a subset of features that show significant 
association to the given phenotype. The results from the association analysis are combined to produce a 
mean GC-value and the corresponding standard deviation which will provide information as to how 
much the value is shifting across the subset cohorts. This will provide information as to whether the 
SNP is consistently associated with the phenotype or is falsely associated with a sample of subjects. 
Continuously mentioned in literature, is the ‘statistical power’ of a study, within genomic studies it is 
generally accepted that the bigger the cohort the less likely a SNP will show false associations; this is 
due to the normalisation of data with the addition of more observations.  While this is true, consider that 
the number of features that are tested during genomic studies is large and as a result the likelihood of 
producing a false positive is also increased. By splitting the cohorts into n*n sections, our sample size 
is improved by n times.  
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Having produced the mean GC-value and associated standard deviation, σ, between all subsets of the 
cohort, a cut-off point is applied. Depending on the desired outcome, a conservative threshold can be 
applied which will indicate the most significant SNPs consistently associated among the feature set. 
Alternatively, a more lenient threshold can be achieved by using a larger σ value. The µ and σ value 
regularise the SNPs to aid in outlining candidates, therefore the consistency of the SNP should still be 
significant among the tested cohorts. Demonstrated in Figure 5-3 is the aim of the process, by choosing 
features that adhere to a particular σ threshold. 
This stage continues the deviation from the standard approaches in GWAS, introduce a new feature 
selection method that uses the consistency of SNP presence as the dominant driver for selecting a 
candidate feature set. This produces regularised SNP selections that are consistently associated to the 
phenotype, employing threshold based on both the standard deviation and mean across the resulting GC-
values. The likelihood of producing a false positive result at this stage is significantly reduced, as the 
subsets of cohorts should regularise the resulting values, bypassing the issues associated with chance 
probability signals. However, it should also be noted that a strong false positive feature signal that 
presents significantly across the cohort is still likely to remain at this stage.  
During this stage, we have chosen to benchmark the results of the analysis against standard methods and 
robust techniques to compare the outcome information (See 6.4 for more information on the chosen 
benchmarks). Refer to 3.2.3 for further explanation on correction methods.  
STAGE 5: EPISTASIS 
We have chosen to use LAMPlink [140] due to the benefits of limitless arity with the additional benefit 
of speed. Acknowledging the use of a dominant model leads to sacrificing potential combinations, the 
purpose of the method is to explore the effects of using random sampling regularisation to produce a set 
of resulting candidates while reducing FP and FN error rates. The method relies on established open 
source software programmes with which the underlying statistical methods can be interpreted and 
understood for reproducibility and understanding of the methods employed. One of the most common 
programmes for epistasis analysis is LAMPlink, an open source software programme that adapts its 
 
FIGURE 5-3: REPRESENTATION OF RASAR FEATURE SELECTION 
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methods from the standard and well-established programme PLINK. The following section outlines the 
statistical methods and techniques employed by LAMPlink to produce epistasis results. 
The purpose of this stage is to sift through the combinations of SNPs to outline potentially significant 
relationships for further analysis.  The use of a software programme that employs a limitless arity 
approach produces exhaustive results that investigate the relationships that exists between all 
combinations (excluding those eliminated during reduction techniques) and the focus phenotype. This 
benefits the methodology as it considers a larger feature set that would otherwise be impractical to 
explore via normal statistical techniques. In the next section LAMPlink is discussed further. 
5.5.1 LAMPLINK 
A software programme called LAMPlink derives its name from methods employed ‘Limitless Arity 
Multiple-testing Procedure’. Provides a method of detecting significant associations using a large 
number of features. Generally, epistasis programmes will perform epistatic interaction tests using two-
way feature sets e.g. PLINK; this significantly reduces the exploratory power of epistasis by by-passing 
the potential for component clusters of 3 or more features. LAMPlink tests the potential of every possible 
combination while reducing the number of tests performed by adjusting the number of SNPs based on 
[85] complexity correction. This significantly reduces computational complexity and also reduces the 
time-consuming process that is generally associated with epistasis approaches. The following section 
outlines the process of LAMPlink. 
5.5.1.1. LAMPLINK GENETIC MODELS 
LAMPlink uses a binary representation for SNPs that can be formatted using two models. Similarly, is 
previously introduced, the dominant and recessive models measure the significance of a SNP in terms 
of the presence of recessive alleles in either heterozygous or recessive homozygous form. The following 
tables represent the binary transformations adopted in LAMPlink for 2 and 3 SNPs although more 
feature combinations are analysed. 
 
 
TABLE 5.2: LAMPLINK DOMINANT MODEL REPRESENTATION FOR 2 SNPS 
 BB (0) Bb (1) bb (1) 
AA (0) 0 0 0 
Aa (1) 0 1 1 
aa (1) 0 1 1 
 
TABLE 5.3: LAMPLINK RECESSIVE MODEL REPRESENTATION FOR 2 SNPS 
 BB (0) Bb (1) bb (1) 
AA (0) 0 0 0 
Aa (1) 0 0 0 
aa (1) 0 0 1 
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Each model analyses the data in difference capacity and therefore both models are important to consider, 
although note that the dominant model is more effective in producing results given that there is a limited 
number of possible combinations to be tested in recessive models. 
LAMPLINK STATISTICAL ANALYSIS 
Statistical analysis of the binary representation is performed using one of two techniques, fisher’s exact 
or Chi-squared test. This can be changed depending on the parameter passed into the program at the 
time of analysis. For further information about fisher’s exact and Chi-Squared test, please refer to section 
3.3.1 . 
LAMPLINK MULTIPLE TESTING, LD AND COMPUTATIONAL COMPLEXITY 
As previously mentioned, the multiple testing problem concerns large dataset analysis as the probability 
of producing a false positive is almost certain. Therefore, LAMPlink uses the complexity inequality 
technique [140] that employs the assumption that probability of at least one significant result showing 
is less than or equal to the sum total of the probabilities taken individually. Using the Bonferroni 
inequality FWER upper bound, the probability of producing one or more false discovery, the tests 
performed are separated into testable and untestable categories that assigns the possibility of producing 
a false positive into possible and not possible, respectively. This is to reduce the number tests included 
as the untestable test will not increase the FWER value. Further to this, LAMPlink also use a technique 
TABLE 5.4: LAMPLINK DOMINANT MODEL REPRESENTATION FOR 3 SNPS 
 BB (0) Bb (1) bb (1)  
AA (0) 0 0 0 CC (0) 
 0 1 1 Cc (1) 
 0 1 1 cc (1) 
Aa (1) 0 0 0 CC (0) 
 0 1 1 Cc (1) 
 0 1 1 cc (1) 
aa (1) 0 0 0 CC (0) 
 0 1 1 Cc (1) 
 0 1 1 cc (1) 
 
TABLE 5.5: LAMPLINK RECESSIVE MODEL REPRESENTATION FOR 3 SNPS 
 BB (0) Bb (1) bb (1)  
AA (0) 0 0 0 CC (0) 
 0 0 0 Cc (1) 
 0 0 0 cc (1) 
Aa (1) 0 0 0 CC (0) 
 0 0 0 Cc (1) 
 0 0 0 cc (1) 
aa (1) 0 0 0 CC (0) 
 0 0 0 Cc (1) 
 0 0 1 cc (1) 
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of ‘itemset mining’ to parse through large sets of features to extract combinations that commonly occur 
across the population. These techniques reduce computational complexity and time. An additional 
process that can be employed is to eliminate SNP combination that contain SNPs in high LD to each 
other. Using LD at this later stage will allow for the creation of combinations that may be reliant on one 
SNP that would have previously been removed during LD pruning but within a combination of SNPs is 
relevant leading to a significant combinatorial collection of features that may have a relationship with 
the focus phenotype. 
LAMPLINK OUTPUT 
LAMPlink produces several files that contain the significant combinations of SNPs along with 
complementary information for SNPs. Analysed SNPs result in singular, two-way and multiple 
combination SNP outcomes. When selecting significant SNP combination, not only the probability of 
the combination should be considered, but also the significance of the singular entity. If one of the 
singular entities results in a higher significance than the total combinations, then this may indicate that 
the combination is only significant due to the presence of the singular entity. However, this may also 
indicate that only a small population of the cohort is affected by the combination, therefore the 
significance is reduced but still significance.  
 
 
TABLE 5.6: OUTPUT FOR .LAMP FILETYPE 
Output Description 
COMBID ID number for combination 
Raw_P p-value before adjustment via Bonferroni Inequality FWER 
Adjusted_P p-value after adjustment via Bonferroni Inequality FWER 
COMB Resulting SNPs for significant combination < significance 
 
TABLE 5.7: OUTPUT FOR .LAMPLINK FILETYPE 
Output Description 
CHR Chromosome location of SNP 
SNP SNP name 
A1 Minor allele nucleotide represented as A, G, C or T 
A2 Major allele nucleotide represented as A, G, C or T 
TEST Test performed 
AFF Genotypes in cases  
UNAFF Genotype in controls 
CHISQ Chi-squared statistic 
DF Degrees of Freedom used for test 
P P Value statistic for test 
OR Odds Ratio value 
COMBi- COMBn Columns denoting n Combinations with binary representation 
for the presence of SNP in each combination. 
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The output file of LAMPlink lists results whose adjust p-value < significance threshold. These results 
can contain combination of 2 to n SNPs, with n being the total number of SNPs input into the analysis 
if there exists a significant relationship between them. LAMPlink also produce singular entities that can 
be used for further analysis but also allow for the comparison of combination against singular entity 
adjusted p-values. Although not an elimination factor, if a singular entity has a higher adjusted p-value 
than its counterpart combination, caution should be taken as this could indicate that the combination’s 
significance is as a result of the significance of the singular entity. It is important to note that even if a 
combination has a lower p-value that it’s singular entity, there could still exist a subpopulation that 
shows increased significance (as later demonstrated in results).  
Figure 5-4 demonstrates an example of the Petal Plot Policy (PPP), with each additional red petal that 
measures as more significant in its singular form than the interaction, the less confidence is found in the 
interaction as indicated by the colour of the centre of the petal plot. Further to this, confidence should 
also be lowered based on the number of variants that exist on the same chromosome. The following 
equation can be used to determine a confidence value for each interaction. 
0.5 0.5
r n s
PPPconfidence
n n
−   
=  +    
   
  EQ. 5-1 
 
Where r represents the number of petals with significance greater than the interaction, s represents the 
number of petals located on the same chromosome and n represents that total number of petals.  
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FIGURE 5-4: PETAL PLOT POLICY CONFIDENCE SCALE A 
 
A Using two different metrics, the interaction measure considers whether the SNP p-value is greater than the 
interaction p-value and if so, the petals are represented as red. The chromosome location marks petals red if 
there are 2 or more petals that sit within the same chromosome. 
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STAGE 6: INFERENCE ANALYSIS  
During this stage, the relationships outlined by LAMPlink are further analysed. As LAMPlink is only 
used to outline the potential relationship, this stage is used to expand the relationships outlined and to 
further analyse them to confirm or disregard the findings. During this stage, relationships that adhere to 
the petal plot policy will be extracted from the training set, with allelic and genotypic states 
combinations explored; as all combination states would be exhaustive to perform manually, the 
following models will be performed during this process: 
 
Cross-Genotypic refers to the analysis of singular interaction states between SNPs as demonstrated in 
Figure 5-5 using inputs SNP 1 (Major Allele (A) Minor Allele (G)) and SNP 2 (Major Allele (T) Minor 
Allele (C)) (See 4.2 for more information on major and minor alleles). This allows for an exhaustive 
search of the genotype states for the interactions. All of these interaction states would be tested to 
produce a value that would indicate whether they were statistically significant. By splitting SNP states 
across genotypes, observation of a small cohort with high association combination may be possible. 
 
The inference of information is important in order to conclude assumptions and present association and 
relationship that show significant in the research. For this process multiple methods are used, firstly 
considered are the methods that will be used to statistically determine information based in the data 
provided. Two methods have been chosen for testing the significance of an association: Fisher’s exact 
TABLE 5.8: MODEL DESCRIPTIONS FOR INFERENCE ANALYSIS 
Model Description 
Dominant All genotype states that contain a minor allele (homozygous recessive 
and heterozygous) will be measure against homozygous dominant states. 
Recessive All genotype states that contain a major allele (homozygous dominant 
and heterozygous) will be measured against homozygous recessive 
states. 
Additive Genotypic stages homozygous dominant, homozygous recessive and 
heterozygous will be measure against one another. 
Cross-Genotype state Every combination that is present in subjects for the explored genotype 
combination will be measure against the remainder. 
 
AATT
AATC
AACC
AGTT
AGTC
AGCC
GGTT
GGTC
GGCC
Major Homozygous Minor HomozygousHeterozygous
SNP 1
SNP 2
Major Homozygous
Heterozygous
Minor Homozygous
 
FIGURE 5-5: CROSS-GENOTYPE DEMONSTRATION 
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test and X2. These methods are tried and tested across many field and disciplines and are widely used in 
the genomics field. By using 2 methods, the limitations of each method can be outlined by validating 
the other as they should come to very similar conclusions as to the significance of an association. 
Two methods have been chosen for the measure of association. As the data used within this research is 
case-control, a measure of the risk ratio is not possible without an odds ratio score. While an odds ratio 
score will provide an estimate of the measure of association, this can be misinterpreted therefore the risk 
ratio will compensate for this. The next process is to test the significant association found with a testing 
set of data that has not been used so far. This indicates whether the association is consistent in other 
samples and also removes any associations that have been outlined as false positives. 
Presented in Table 5.8 are the models used to analyse the information, of these models there are 
combinations of missing information that should be explored before any conclusions can be drawn. 
Previously discussed in section 3.3.2  are classification techniques that in this instance will be used as a 
feature selection process to outline the most significant combinations of variants. To demonstrate this, 
Figure 5-6 show the states that have been analysed by this point (example State 1) but the analysis has 
not taken in consideration the potential that two or more alleles (example State 2) could be more 
significant regardless of the information that is present as a genotype. 
 
To perform that analysis, a CHAID model is used. The CHAID tree offers an interpretable option for 
exploratory analysis of variables using standard methods that are tried and tested. Using the ‘trunk’ of 
the tree to demonstrate the response variable and the categorical percentages, the independent features 
are analysis to outline the feature with the greatest impact to the response variable. The categories of the 
feature with the greatest impact are then analysed for their significance to the response variable with a 
threshold of alpha < 0.05 using the chi-squared test of association and the complexity correction method 
A G A A
SNP 1 SNP 2
A ? ? A
SNP 1 SNP 2
State 1
AGAA
State 2
A??A
 
FIGURE 5-6: SNP STATE A??A A 
 
A Pink represents SNP allele 1, Grey represents SNP allele 2 
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for type 1 errors. If the variable remains significant it is added to the tree. This is an iterative process 
that is performed with each feature that is added to the tree until the number of response variables is too 
low to reliably produce a split. 
CHAID parameters allow for additional adaptations and corrections such as cross-validation, the ability 
to define the minimum cases for node split, the maximum number of nodes and the probability for 
merging and splitting. Within the proposed methodology, the parameter of cross validation has been 
utilised and no further parameters defined in order to outline even small patterns of significance. For the 
purpose of this methodology, only categorical variables will be used, but CHAID is also applicable to 
continuous variables of which the values are categorised into bins. Using the combinations output during 
epistasis stage, further analysis is required to evaluate its reliability, replicability and the existing 
statistical relationship between the feature set and the phenotype. In this research, the definition used to 
measure the reliability of the outlined combinations refers to the statistical confirmation using standard 
statistical methods Odd’s Ratio (OR) and Fisher’s Exact Test which use training and test sets to replicate 
and confirm or reject the outlined interactions (See 3.3.3 and 6.6 for more information on the statistical 
measures). 
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DISCUSSION 
Discussed is the proposed methodology, each aspect of this methodology has carefully considered and 
serves a purpose for filtering and extraction of features of significance approaching the problem for the 
detection of epistasis. The methodology aims to address a series of issues including: 
 
Reducing FDR Stage 2 introduces the first stage that aims to address the issue of 
FDR by tackling the problem before it occurs. Finalising in Stage 3 
using multiple association analysis to build a picture of how genetic 
component behaves among varying sample populations. 
Computational 
expense 
Exhaustive Epistasis searches requires extended time allowances or 
require substantial hardware for processing. This method aims to 
outline a representative set of SNPs that do not require substantial 
hardware but is a small enough set of representative SNPs that 
epistasis can be performed on in a reasonable time constraint. 
Improvement of 
epistasis detection 
One of the most challenging problems in epistasis is the detection 
of interactions while accounting for the influencing pitfalls of FDR, 
computational complexity and the statistical filtering that is 
commonly used to reduce this. This method aims to outline the 
most prominent SNPs for epistasis from a large feature set that can 
commonly become lost in the expanse of information. 
Concise identification 
of interaction 
combinations 
Further to the identification of SNP for epistasis, the aim of this 
method is to concisely outline combinations that show significance 
with the phenotype. Commonly many combinations will be 
outlined for significance with the phenotype due to FDR and SNP 
selection; the aim of this method is to combat these issues. 
 
Further to this, the methodology addresses the problems defined for this methodology using 
interpretable methods and introducing procedure and best practice to optimise the use of this method. In 
order to verify the claims of this thesis, the next section applies the proposed methodology to the data 
described in section Chapter 5:, using standard approaches and thresholds to benchmark the success of 
the methodology. 
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Chapter 6: RESULTS 
The following section presents the results obtained using the proposed methodology as outlined in 
Chapter 5:. In order to measure the effectiveness of the proposed methodology, alternate cases of 
standard practice have been provided with the resulting output when analysing for Epistasis. The 
processes and output of quality control are outlined providing visualise aids to represent some of the 
processes.  
Stage 2 provides the outcome frequencies for the subsets of individuals that are to be used in the 
following stage. Stage 3 outlines the results from the association analysis, providing a comparison 
against standard case-control and visualising the vast difference between output values. Feature 
selection introduces the methods of evaluation that will be used to benchmark the performance of the 
methodology in comparison to using standard case-control methods.  
This describes the processes of obtaining the features selected and an overview of the information. Stage 
5 performs 4 separate epistasis analysis for features outlined from each method. Given that many of the 
same features have been outlined through each method with slight variations, the output combinations 
of each method have been combined to show the detected combinations from each case analysis. Stage 
6 then uses the information from Stage 5 to expand the outlined interactions and analyse the information 
to infer the relationship that exist while testing the significance using separate datasets to observe 
retention in significance. This chapter concludes with an in-depth results discussion that outlines the 
results and further demonstrates the performance of the methodology. 
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STAGE 1: QUALITY CONTROL 
QC was performed as outlined in the proposed methodology (See section 5.1 ). Plots provide a 
visualisation for QC outcomes and threshold decisions. Table 6.1 below records the number of removed 
observations and features after each step has been performed and provides a breakdown of the processes, 
how many SNPs or Individuals were available before QC, removed with each stage and remained after 
QC. The remaining dataset is comprised of 13,649 (7136 cases), (6513 controls) observations and 
320,247 features, or SNPs. Additionally Figure 6-1 to Figure 6-3 provide visualisations of processes 
Heterozygosity, Relatedness and Duplicates and Ancestry Divergence to demonstrate the thresholds 
used to remove individuals during this process. 
 
 
TABLE 6.1: QUALITY CONTROL PROCESS EXCLUSION VALUES 
Process Removed Remaining 
 Subjects Variants Subjects Variants 
Before QC - - 28281 528620 
Ancestry Divergence 675 - 27606 - 
Relatedness and Duplicates 7750 - 19856 - 
Heterozygosity 301 - 19555 - 
Sex Inconsistencies 72 - 19483 - 
Linkage Disequilibrium Pruning - 116115 - 412505 
Threshold Measures     
Missingness in Individuals 4399 - 15084 - 
Genotype Call Rate - 21561 - 390944 
Hardy Weinberg Equilibrium - 1269 - 389675 
Minor Allele Frequency - 69428 - 320247 
Missing Phenotype 1355 - 13729 - 
Exc. Criteria: Age < 40 80 - 13649 - 
After QC   13649 320247 
 
 
FIGURE 6-1: HETEROZYGOSITY DENSITY PLOT WITH EXCLUSION THRESHOLDS AT X AND 
Y AXIS. HORIZONTAL RED THRESHOLDS INDICATE 2σ FROM THE DENSITY MEAN. 
VERTICAL RED THRESHOLD SHOWS OUTLIERS BY MISSING GENOTYPE PROPORTION. 
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FIGURE 6-2: SUBJECTS EXCLUDED FOR RELATEDNESS OF FIRST, SECOND OR THIRD DEGREE. 
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FIGURE 6-3: ANCESTRY DIVERGENCE USING 3 POPULATIONS TO PLOT THE ASSOCIATION. 
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STAGE 2: RANDOM COHORT SAMPLING 
 
Figure 6-4 provide the frequency of case and control status subjects that were included in each fold. S 
includes the total case and control status subjects included in the training set. Within each table, the 
subset is identified by the fold number 1, 2 or 3 and the subset letter a, b or c. Therefore, S1a includes 
information for the first fold and the subject status distribution for subset a. S1b includes the subject’s 
distribution between case and control for fold 1, subset b. S2a includes the distribution between case and 
control for fold 2, subset a.  
S = {S1, S2, S3} 
S1 = {S1a, S1b, S1c} 
S2 = {S2a, S2b, S2c} 
S3 = {S3a, S3b, S3c} 
 
These tables outline the distribution of each subset; taking into consideration both the effects of sample 
size and case-control status. Each subset is extracted from the original file to produce a binary replication 
with only the assigned subjects. This is then used within the next stage, Association Analysis. 
 
  
 Control (0) Case (1) 
S 5214 5706 
 
S1 
 0 1  0 1  0 1 
S1a 1702 1938 S1b 1772 1868 S1c 1740 1900 
 
S2 
 0 1  0 1  0 1 
S2a 1723 1917 S2b 1789 1851 S2c 1702 1938 
 
S3 
 0 1  0 1  0 1 
S3a 1701 1939 S3b 1800 1840 S3c 1713 1927 
 
FIGURE 6-4: DISTRIBUTION OF CASE-CONTROL STATUS PER FOLD SUBSETS 
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STAGE 3: ASSOCIATION ANALYSIS 
The following section outlines the results obtained from performing association analysis using 2 
different approaches; standard case-control and proposed random sampling regularisation method. Both 
approaches were conducted using the same techniques only varying the input information. An allelic 
model, adjusted by genomic control, included remaining subjects and SNPs from the quality control 
stage with variation conducted for the Random Sampling Regularisation approach using cohort samples 
as reported in ‘Random Cohort Sampling’. 
Commonly in standard case-control approaches, QQ plots are used to indicate the success of the quality 
control procedure. Although this is not a definitive measure, it can provide an indication if are any 
problems in the data such as population stratification. Figure 6-5 shows an expected tail-end deviation 
from the null hypothesis, which is the expected values. 
 
Figure 6-6 visualises the -log10 p-values produced from the association analysis using standard case-
control approach in a Manhattan plot. Values exceeding the blue threshold are indicated as suggestive 
significance. A standard approach in genomics is to use the genome-wide significance line (not visible 
on this plot), a more stringent threshold, however the results do not indicate the significance of any of 
the SNPs exceeds this threshold. 
Figure 6-7 visualises the -log10 p-values produced using the RaSaR methodology. Visible is the clear 
decrease in significance for all SNPs. As the mean of 9 p-values for each SNP is used to create the mean 
values, any sample p-values that show little significance for the SNP will reduce the mean value but will 
reduce the presence of False Positives based on chance. This figure is scaled to show the difference 
between the values generated from standard case-control process and random sampling regularisation 
method. Figure 6-8 provides a zoomed view of the random sampling regularisation method values. 
 
FIGURE 6-5: QQ-PLOT SHOWS THE DEVIATION FROM THE NULL HYPOTHESIS LINE.  
Deviation begins >3 which indicates that the quality control process was successful. 
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FIGURE 6-6: MANHATTAN PLOT FOR STANDARD CASE-CONTROL METHOD USING ALLELIC MODEL AND 
GENOMIC CONTROL. 
 
 
FIGURE 6-7: MANHATTAN PLOT GENERATED FROM MEAN OF 9 SNP -LOG10 P-VALUES USING RANDOM 
SAMPLING REGULARISATION METHOD SCALED FOR COMPARISON TO STANDARD CASE-CONTROL 
 
FIGURE 6-8: ZOOMED VIEW (FIGURE 6-7) MANHATTAN PLOT GENERATED FROM MEAN OF 9 SNP -LOG10 P-
VALUES USING RANDOM SAMPLING REGULARISATION METHOD 
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To further support this, Figure 6-9 uses the top SNPs values from chromosome 6 standard case-control 
approach (Figure 6-6) that exceed the suggestive significance threshold (See 3.2.1.3. for more 
information about genome-wide and suggestive significance thresholds) to represent the fluctuation in 
values when varying subjects between cohort samples. As demonstrated by Figure 6-10, the consistency 
of the top SNPs outlined by standard case-control methods fluctuate across the analyses but present 
strongly when using the full cohort.  
 
 
FIGURE 6-10: DOT PLOT COMPARISON OF STANDARD CASE-CONTROL VS. RANDOM SAMPLING REGULARISATION  
The difference between the values produced using standard case-control methods (with genomic control), represented by 
blue points, and the values produced by random sampling regularisation. Each of the subset analyses are represented by 
black dots while the mean is represented in salmon. 
 
FIGURE 6-9: SAMPLE MANHATTAN PLOT SHOWING SNP -LOG10 P-VALUES ACROSS CHROMOSOME 6 BY BASE-
PAIR (BP).  
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STAGE 4: FEATURE SELECTION 
Producing a set of representative features that are most likely to indicate the presence of a significant 
relationship is one of the main challenges of this methodology. Benchmarking against standard 
approaches and correction methods will indicate the effectiveness of the methodology and could 
potentially outline areas of improvement. The following section outlines 3 additional cases of threshold 
choices that use multiple testing technique q-value (see section 3.2.3 to produce a feature set. 
For benchmarking, a number of methods were considered including the genome-wide significance 
threshold (See 3.2.1.3. ) and the p-value < 0.05, however each of these thresholds yielded a feature set 
that was either too small or too large to be used with the current set-up for epistasis. Figure 6-11 
demonstrates the methods chosen in cases 2-3 long with the other considered statistical methods, with 
the novel methodology of this thesis being represented as case 1. As is visible, the genome-wide 
significance threshold was only able to yield 1 significant result which is not viable to perform an 
epistasis model with, and p-value < 0.05 yielded a feature set of >5000 which would increase the 
computational complexity of the methodology, requiring HPC.  
 
TABLE 6.2: THRESHOLDS AND FEATURES OF BENCHMARK CASES AND RASAR 
ID Adjustment Methods Applied Threshold Features 
C1 RaSaR Cohort Sampling, RaSaR Feature Selection µ < 0.05, σ < 0.025 41 
C2 q-value, Genomic Control α < 0.3 17 
C3 q-value, Genomic Control α < 0.4 37 
C4 q-value, No Genomic Control α < 0.01 48 
 
Table 6.2 outlines the number of features and the thresholds used to filter those features. In order to 
decide the thresholds of the benchmarked cases and RaSaR feature selection methodology, the following 
sections outline the systematic approach. 
Conservative Leniant
Genome-wide 
Significance 
Threshold 
P < 0.05C4C1C3C2
No. of Features
1 17 37 41 57 >5000
 
FIGURE 6-11: COMPARISON OF LENIENCE/ CONSERVATIVE METHODS ALONG WITH THE NUMBER OF FEATURES 
PRODUCED BY EACH. A 
 
A Information on the bottom refer to the methods used including the ID for cases 1-4, as outlined in Table 6.2. 
Information on the top refers to the number of features outlined by each. 
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6.4.1 CASE 2-3 
The most conservative method out of the chosen benchmarks is the q-value in conjunction with the 
Genomic Control adjustment method. Therefore, in order to create a comparable set of features, case 2-
3 were first explored. Table 6.3 shows the results from the multiple testing analysis. 
 
 
Visible in Table 6.3, there is a lack of significant results that are present for q-value. Given this, the 
common threshold α < 0.05 has been increased to 0.3. While this is high, this only results in feature set 
of 17 SNPs, a low amount when analysing for epistasis. Selected features are visualised in Figure 6-12 
highlighted in green. 
 
 
FIGURE 6-12: MANHATTAN PLOT SHOWING THE FEATURE SET SNPS HIGHLIGHTED IN GREEN WHEN 
APPLYING THE THRESHOLD Q(α) < 0.3 USING STANDARD CASE-CONTROL APPROACH (N = 17). 
 
 
FIGURE 6-13: MANHATTAN PLOT SHOWING THE FEATURE SET SNPS HIGHLIGHTED IN GREEN WHEN 
APPLYING THE THRESHOLD Q(α) < 0.4 USING STANDARD CASE-CONTROL APPROACH (N = 37). 
 
TABLE 6.3: FDR VALUES FOR P-VALUES ADJUSTED BY GENOMIC CONTROL 
 <1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1 
p-value 68 458 4207 10529 20868 41071 404980 
q-value 0 0 0 0 0 0 405003 
Local FDR 0 0 0 0 0 0 392897 
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As can be seen from Figure 6-14, the number of features that are considered significant are small, 
maintained a small increase in feature as the threshold is increased. Given the q-value correction method 
use the number of significance results and provide a probability of observing a false positive with that 
set, the threshold must be maintained under 0.5, which indicates an even probability of observing a false 
positive.  
 
Therefore, as demonstrated in Figure 6-14, the chosen thresholds explore the increase in that threshold 
0.3 and 0.4, with varying feature set sizes, it provides an indication of the potential of the q-value 
combined with the GC method to produce interaction sets unhindered by small thresholds. Case 2 
threshold, 0.3, was chosen as a lower threshold as from 0.2 to 0.3 is the first instance in which features 
surpass a significance threshold; within this case either 0.2 or 0.3 could have been used with neither 
affecting the outcome of feature set. Case 3 threshold, 0.4, was chosen given its’ increase in feature set 
size with consideration to the 0.5 problematic area.  
6.4.2 CASE 4 
Continuing from this, the thresholds chosen for the remaining method should reflect a comparable 
feature set size. As case 4 represents the most lenient method chosen for benchmarking, the feature set 
size is expected to be the largest. Table 6.4 shows the multiple testing analysis and the resulting features 
that qualify for each bin. Visible in the table is the large number of features indicated to have extremely 
significant relationship with the phenotype, Breast Cancer. This is a good example of the importance of 
using multiple testing while analysing large datasets as this bin is likely heavily populated with false 
positive results. Therefore, referring to the q values proposes more realistic significance estimates. 
Case 2
Case 3
 
FIGURE 6-14: THRESHOLD MEASURES FOR CASE 2 AND CASE 3 
104 
 
Figure 6-16 provides the increase in feature size set as the threshold is increased. Notable in this method 
is the feature set size are much larger regardless of using method q-value, evidencing the strict 
adjustments of GC. 
 
TABLE 6.4: FDR VALUES FOR P-VALUES  
 <1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1 
p-value 506 2529 12901 25004 41142 68019 404982 
q-value 0 7 48 91 243 1157 405003 
Local FDR 0 6 17 51 129 591 404924 
 
Included in this figure are the number of features of case 2 and case 3, highlighted in yellow, while the 
threshold chosen for case 4 is represented by the pink line. This method offers an opportunity to observe 
the outcome interactions of the feature set given more leniency in the feature selection process. An 
important note at this stage is to point out that p-values which are used within q-value and adjusted for 
genomic control are derived from the same association analysis, therefore the features selected by case 
2-4 will represent a crossover number of the same features e.g. case 3 is superset of case 2.  
 
 
FIGURE 6-15: MANHATTAN PLOT SHOWING THE FEATURE SET SNPS HIGHLIGHTED IN GREEN WHEN 
APPLYING THE THRESHOLD Q(α) < 0.01 USING STANDARD CASE-CONTROL APPROACH (N =48). 
 
Case 3
Case 2
Case 4
 
FIGURE 6-16: THRESHOLD MEASURE FOR CASE 4 IN COMPARISON TO CASE 2 AND 3 
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6.4.3 CASE 1 
Case 1 refers to the novel methodology and is the last method to have a feature selection threshold 
applied. In order to decide the threshold for the RaSaR method, it was important to concentrate on 
filtering a comparable number of features to cases 2-4 which ideally would result in an amount within 
the feature sizes already outlined. The proposed methodology of this research used standard deviation 
and mean to produce a unique threshold that takes into consideration the fluctuation of values across 
random cohorts.  
Figure 6-17 shows the selected feature set for case 1 in green using -log10 p-values adjusted by GC. 
Visible is the distinct difference in the -log10 p-values scale which indicates lower association throughout 
the SNP set due to the use of the mean value, however the differences visible between Figure 6-12, 
Figure 6-13 and Figure 6-15 to Figure 6-17 show that the overall structure of the data points has changed, 
indicating that many of the SNPs with higher association in Cases 2-4 had a fluctuating presence 
depending on the cohort being analysed. 
 
 
 
By using the standard deviation values alongside the mean, this approach also considers any SNPs that 
have an inflated mean due to anomaly results will be excluded based on standard deviation value. The 
purpose of this feature selection method is to produce a feature set that includes SNPs that show 
significance but more importantly are consistently significant regardless of the subjects included in the 
cohort.  
 
FIGURE 6-17: MANHATTAN PLOT SHOWING THE FEATURE SET SNPS HIGHLIGHTED IN GREEN WHEN APPLYING 
THE THRESHOLDS µ < 0.05 AND σ < 0.025 USING RASAR. (N = 41) 
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FIGURE 6-18: SYSTEMATIC FEATURE EXPLORATION USING STANDARD DEVIATION AND MEAN THRESHOLDS 
A. 
0.0    0.1       0.2          0.3 0.4
Mean
Fr
e
q
u
e
n
cy
0
   
   
   
1
0
0
0
0 
   
20
0
0
0
  3
0
00
0
   
 4
0
00
0
   
  5
0
0
0
0
Mean
0.05
 
B. 
Fr
e
q
u
e
n
cy
0
   
  1
0
0
0
0 
  2
0
0
00
  3
00
0
0
  4
0
0
0
0
  5
0
0
00
  6
0
00
0
0.0      0.2          0.4  0.6       0.8
Standard Deviation
Standard Deviation
0.025
 
FIGURE 6-19: HISTOGRAMS GENERATED FROM ASSOCIATION ANALYSIS USING RANDOM SAMPLING 
REGULARISATION SHOWING A. µ AND B. σ, WITH THRESHOLD EXCLUSION MEASURES. 
107 
 
Using a systematic approach of increasing the mean value and using a selection of standard deviation 
thresholds that increase by 0.05, but do not exceed the mean value for each test, the feature set sizes 
were explored. One main feature of the RaSaR feature selection method is to emphasise the use of 
standard deviation to filter SNPs that exhibit fluctuating behaviour dependent on the cohort sample that 
was used, therefore restricting the standard deviation is more important than restricting the mean. Figure 
6-18 visualises these tests and shows the different feature set sizes dependent on the threshold explored. 
Highlighted in green is the feature selection threshold chosen which exists at the junction of the mean 
threhold 0.05 and the standard deviation threshold of 0.025. Histograms in Figure 6-19 indicate the 
thresholds that are used for each extracted feature. A lenient threshold of mean, µ < 0.01 and standard 
deviation, σ < 0.03. 
Figure 6-20 provides a comparable graph in which the SNPs selected via the RaSaR technique are 
outlined using the GC adjusted p-values obtained from Case 2-4. In comparison with Figure 6-12, Figure 
6-13 and Figure 6-15, the RaSaR method excludes SNPs whose presence among the 9 GC adjusted p-
values obtained during association analysis do not adhere to the set consistency threshold, which in this 
case is, σ <0.025. 
 
Outlined feature set numbers from Cases 1-4 are displayed in Table 6.5. Lists of all features and their 
significance values can be found in Appendix A . These features were extracted from the main dataset 
and used in the next stage of Epistasis Analysis. 
 
 
FIGURE 6-20: MANHATTAN PLOT SHOWING THE FEATURE SET SNPS HIGHLIGHTED IN GREEN WHEN APPLYING THE 
THRESHOLDS µ < 0.01 AND σ < 0.03 USING RASAR APPROACH WITH CASE 2-4 GC ADJUSTED P-VALUE DATA. (N = 41) 
TABLE 6.5: SELECTED FEATURES OF EACH THRESHOLD MEASURE 
Case ID Threshold No. of Features 
1 RaSaR 41 
2 q-value (p-values) (0.01) 48 
3 q-Value (GC adjusted) (0.3) 17 
4 q-Value (GC adjusted) (0.4) 37 
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STAGE 5: EPISTASIS ANALYSIS  
Features selected using the previous process are inputted into software LAMPlink, using a dominant 
model. Linkage Disequilibrium pruning is used to remove redundant features that exist as relationship 
as a result of high LD. Given that association analysis has already been performed with the outlined 
features being selected as result of significance measures during this process, the threshold used in this 
stage also has to be more conservative as the false positive presence is already established. Given this, 
a threshold, α < 0.005 has been applied.  
 
Table 6.6 outlines the interaction results from LAMPlink along with the case number of thresholds that 
detected the interaction. All outputs can be found in Appendix B . As can be seen, there are a few 
interactions that have been outlined by multiple cases and one interaction that shows a low PPP 
confidence value to evidence the suggestive effect of the PPP. Normally within this method an 
interaction with PPP confidence value of < 0.5 would be discarded, however in order to show the effects 
of a combination with low PPP confidence, combination 9q21.13-9q21.13 highlighted in red, has been 
evaluated in the next stage. Adjusted p-values are used to produce petal plots that show the significance 
value of each singular feature in relation to the overall interaction score.  Table 6.7 shows the PPP results 
of interaction rs4602520; rs6910087; rs7246472 values for both the singular and combination outlined 
using case 1 and 2 methods. Figure 6-21 shows the petal plot for interaction rs4602520; rs6910087; 
rs7246472 where one of the singular SNPs shows a greater p-value (red) than the combined interaction 
p-value (orange) which reduces the confidence of the interaction.  
TABLE 6.6: COMBINATIONS OUTLINED THROUGH LAMPLINK. 
Combination PPP Conf. C1 C2 C3 C4 
rs4602520-rs6910087-rs7246472 0.833 O O   
9q21.13-9q21.13 0.25 O    
rs4602520-rs4144827 0.5 O    
1q41-rs3924215 0.75  O  O 
rs6911024-rs12170250 0.75  O   
rs6852865-rs4602520 1  O   
rs6852865-rs4602520-rs6910087-rs7246472 0.375  O   
rs6852865-rs6910087-rs7246472 0.667  O   
rs3924215-rs6011609 0.5   O  
1p12-rs6011609 0.5   O  
rs4602520-rs6911024-rs7246472 0.5    O 
rs6911024-rs7246472 0.5    O 
rs4602520-rs7246472 0.5 O O  O 
rs4602520-rs6911024 0.5    O 
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Secondly, the location of the SNPs is considered to focus on interactions that occur cross-chromosome. 
Figure 6-21 (Refer to Appendix C for interaction values), shows the locations of the SNPs included in 
the interaction are dispersed across three different chromosomes that could be an indication that 
functionality of these SNPs interferes or cooperates with one another, leading to the focus phenotypic 
expression. A few of the combinations outlined in Figure 6-7 contain SNPs that are located in the same 
chromosome, however these are extended into the next process to investigate the outcome and 
implications of these interactions. All PPP Confidence workings can be found in Appendix C  
  
 
FIGURE 6-21: PETAL PLOT FOR INTERACTION RS4602520; RS6910087; RS7246472 A 
 
A Petals in red present a lower p-value than the interaction centre, petals in green present a higher p-value than the 
interaction centre. Therefore, the interaction PPP confidence value is lowered as represented by Table 6.7. 
 
TABLE 6.7: EXAMPLE OF INTERACTION OUTCOME VALUES 
 Combination Raw p-value Adjusted p-
value 
Case 1 rs4602520; rs6910087; rs7246472 1.8291e-06 0.00053227 
 rs4602520 7.6298e-09 2.2203e-06 
 rs6910087 4.9796e-06 0.0014491 
 rs7246472 2.1604e-06 0.00062868 
 
PPP Confidence = 
2 3 3
0.5 0.5 0.833
3 3
−   
 +  =   
   
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STAGE 6: INFERENCE ANALYSIS 
Combinations including singular, two-way and three-way along with all possible combination states 
(excluding combinations that do not contain more than 10 values in one cell of case-control based 
contingency table) are analysed to expand and explore the relationships outlined during the previous 
stage. 
6.6.1 ANALYSIS OF BREAST CANCER TRAINING SET 
As LAMPlink is used to outline potential relationships between variants, further analysis is used to 
investigate those relationships with the main focus on identifying causal variant combinations that effect 
either a larger population and/or present an increased association between the interaction and the 
phenotype.  
All interactions have been extended to include all possible relationships between outlined variant within 
the combination e.g.  
B A  
4602520 7246472 4602520 6910087 7246472rs rs rs rs rs−  − −  
 
Further to this, also considered is every state combination within the relationship that is present in the 
sample population with each cell of a 2x2 contingency cell contained a frequency >10, Figure 6-22 
demonstrates 2 states that were analysed from combination rs4602520-rs6910087-rs7246472. 
 
In order to focus the results in this section, Table 6.8 to Table 6.9 provides the results from the analysis 
that outline any interaction combinations that produced a significant result of p-value < 0.05. All results 
can be found in 0with contingency table values in Appendix F . Each analysis is performed using Chi-
Squared (X2), Fisher’s Exact Test (F) and Odd’s Ratio (OR) risk, p-value (OR P) and upper (>CI) and 
lower (CI<) confidence intervals. 
 
FIGURE 6-22: REPRESENTATION OF ANALYSED ALLELIC STATES 1 AND 2. ALLELE 1 IS REPRESENTED IN 
PINK WHILE ALLELE 2 IS IN GREY 
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TABLE 6.8: STATISTICALLY SIGNIFICANT COMBINATION STATES FROM TRAINING DATA 
ID Variant/s Model/ 
Comb 
Results      
   F X2 CI < OR > CI  OR P 
1 rs4602520 Dominant 0.000 0.000 1.253 1.370 1.498 0.000 
rs6910087 Dominant 0.000 0.000 1.152 1.241 1.337 0.000 
rs7246472 Dominant 0.000 0.000 1.178 1.281 1.394 0.000 
rs4602520, rs6910087 Dominant 0.000 0.000 1.296 1.531 1.809 0.000 
AAAA   1.091 1.388 1.766 0.025 
AAAG     1.036 1.125 1.221 0.019 
AAGG   0.707 0.756 0.808 0.000 
GAAG     1.273 1.525 1.828 0.000 
GAGG   1.160 1.286 1.426 0.000 
rs4602520, rs7246472 Dominant 0.001 0.001 1.257 1.544 1.896 0.001 
AAAA     1.254 1.877 2.808 0.010 
AAAC   1.081 1.185 1.298 0.002 
AACC     0.684 0.733 0.786 0.000 
GAAC   1.195 1.481 1.835 0.003 
GACC     1.187 1.310 1.446 0.000 
rs6910087, rs7246472 Dominant 0.000 0.000 1.174 1.277 1.390 0.000 
AAAC   1.138 1.978 3.438 0.042 
AGAC     1.181 1.400 1.660 0.001 
AGCC   1.041 1.131 1.229 0.015 
GGAA     1.136 1.723 2.615 0.032 
GGAC   1.048 1.154 1.271 0.015 
GGCC     0.730 0.780 0.833 0.000 
rs4602520, rs6910087, 
rs7246472 
Dominant 0.000 0.000 2.150 3.335 5.174 0.000 
AAGGAA   1.107 1.712 2.648 0.042 
AAGGAC     1.036 1.149 1.274 0.027 
AAGGCC   0.681 0.726 0.773 0.000 
GAAGAC     1.971 3.196 5.181 0.000 
GAAGCC   1.041 1.269 1.548 0.048 
GAGGCC     1.166 1.303 1.458 0.000 
2 9q21.13 Dominant 0.000 0.000 0.711 0.775 0.846 0.000 
9q21.13 Dominant 0.000 0.000 0.692 0.762 0.839 0.000 
9q21.13 
9q21.13 
Dominant 0.000 0.000 0.688 0.758 0.835 0.000 
AGCA     0.701 0.774 0.855 0.000 
GGAA     1.179 1.285 1.401 0.000 
3 rs4144827 Dominant 0.000 0.000 1.154 1.296 1.457 0.000 
rs4144827 
rs4602520 
Dominant 0.000 0.000 1.443 1.801 2.248 0.000 
AAAA     0.692 0.744 0.801 0.000 
AAGA   1.151 1.268 1.397 0.000 
GAAA     1.052 1.170 1.302 0.015 
GAGA     1.502 1.906 2.419 0.000 
4 1q:44 Dominant 0.000 0.000 0.710 0.774 0.844 0.000 
rs3924215 Dominant 0.000 0.000 0.724 0.779 0.838 0.000 
1q:44 
rs3924215 
Dominant 0.000 0.000 0.495 0.586 0.694 0.000 
AAAA   1.220 1.303 1.391 0.000 
GAGA     0.485 0.581 0.695 0.000 
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TABLE 6.9: STATISTICALLY SIGNIFICANT COMBINATION STATES FROM TRAINING DATA CONT. (1) 
ID Variant/s Model/ 
Comb 
Results      
   F X2 CI < OR > CI  OR P 
5 rs6911024 Dominant 0.000 0.000 1.157 1.247 1.343 0.000 
rs12170250 Dominant 0.000 0.000 1.459 1.779 2.170 0.000 
rs6911024 
rs12170250 
Dominant 0.000 0.000 2.028 2.884 4.101 0.000 
AAGG     0.733 0.789 0.849 0.000 
GAAG     1.868 2.716 3.950 0.000 
6 rs6852865 Dominant 0.000 0.000 1.199 1.314 1.438 0.000 
rs4602520 Dominant 0.000 0.000 1.253 1.370 1.497 0.000 
rs6852865 
rs4602520 
Dominant 0.000 0.000 1.230 1.357 1.496 0.000 
AGGA   1.236 1.368 0.514 0.000 
GGAA     0.689 0.749 0.815 0.000 
7 rs6852865 Dominant 0.000 0.000 1.200 1.314 1.439 0.000 
rs6852865 
rs4602520 
rs6910087 
rs7246472 
Dominant 0.000 0.000 2.303 3.832 6.376 0.000 
AGGAGGCC   1.140 1.292 1.464 0.001 
GGAAGGAC     1.035 1.148 1.275 0.029 
GGAAGGCC   0.685 0.730 0.778 0.000 
GGGAGGCC     1.052 1.328 1.676 0.045 
8 rs6852865 
rs6910087 
rs7246472 
Dominant 0.000 0.000 2.180 3.422 5.370 0.000 
AGAGAC     2.268 3.938 6.839 0.000 
AGGGCC   1.097 1.230 1.378 0.003 
GGGGAC     1.031 1.143 1.267 0.033 
GGGGCC     0.699 0.744 0.793 0.000 
9 rs3924215 Dominant 0.000 0.000 0.723 0.778 0.838 0.000 
rs6011609 Dominant 0.000 0.000 0.411 0.504 0.619 0.000 
rs3924215 
rs6011609 
Dominant 0.000 0.000 0.229 0.354 0.546 0.000 
AAAG   0.448 0.566 0.716 0.000 
AAGG     1.249 1.342 1.442 0.000 
10 1p12 Dominant 0.000 0.000 0.402 0.495 0.610 0.000 
1p12 
rs6011609 
Dominant 0.001 0.001 0.034 0.115 0.396 0.004 
AAAG   0.438 0.541 0.668 0.000 
AAGG     1.690 1.963 2.281 0.000 
GAGG     0.427 0.529 0.657 0.000 
11 rs6911024 Dominant 0.000 0.000 1.167 1.258 1.356 0.000 
rs6911024 
rs7246472 
Dominant 0.000 0.000 1.295 1.522 1.790 0.000 
AAAA     0.348 0.534 0.821 0.016 
AAAC   0.794 0.874 0.963 0.022 
AACC     1.210 1.293 1.381 0.000 
GAAC   0.592 0.703 0.834 0.001 
GACC     0.801 0.871 0.947 0.007 
rs4602520 
s6911024 
Dominant 0.000 0.000 1.311 1.550 1.834 0.000 
AAAA     1.250 1.337 1.429 0.000 
AAGA   0.805 0.875 0.951 0.008 
AAGG     0.574 0.731 0.930 0.032 
GAAA   0.702 0.778 0.862 0.000 
GAGA     0.542 0.650 0.781 0.000 
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6.6.1 ANALYSIS OF BREAST CANCER TESTING SET 
Having conducted the inference analysis using the training data, the next process is to analyse the 
significant combinations outlined using a separate dataset. The purpose of this process is to analyse 
whether the significant combinations outlined retain significance using an unused set of data which 
increases confidence in a true positive association. Table 6.10 to Table 6.11 provide the results from the 
testing set using all significant relationships outlined in Training. Combinations with NA values were 
omitted as a result of a cell frequency < 10 in a 2x2 contingency table. Combination outlined in grey 
indicate associations that retained significance using the testing dataset and will therefore be carried 
forward. 
Table 6.10: Statistical analysis of outlined significant variants using Testing Dataset 
ID Variant/s Model/ Comb Results 
   F X2 CI < OR > CI  OR P 
1 rs4602520 Dominant 0.672 0.677 0.849 1.051 1.302 0.672 
rs6910087 Dominant 0.016 0.017 1.073 1.242 1.439 0.015 
rs7246472 Dominant 0.032 0.034 1.054 1.243 1.466 0.030 
rs4602520 
rs6910087 
Dominant 0.263 0.296 0.902 1.266 1.778 0.253 
AAAA   0.814 1.305 2.093 0.354 
AAAG     1.015 1.192 1.400 0.073 
AAGG   0.742 0.846 0.965 0.037 
GAAG     0.931 1.349 1.956 0.185 
GAGG   0.769 0.938 1.145 0.600 
rs4602520 
rs7246472 
Dominant 0.002 0.002 0.317 0.472 0.704 0.002 
AAAA   0.509 1.170 2.687 0.756 
AAAC     0.909 1.088 1.302 0.439 
AACC   0.801 0.919 1.054 0.312 
GAAC     1.283 1.925 2.887 0.008 
GACC   0.693 0.842 1.024 0.148 
rs6910087 
rs7246472 
Dominant 0.045 0.055 1.068 1.453 1.976 0.046 
AAAC   0.247 0.648 1.702 0.460 
AGAC     1.145 1.597 2.229 0.021 
AGCC   0.961 1.132 1.333 0.213 
GGAA     0.654 1.640 4.115 0.376 
GGAC   0.933 1.127 1.360 0.299 
GGCC     0.691 0.787 0.897 0.003 
rs4602520 
rs6910087 
rs7246472 
Dominant 0.068 0.076 1.129 2.355 4.913 0.055 
AAGGAA     0.485 1.274 3.345 0.680 
AAGGAC   0.828 1.014 1.241 0.911 
AAGGCC     0.747 0.848 0.963 0.032 
GAAGAC   1.259 2.931 6.824 0.036 
GAAGCC     0.701 1.067 1.626 0.799 
GAGGCC     0.647 0.804 0.999 0.098 
2 9q21.13 Dominant 0.438 0.453 0.776 0.920 1.091 0.423 
9q21.13 Dominant 0.731 0.740 0.792 0.956 1.155 0.697 
9q21.13 
9q21.13 
Dominant 
0.730 0.743 0.792 0.957 1.156 0.700 
 AGCA     0.797 0.969 1.179 0.793 
 GGAA     0.917 1.087 1.288 0.421 
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TABLE 6.11: STATISTICAL ANALYSIS OF OUTLINED SIGNIFICANT VARIANTS USING TESTING DATASET CONT. (1) 
ID Variant/s Model/ Comb Results 
   F X2 CI < OR > CI  OR 
P 
3 rs4144827 Dominant 0.063 0.063 1.032 1.252 1.518 0.056 
rs4144827 
rs4602520 
Dominant 0.009 0.013 1.290 2.042 3.232 0.011 
AAAA     0.795 0.919 1.062 0.337 
AAGA   0.737 0.891 1.077 0.319 
GAAA     0.860 1.065 1.319 0.625 
GAGA     1.290 2.151 3.588 0.014 
4 1q:44 Dominant 0.383 0.408 0.772 0.914 1.082 0.379 
rs3924215 Dominant 0.633 0.649 0.886 1.055 1.257 0.611 
1q:44 
rs3924215 
Dominant 0.897 0.990 0.675 1.038 1.597 0.886 
AAAA   0.898 1.031 1.183 0.718 
GAGA     0.534 0.840 1.321 0.526 
5 
 
 
rs6911024 Dominant 0.018 0.020 1.067 1.237 1.433 0.018 
rs12170250 Dominant 0.328 0.336 0.790 0.914 1.058 0.314 
rs6911024 
rs12170250  
Dominant 0.690 0.698 0.829 1.078 1.402 0.640 
AAGG     0.415 0.723 1.260 0.337 
GAAG     NA NA NA NA 
7 rs6852865 Dominant 0.550 0.581 0.893 1.068 1.278 0.544 
rs6852865 
rs4602520 
rs6910087 
rs7246472 
Dominant 0.175 0.240 0.876 1.979 4.467 0.168 
AGGAGGCC     0.644 0.820 1.042 0.173 
GGAAGGAC   0.829 1.078 1.402 0.640 
GGAAGGCC     0.746 0.847 0.961 0.031 
GGGAGGCC     0.456 0.754 1.246 0.355 
8 rs6852865 
rs6910087 
rs7246472 
Dominant 0.099 0.107 1.059 2.222 4.665 0.076 
AGAGAC     1.358 3.435 8.686 0.029 
AGGGCC   0.688 0.860 1.075 0.267 
GGGGAC     0.840 1.026 1.253 0.835 
GGGGCC     0.732 0.831 0.944 0.017 
9 rs3924215 Dominant 0.633 0.649 0.886 1.055 1.257 0.611 
rs6011609 Dominant 0.232 0.243 0.495 0.735 1.091 0.200 
rs3924215 
rs6011609 
Dominant 0.468 0.518 0.287 0.646 1.458 0.377 
AAAG   0.489 0.767 1.204 0.333 
AAGG     0.985 1.137 1.312 0.140 
10 1p12 Dominant 0.000 0.001 0.252 0.394 0.615 0.001 
1p12 
rs6011609 
Dominant NA NA NA NA NA NA 
AAAG   0.532 0.796 1.190 0.351 
AAGG     1.316 1.774 2.390 0.002 
GAGG   0.269 0.422 0.662 0.002 
11 rs6911024 Dominant 0.018 0.019 1.068 1.238 1.434 0.017 
rs6911024 
rs7246472 
Dominant 0.068 0.070 1.047 1.422 1.930 0.058 
AAAA     0.243 0.610 1.530 0.377 
AAAC   0.736 0.888 1.073 0.302 
AACC     1.110 1.265 1.442 0.003 
GAAC   0.462 0.643 0.895 0.028 
GACC     0.749 0.883 1.040 0.212 
rs4602520 
rs6911024 
Dominant 0.220 0.249 0.922 1.297 1.826 0.211 
AAAA     1.032 1.177 1.342 0.041 
AAGA   0.721 0.847 0.995 0.090 
AAGG     0.478 0.767 1.230 0.355 
GAAA   0.874 1.067 1.302 0.595 
GAGA     0.495 0.719 1.046 0.148 
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6.6.2 DECISION TREES 
During the previous analysis, every combination state of SNP was analysed. However, it is 
important to consider the allelic expression in combinatorial states that omit 1 or more states to 
achieve better penetrance and/or incidence that may present more significantly than the previously 
outlined interaction states. Further to this, decision trees are able to outline cohort sets that appear 
distinct in association. Refer to section 3.3.3 and section 3.4 for more information about the 
decision to use CHAID. During this stage, each combination state outlined in Table 6.6 is used to 
produce feature sets for further analysis using a CHAID method (See 3.4 for discussion),(See for 
full decision tree results Appendix G). Table 6.12 provides a summarisation of the most 
significant nodes that were outlined from these analyses. Note: Results present the variant, allele 
(A1/A2) and corresponding nucleotide (A/G/C/T).  
TABLE 6.12: CHAID ANALYSIS NODE RESULTS 
ID Appendix Reference Combination Node Data 
1 Combination 1 
rs4602520 (A1) (A) 
rs7246472 (A1) (A) 
rs7246472 (A2) (A) 
 
 
 
3 Combination 3 
rs4144827 (A1) (G) 
rs4602520 (A1) (G) 
 
4 Combination 4 
1q14 (A1) (G) 
rs3924215 (A1) (A) 
 
5 Combination 5 
rs12170250 (A1) (G) 
rs6911024 (A1) (G) 
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8a Combination 8 
rs6852865 (A1) (A) 
rs7246472 (A1) (A) 
 
8b Combination 8 
rs6852865 (A1) (A) 
rs7246472 (A1) (A) 
rs6910087 (A1) (A) 
 
9a Combination 9 
rs3924215 (A1) (A) 
rs6011609 (A1) (A) 
 
9b Combination 9 
rs3924215 (A1) (G) 
rs6011609 (A1) (A) 
 
10a Combination 10 1p12 (A1) (G) 
 
10b Combination 10 
1p12 (A1) (A) 
rs6011609 (A1) (A) 
 
11 Combination 11 
rs7246472 (A1) (A) 
rs7246472 (A2) (A) 
 
 
Given that the combinations outlined above vary slightly from those outlined during the inference 
analysis, OR and p-values were generated based on the testing set to confirm the cohorts outlined. 
Full decision trees can be found in Appendix G. Using the information from the CHAID analysis, 
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combinations outlined were analysed using the testing set. Table 6.13 outlines the results of the 
remaining combinations, where ‘?’ refers to combination inputs that are not factored in and do 
not affect the outcome. Results outlined in grey resulted in a p-value < 0.05 using the testing 
dataset and are carried forward. 
 
6.6.3 COMBINATION RELEVANCE 
Using the combinations outlined from Table 6.10 to Error! Reference source not found. and 
Table 6.13, further analysis is performed to consider their context to real-world information. 
Using penetrance and incidence to map the extent of their effect, a threshold of >60% is used to 
outlined results that present more effective significance to breast cancer. Table 6.15 presents data 
to outline the penetrance and incidence of each combination. Results outlined in grey surpassed 
the threshold of 60% penetrance. 
Penetrance: How many subjects have been affected by the phenotype that also carry the 
genomic interaction state? 
( | )
a
P Phenotype Genotype
a b
=
+
 
 
Incidence: What percentage of the sample population carry this genomic interaction state? 
( | )
a b
P Phenotype SamplePopulation
n
+
=  
 
Risk: How strongly associated is the presence of the genomic interaction state with the presence 
of the phenotypic state? 
odds of diseaseamong exposed ad
odds of diseaseamong unexposed bc
=  
 
TABLE 6.13: CHAID OUTPUT TESTING 
Interaction Model OR P 
1 A?AA 1.170 0.756 
3 G?G? 2.151 0.014 
4 G?A? 0.900 0.330 
5 G?G? 1.080 0.632 
8a A?A? 1.099 0.127 
8b A?A?A? 3.435 0.029 
9a A?A? 0.768 0.333 
9b G?A? 0.554 0.254 
10a G? 0.396 0.000 
10b A?A? 0.796 0.351 
11 AA 1.870 0.174 
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Table 6.16 presents the statistical characteristics of the top variants and interactions that were 
identified during this research.  
TABLE 6.14: REFERENCE OF MEASURE FOR REAL-WORLD RELEVANCE 
 Case Controls Total 
Exposed a b a+b 
Not Exposed c d c+d 
Total a+c b+d n 
 
TABLE 6.15: PENETRANCE AND INCIDENCE OF RESULT COMBINATIONS 
Interaction Model OR Penetrance Incidence (%) P 
rs4144827 (A1) (G) - rs4602520 (A1) (G) G?G? 2.151 60.0 1.90 0.0140 
rs6852865 (A1) (A) - rs7246472 (A1) (A) –  
rs6910087 (A1) (A) 
A?A?A? 3.435 56.2 0.70 0.0290 
1p12 (A1) (G) G? 0.396 60.3 2.44 0.0000 
rs6910087 Dominant 1.243 56.4 25.0 0.0151 
rs7246472 Dominant 1.243 54.0 18.2 0.0302 
rs4602520-rs6910087 
AAAG 1.192 56.0 19.4 0.0726 
AAGG 0.846 50.8 63.1 0.0369 
rs4602520-rs7246472 
Dominant 0.472 51.8 97.0 0.0020 
GAAC 1.925 67.5 3.00 0.0079 
rs6910087-rs7246472 
Dominant 1.453 61.1 5.00 0.0456 
AGAC 1.597 63.3 4.00 0.0208 
GGCC 0.787 50.0 61.5 0.0026 
rs4602520, rs6910087, rs7246472 
AAGGCC 0.848 50.4 51.6 0.0323 
GAAGAC 2.931 76.2 0.80 0.0364 
rs4144827 Dominant 1.252 57.2 12.5 0.0555 
rs4144827-rs4602520 
Dominant 2.042 68.9 2.30 0.0106 
GAGA 2.151 70.0 2.00 0.0138 
rs6852865-rs4602520-rs6910087-rs7246472 GGAAGGCC 0.847 50.3 50.5 0.0307 
rs6852865-rs6910087-rs7246472 
AGAGAC 3.435 79.0 0.70 0.0287 
GGGGCC 0.831 50.1 52.2 0.0165 
1p12 Dominant 0.394 69.7 2.50 0.0006 
1p12-rs6011609 
AAGG 1.774 52.6 95.0 0.0016 
GAGG 0.422 47.0 2.40 0.0016 
rs6911024 Dominant 1.237 56.4 25.0 0.0171 
rs6911024,rs7246472  
AACC 1.265 56.0 38.5 0.0030 
GAAC 0.643 52.0 96.0 0.0279 
rs4602520,rs6911024 AAAA 1.177 55.0 37.0 0.0414 
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Using the OR value from each of the combinations produced from the testing dataset, Figure 6-23 
demonstrates the deviation from OR = 1. This provides information as to whether the interaction 
combination presents a risk or protective factor and how big that factor is. Additionally, the 
confidence intervals show the precision of the OR. 
 
As presented from Figure 6-23, most interactions indicate a risk factor, with only one set 
indicating a protective factor (1p12 (Dominant) (G?G?)). Here it is possible to compare the 
statistically available risk score for each interaction outlined during the process. While it would 
seem the most affecting interaction would be rs6852865-rs6910087-rs7246472-AGAGAC, this 
interaction also presents a large confidence interval, limiting the amount of confidence in the 
interaction. Further to this, the confidence intervals of the interactions varies with the largest 
TABLE 6.16: STATISTICAL CHARACTERISTICS OF TOP INTERACTIONS 
ID Interaction State OR RR 
Penetrance  
(%) 
Incidence  
(%) 
P 
1 1p12 Dominant 0.394 0.578 69.7 2.50 0.0006 
2 1p12  G? 0.396 0.397 60.3 2.44 0.0000 
3 rs4144827-rs4602520 Dominant 2.041 1.324 68.9 2.30 0.0106 
4 rs4144827 - rs4602520  G?G? 2.151 2.141 60.0 1.90 0.0140 
5 rs4144827-rs4602520 GAGA 2.151 1.345 70.0 2.00 0.0138 
6 rs4602520-rs7246472 GAAC 1.925 1.119 67.5 3.00 0.0079 
7 rs4602520- rs6910087-rs7246472 GAAGAC 2.931 1.460 76.2 0.80 0.0364 
8 rs6910087-rs7246472 Dominant 1.453 1.176 61.1 5.00 0.0456 
9 rs6910087-rs7246472 AGAC 1.597 1.219 63.3 4.00 0.0208 
10 rs6852865-rs6910087-rs7246472 AGAGAC 3.435 1.513 79.0 0.70 0.0287 
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FIGURE 6-23: ODDS RATIO PLOT FOR TOP RESULTS 
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observable in risk interaction, rs6852865-rs6910087-rs7246472-AGAGAC and the smallest 
observable in risk interaction, rs6910087-rs7246472-AGAC.  
DISCUSSION 
The proposed methodology functions as a filter, reducing the feature set through the stages 
performed. The first stage, QC, used ~500K SNPs and ~28K subjects provided by the DRIVE 
project. The performed processes are further defined in section 5.1  but an overview of the process 
results are available in Table 6.1. This stage resulted in a dataset of 320,247 features and 13,649 
observations. Using the output from QC, training and testing datasets were split 75:25. Random 
Cohort Sampling was performed to split the training dataset into 9 sizeable subsets of individuals 
to create a viable averaging sample size for later in further stages. The sample sizes were 
proportional in the number of cases and controls that were assigned to each subset as demonstrated 
in  
Figure 6-4. 
The first set of results that were provided during the methodology that demonstrated the 
significance of features within the data were obtained during the association analysis stage. 
During this stage, an association analysis was performed for each of the 9 outlined subsets from 
previous stages. A further association analysis was performed on the full data output after the QC 
stage for the purpose of a comparison with standard methods and was further used in the feature 
selection stage. The results from the association analysis showed a number of suggestive values 
within the standard GWAS approach, however there were no features that exceeded the genome-
wide significance threshold. In Figure 6-10 a comparison was undertaken to view the difference 
between the values obtained from the standard GWAS and the proposed ‘random sampling 
regularisation’ method. This shows a vast difference between the values obtained by each method 
that indicate that either the features from the standard GWAS are inflated or that the values from 
the ‘random sampling regularisation’ method are extremely undervaluing the expression of the 
feature. 
Using the standard GWAS and ‘random sampling regularisation’ method results, feature selection 
was performed. At this stage, benchmarking was outlined to measure the performance of the 
proposed methodology against standard methods while using a balanced multiple testing 
adjustment method to optimise false discovery rate outcomes against the proposed methodology. 
These methods were split into cases 1-4. Case 1 represented the proposed methodology and used 
the mean and standard deviation of the 9 sample measures from association analysis to control 
for consistency in the feature set, resulting in an output of 57 variables. Within this method, 
genomic control was used to control for population stratification. Case 2 was applied to the 
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standard GWAS method and represented a lenient approach, foregoing the use of genomic control 
to increase the feature set size to 48. Case 3 represented the most conservative approach, using 
genomic control and a threshold of p<0.3 that, while very lenient for q-value, resulted in a feature 
set of 17. Finally, Case 4 provided a balance between the two, applying genomic control and q-
value but increasing the threshold to 0.4, yielding a feature set of 37.  
Feature sets extracted from feature selection for each case were input into LAMPlink which 
outlined combination relationships that were evidenced in the data with threshold <0.005. As 
many of the feature sets contained the same SNPs, it was expected that there would be overlap in 
the combinations detected by each method. Therefore, the combinations were combined into one 
set. At this stage, the first deviation within the utilised methods is visible; Table 6.6 displays the 
combinations alongside the case methods that detected them. It is important to note at this stage 
that any methods that detected combinations that encompassed others were also noted to have 
detected the subset e.g. rs4602520-rs7246472 is a subset relationship of rs4602520-rs6910087-
rs7246472. Case 1 detected 4 combinations, case 2 detected 7 combinations, case 3 detected 2 
combinations and case 4 detected 5 combinations. From the standard method cases, it appears that 
the number of combinations that were detected depended on the number of SNPs that were input 
into LAMPlink, however it should be noted at this stage that while the proposed methodology 
had the largest feature set it produced the lowest number of combinations. Further to this, it is 
also noted that one of the combinations outlined by case 1 did not present cross-chromosome 
interaction; during this study it has not been omitted in order to demonstrate the lack of 
information presented from such interactions. Therefore, it would be considered that the proposed 
methodology only detected 3 viable combinations. 
Using the combinations outlined from LAMPlink, each interaction was expanded and explored 
to consider the relationships between all SNPs and genomic states. During this stage, 3 different 
statistical methods were applied in order to compare results using various assumptions, this also 
serves as an outcome control to produce results that conclusively agree upon a result (within a 
small deviation from one another). Odds Ratio would give a measure of the effect size of the 
association between the genotypic presence and phenotypic presence. The genomic states were 
based on additive, dominant and recessive models, additionally exhaustive allelic states were also 
tested. This would consider the effect of the presence of dominant and recessive alleles while 
taking into consideration the singular genotypic states. Allelic states were used to consider the 
potential effect of a singular genomic state in the population. Results indicated an abundance of 
combinations that showed significance with the phenotype, any and all results that expressed < 
0.05 were further analysed using a fresh testing dataset. 
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During the testing phase, a large majority of the outlined combinations were excluded due to low 
significance p-value. Penetrance and incidence were computed for the remaining combinations to 
consider the real-world effect of the combination. Using a lenient threshold of >60%, any 
combinations that showed a penetrance greater than this threshold were outlined. Further to this, 
it was considered that although every combination state had been analysed, an exhaustive search 
had not been performed. By using the allelic forms of the SNP combinations, further exploration 
using CHAID trees was able to outline further combinations that showed significance. These 
combinations were generated by omitting features to consider the presence effect of one allele 
within a SNP. These results are outlined in Table 6.12. 
At this stage, an example of the predictive power available when using ML methods is provided 
in order to concur the suitability of alternative classification method CHAID in scenarios where 
few variants are outlined for classification analysis. Figure 6-24 provides a demonstration of 
machine learning model, Multi-Layered Perceptron, with small sets and shows the limitations that 
exist when applying classification to small feature sets, particularly in cases of linearly separable 
problems that do not warrant autonomous processes such as machine learning.  
 
In order to confirm these finding, each combination was first compared against the previously 
outlined combinations to ensure that each new combination was presenting a better genomic 
option in either penetrance or incidence. Combinations outlined in grey in did not present a more 
significant option. Further to this, each combination was testing using the test dataset to confirm 
the finding from the CHAID analysis, however many of the combinations did not confirm a 
significant p-value, and those that did, showed little penetrance in the population.  
 
FIGURE 6-24: STANDARD MLP CLASSIFICATION USING FEATURE INTERACTION RS4602520 – RS7246472 
–GAAC. 
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The final set of variants as outlined in Table 6.16 showed a penetrance of >60%, significant p-
value <0.05 and an OR >1 or OR <1. A focus of analyses in biomarkers requires real-world effect; 
this would entail reproducing the information in a clinical setting; however, this is not option at 
this point in time. The visualisation in Figure 6-27(a)-(d) provide a guidance for how significant 
these biomarkers appear to be given the information produced from this study using a separate 
colour for each case.. These bubble plots visualise the OR by the penetrance, while the size of the 
bubble indicates the incidence (population size) that carry the biomarker.  
To further contextualise this information, Figure 6-26 presents a visualisation of the interactions 
with reference to the infamous BRCA1 gene using stats from Table 6.16 to plot by penetrance, 
incidence and risk association. Visible is the difference in effected size, BRCA1 is present in 
between 5%-15% of familial cases. The most prominent interactions found were collectively 
assembled using one or more of the SNPs in Table 6.17. 
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FIGURE 6-25: INTERACTIONS DETECTED USING THE PROPOSED METHODOLOGY. INTERACTIONS HIGHLIGHT 
IN GREY WERE NOT DETECTED. 
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Using online tool SNPNexus [194], each SNP was explored for related publications that have 
highlighted or used SNPs in the context of histology and/or cancer. According to this tool, there 
are no publications in relation to cancer for these SNPs.  
The 1p12 region of chromosome 1 appeared in a number of publication referring to its effect in 
breast cancer. [195] referred to its copy number imbalances, specifically in the case of losses 
could be used as a prognostic marker. Similarly [196] claims that alterations on 1p12 in relation 
to gene PHGDH are amplified in ~6% of breast cancers and 40% of melanomas. 
The consequences of the outlined SNPs could lead to classification, prognostic, susceptibility or 
treatment guidance health systems particularly concerning the age of personalised medicine 
during which treatment will be catered to individual biomarkers including genetic variants. From 
the research presented, novel candidate variants have been outlined (See Table 6.17) as 
interactions as outlined in Table 6.16. 
It should also be noted that the novel variants outlined during this study could be due to the 
optimised Illumina array whose specified 570K genotypic marker not only contain the most 
common 260K variants but additionally focus on the markers of interest for 5 cancer diseases. 
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FIGURE 6-26: INTERACTIONS DETECTED IN COMPARISON WITH THE INFAMOUS BRCA1 GENE. 
 
 
TABLE 6.17: GENOMIC CHARACTERISTIC OF INTERACTION VARIANTS 
Variant Chr Pos (BP) Allele Gene/Nearest 
1p12 1 120124218 C/T HSD3BP4 (nearest(bp=9484) 
rs4602520 4 61360284  AC095061.1 (nearest(bp=169383) 
rs6910087 6 31377047 
 
MICA/HCP5 
rs7246472 19 29389111 C/A AC011524.1 
rs6852865 4 61251815 C/T AC095061.1 (nearest(bp=277852) 
rs4144827 2 164114775 T/C RNU6-627P (nearest(bp=30730) 
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 (a) 
(b) 
(c) 
(d) 
FIGURE 6-27: DETECTED INTERACTIONS BASED ON EMPLOYED METHOD (A) CASE 1 (B) CASE 2 (C) CASE 3 (D) 
CASE 4. 
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Chapter 7: CONCLUSION & FUTURE WORK 
In this research, a novel methodology was proposed that caters for the needs of epistasis 
improving flexibility and inspired by random forests machine learning method. The novel 
methodology outlined in this research presents a statistically conservative option that outlines a 
number of interactions that present viable and reliable options that aim to improve reproducibility 
by using consistently transparent methods that are fully interpretable. To elaborate, the viability 
of these variants is conferred by the penetrance and risk, with initial results indicating its relevance 
using a variety of permutation tests in both training and testing datasets to indicate its significance 
of <0.05. Reliability is conferred using cascading statistical filters that aim to investigate and 
reduce the candidate set assuming a null hypothesis. In the context of this research, reliability is 
defined as the performance in relation to Odd’s Ratio and Fisher’s exact test, of which the novel 
methodology presents interaction candidates with unwavering performance of the feature 
regardless of the observations presented.  
Reproducibility can be split into two different applications; reproducibility of the study is 
conferred using interpretable methods that can be replicated. Reproducibility of the variants can 
only be determined with a second study using an entirely different cohort set; this is harder to 
determine as although the evidence within this research suggest high significance in these 
candidate variants in relation to breast cancer, an additional dataset must be used to confirm the 
findings. The following sections discuss the contributions of the research with respect to the 
disciplines presented in this thesis.  
The proposed methodology, RaSaR, outlined in this research has identified all but one of the most 
prominent and reliable variant interactions identified through each method. Figure 6-27 provides 
an overview of the interactions identified by each method as outlined in section 6.4 . Visible in 
Figure 6-27 is the clear distinction between the number of interactions identified by each method. 
The most successful method during this research next to the proposed methodology is Case 2 
which used a threshold of p<0.01 without applying genomic control. Case 3, using a threshold of 
q < 0.3, produced no interaction results, but was still able to pick the variant that effected the 
largest proportion of the population. Case 4, using a threshold of q < 0.4, was a more lenient 
approach but was still only able to identify a minority of the interaction results.  
This indicates that while multiple testing approaches can successfully identify the most prominent 
and reliable single-variant SNPs, they lack the statistical flexibility that is required when 
performing an Epistasis approach. Interactions that would indicate significance with a given 
phenotype will commonly be masked by other more dominating variants, particularly taking into 
consideration the long-standing issue of false positive rate. Therefore, the proposed methodology 
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attempts to address the issue before the false detection rate becomes a problem. This method also 
affords the flexibility and lenience required to identify candidate variants for further analysis by 
applying a threshold that is lenient (µ<0.05) but demanding consistency in this threshold by 
excluding any values whose σ sits outside of the specified threshold (σ. <0.025). 
To discuss the issue that is present in the method of case 2, the abundance of interactions initially 
identified by this method could demonstrate and indicate the effects of not employing the genomic 
control method. By overlooking population stratification and omitting methods to control for 
population structure, the number of identified interactions is increased. While it could be argued 
that the number of interactions is directly related to the number of variants outlined during feature 
selection, it should be noted that the proposed methodology uses a much larger selection that did 
not produce as many interactions.  
LIMITATIONS OF THE METHOD 
While the performance of the method has been proven significant in this research, there still 
remains issues that will likely effect outcomes either in a lenient or conservative fashion. One of 
the most prominent issues is the balance of the standard deviation threshold. While the method is 
adaptable to specify lenient or conservative thresholds, it is subject to the effects of anomalous 
data points; this occurrence would present a particular problem in cases were the majority of data 
points for one variant crowd in a tight cluster with one data point expressing in an anomalous 
range. The difficulty in addressing this point is the removal of any information could be extracting 
from the true representation of the variant.  
Further to this, due to the nature of the method, it is accepted that an increase in False Negatives 
is a likely outcome of the use of this methodology. Additionally, rare alleles may be overlooked 
during association analysis due to lack of supporting evidence in each subset. Therefore, it is 
proposed that the outlined methodology would perform optimally for complex and common 
diseases.  
While this research aims to address the issues that consistently plague the genomic research 
community, its viability has not been confirmed during this preliminary study. Further to this, 
while the exposure to type 1 errors is reduced in this method, it is still susceptible to the probability 
of chance, and will therefore still present type 1 errors. 
FUTURE WORK 
While novel contributions have been provided using the proposed methodology there are still 
areas that can be improved, and further research undertaken within the genomic community. The 
following section outlines areas for improvement pertaining to the methodology and further work 
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that can be conducted using the proposed methodology. In its’ early stages, one of the main areas 
for future work is related to RO2, false discovery rate, which would encourage the further 
development and confirmation of false positive rate reduction across a number of datasets to 
empirically measure the rate of improvement. This work requires further analyses to confirm the 
reliability of results, using a variety of datasets that range from small to large within the area of 
complex diseases. This will test the effects of the methodology and the efficacy of the epistasis 
detection capabilities given varying circumstances of the data.  
Another effort of this research would be in the event of higher computational power, to benefit 
from the use of bootstrapping [197]. A large part of the effectiveness of this methodology lends 
itself to the effects of random sampling distribution; bootstrapping would provide an option to 
extend the k-fold sampling options to k > 1000, improving the standard deviation distribution 
metric that is heavily relied on in the feature selection method. 
Further to this, the proposed methodology requires a lot of manual work to produce results, future 
work would focus on creating an autonomous algorithm that can perform stages 2-3, Random 
Cohort Sampling and Association Analysis. With its adaptability, the algorithm could be 
applicable in other fields outside of genomics such as social response; exploration into its 
transferrable aspects would be applicable for fields that use large datasets. 
Concerning Breast Cancer, further research would focus on the reproducibility of these results 
using a separate dataset. A large sample size is required to pick up small interactions as the ones 
outlined in the results however with the current efforts in breast cancer, many large data samples 
are available via repositories such as DBGaP. The outlined future work demonstrates the intended 
efforts of the research to further evaluate the methodology. This discussion also outlines the 
potential adaptability of the methodology and areas for progression outside of the current field. 
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APPENDIX A  
Selected Features Pre-Epistasis 
CASE 1 
SNP CHR f_1 f_2 f_3 f_4 f_5 f_6 f_7 f_8 f_9 σ µ 
chr1_120124218_C_T 1 0.00182 0.000126 0.005829 0.001369 0.000856 0.001115 0.002829 0.03847 0.000913 0.005925 0.012318 
chr2_121527169_A_G 2 0.1113 0.01447 0.01938 0.001959 0.002855 0.1026 0.000592 0.004446 4.08E-05 0.028627 0.044939 
chr2_216887593_A_G 2 0.003812 0.06652 0.001706 0.002489 0.003678 0.03752 0.03734 0.001355 0.004537 0.017662 0.023662 
chr2_47786807_A_C 2 0.01738 0.000375 0.000152 0.01725 0.0389 0.03229 0.003164 0.02648 0.06438 0.022263 0.021067 
chr3_119792288_A_G 3 0.000993 0.1113 0.005661 0.09253 0.000241 0.000483 0.000303 0.000394 0.0117 0.024845 0.044109 
chr6_31240692_A_G 6 0.006081 0.02646 0.118 0.01452 0.003859 0.000523 0.00456 0.003871 0.002688 0.020062 0.037596 
chr6_31330066_A_G 6 0.005048 0.02416 0.004371 0.01483 0.00084 0.000487 0.000649 0.002386 0.01676 0.007726 0.008653 
chr6_31336100_A_C 6 0.004838 0.02507 0.004706 0.01985 0.001114 0.00054 0.000683 0.002495 0.01945 0.00875 0.009783 
chr6_31342960_A_C 6 0.01365 0.03372 0.002003 0.04623 0.003024 0.002536 0.001411 0.01107 0.1018 0.023938 0.033186 
chr6_31368964_A_G 6 0.004065 0.06527 0.0187 0.04392 0.03023 0.01131 0.005611 0.000279 0.004602 0.020443 0.022047 
chr9_74065947_C_T 9 0.002531 0.04396 0.000805 0.004719 0.000763 0.01025 0.0266 0.006482 0.03447 0.014509 0.016243 
chr9_74076686_A_C 9 0.002709 0.03031 0.004877 0.0117 0.000573 0.001676 0.02811 0.02879 0.086 0.021638 0.027136 
kgp12436430 8 0.009594 0.02186 0.000119 0.003364 0.02802 0.05406 0.02533 0.001156 0.03869 0.020244 0.018508 
rs11609829 12 0.01699 0.02939 0.06681 0.02777 0.01285 0.02808 0.01992 0.02397 0.003893 0.025519 0.017558 
rs11640710 16 0.07423 0.02145 0.02478 0.005283 0.0409 0.01157 0.0119 0.005686 0.01879 0.023843 0.021878 
rs11876265 18 0.005667 0.002553 0.02367 0.001862 0.003959 0.002207 0.002639 0.002979 0.000346 0.005098 0.007115 
rs11994 5 0.03106 0.006043 0.02204 0.000508 0.05345 0.005827 0.01599 0.000803 0.002904 0.015403 0.017705 
rs1550638 15 0.0119 0.006787 0.001119 0.02548 0.008662 0.02758 0.01736 0.06301 0.07601 0.026434 0.026063 
rs17330266 18 0.002136 0.000193 0.008551 0.001067 0.002476 0.000189 0.000789 0.003275 0.000726 0.002156 0.002624 
rs1851736 1 0.000658 0.01329 0.01798 0.0783 0.006799 0.0136 0.04949 0.04732 0.01708 0.027169 0.025494 
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rs2216470 12 0.04042 0.001243 0.01474 0.01813 0.004552 0.03631 0.000568 0.07027 0.000671 0.020767 0.023921 
rs2428486 6 0.003534 0.07156 0.02052 0.04497 0.02519 0.005154 0.004643 0.000206 0.006785 0.020285 0.023985 
rs247930 12 0.003459 0.005506 0.000288 0.1397 0.006085 0.06417 0.000736 0.02051 0.01346 0.028213 0.046303 
rs2507976 6 0.02488 0.01888 0.04445 0.0744 0.04608 0.01164 0.002606 0.005862 0.009081 0.026431 0.023931 
rs2523467 6 0.005946 0.05795 0.02307 0.04159 0.04347 0.01039 0.004396 0.000203 0.004172 0.021243 0.021297 
rs2596542 6 0.004849 0.05725 0.01852 0.03598 0.03433 0.0129 0.006809 0.000337 0.004564 0.019504 0.019128 
rs28391573 18 0.03864 0.001486 0.01391 0.000672 0.01387 0.03901 0.03298 0.05101 0.001915 0.021499 0.01916 
rs2844529 6 0.003628 0.07022 0.02098 0.04331 0.02519 0.005154 0.004643 0.000208 0.00648 0.019979 0.023431 
rs2844551 6 0.004967 0.01009 0.001794 0.02926 0.02913 0.003048 0.001096 0.000453 0.02299 0.011425 0.012241 
rs2974161 2 0.02873 0.02691 0.02412 0.003423 0.006656 0.06097 0.04284 0.03296 0.002816 0.025492 0.019319 
rs34821683 6 0.05632 0.08188 0.006892 0.02612 0.02817 0.02521 0.00381 0.002211 0.03115 0.029085 0.026008 
rs3819301 6 0.08141 0.02584 0.03642 0.001338 0.01626 0.002445 0.01476 0.006418 0.02749 0.023598 0.024741 
rs3924215 9 0.004817 0.00149 0.01314 0.002765 0.01826 0.000105 0.004169 0.001316 0.01934 0.007267 0.007558 
rs4144827 2 0.01268 0.009614 0.01489 0.02963 0.04619 0.08597 0.00905 0.006917 0.001235 0.02402 0.026963 
rs4313504 10 0.000143 0.01838 0.003775 0.01751 0.01612 0.105 0.08949 0.001705 0.000804 0.028103 0.040074 
rs4357555 1 0.001442 0.09346 0.008807 0.05822 0.001121 0.02388 0.01442 0.01112 0.008245 0.024524 0.031149 
rs4602520 4 0.001682 0.06598 0.002737 0.000396 0.00037 0.1038 0.00943 0.000108 5.14E-06 0.020501 0.037823 
rs4624908 6 0.01399 0.03197 0.001756 0.05327 0.003114 0.002584 0.001129 0.01149 0.1094 0.025411 0.035995 
rs4959071 6 0.01352 0.01276 0.000461 0.00325 0.004586 0.001637 0.000631 0.00055 0.0243 0.006855 0.008279 
rs6011609 20 5.22E-05 0.002207 0.001765 0.003905 0.000251 0.002862 0.04853 0.026 0.004507 0.010009 0.016513 
rs6457402 6 0.003945 0.03393 0.003413 0.02647 0.002142 0.001092 0.00159 0.002383 0.03262 0.011954 0.014453 
rs6602225 10 0.003387 0.02439 9.63E-05 0.000232 0.000402 0.000199 0.02661 0.002504 0.2036 0.029047 0.066314 
rs6842825 4 0.000709 0.003448 0.01009 0.0212 0.02919 0.02815 0.009897 0.002404 0.000386 0.011719 0.011597 
rs6910087 6 0.07913 0.02305 0.000698 0.003268 0.003939 0.004515 0.001973 0.00919 0.09944 0.025023 0.037386 
rs6911024 6 0.07119 0.0185 0.000366 0.001538 0.002153 0.002887 0.001472 0.007005 0.08943 0.021616 0.03404 
rs6932730 6 0.03496 0.09316 0.009491 0.02453 0.02483 0.01279 0.007462 0.002182 0.0447 0.028234 0.027967 
rs6936035 6 0.007011 0.03223 0.001297 0.04873 0.000881 0.001464 0.000885 0.01216 0.09253 0.02191 0.031339 
rs7246472 19 0.01032 0.005216 0.00598 0.000163 0.002913 0.001664 0.04812 0.01114 0.01721 0.011414 0.014765 
rs7754026 6 0.01635 0.03372 0.002003 0.04348 0.003306 0.003153 0.001411 0.01146 0.09688 0.023529 0.031337 
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rs7775117 6 0.01477 0.03372 0.002003 0.04348 0.003306 0.002775 0.001411 0.01036 0.09688 0.023189 0.031472 
rs7822226 8 0.02228 0.000107 0.04509 0.003857 0.02694 0.02529 3.84E-05 0.001079 4.07E-07 0.013854 0.016521 
rs787025 10 0.03863 0.02815 0.001523 0.004796 0.001821 0.1349 0.009349 0.02958 0.005688 0.028271 0.042298 
rs8066706 17 0.006088 0.001389 0.00598 0.02501 0.03331 0.1496 0.002088 0.006453 0.000165 0.025565 0.047898 
rs8182119 16 0.1238 0.02538 0.01492 0.006323 0.01586 0.002915 0.00178 0.006008 0.03626 0.025916 0.03841 
rs859767 2 0.02451 0.001383 4.48E-05 0.003264 0.01783 0.01585 9.73E-05 0.000343 0.00635 0.007741 0.009244 
rs9263475 6 0.05646 0.007221 0.014 5.40E-05 0.01736 0.007351 0.08937 0.0111 0.01512 0.024226 0.029257 
rs9958743 18 0.002309 0.0002 0.00809 0.00129 0.002492 0.000212 0.000578 0.003044 0.000658 0.002097 0.00248 
 
132 
 
CASE 2 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR 
1 chr1_120124218_C_T 1.2E+08 G 0.00884 0.01772 A 33.06 8.93E-09 0.4943 
1 chr1_214950361_A_G 2.15E+08 G 0.07362 0.09216 A 24.74 6.56E-07 0.7829 
2 chr2_121527169_A_G 1.22E+08 A 0.02629 0.03834 G 25.35 4.78E-07 0.6774 
2 rs859767 1.35E+08 G 0.3967 0.3596 A 31.84 1.67E-08 1.171 
2 rs2280219 1.35E+08 A 0.3826 0.3507 G 23.88 1.02E-06 1.147 
2 rs6750788 1.35E+08 A 0.3933 0.3596 G 26.28 2.95E-07 1.154 
2 rs6759065 1.35E+08 A 0.3945 0.3607 G 26.52 2.61E-07 1.155 
2 rs6705916 1.35E+08 G 0.4691 0.4357 A 24.41 7.79E-07 1.144 
2 rs6430538 1.36E+08 A 0.4567 0.4182 G 32.85 9.96E-09 1.17 
2 rs3769027 1.36E+08 G 0.2764 0.2466 A 24.91 6.01E-07 1.167 
2 rs3814354 1.36E+08 A 0.4831 0.4468 G 28.87 7.74E-08 1.157 
2 chr2_216887593_A_G 2.17E+08 A 0.3378 0.3697 G 24.24 8.51E-07 0.8698 
3 chr3_119792288_A_G 1.2E+08 A 0.02366 0.01371 G 29.05 7.04E-08 1.743 
4 rs6842825 57125176 A 0.02007 0.01141 G 26.03 3.36E-07 1.774 
4 rs6852865 61251815 A 0.08693 0.06933 G 23.31 1.38E-06 1.278 
4 rs4602520 61360284 G 0.09108 0.06984 A 32.8 1.02E-08 1.334 
5 rs3756765 1.38E+08 A 0.2056 0.2329 G 23.72 1.11E-06 0.8525 
5 rs11994 1.5E+08 A 0.3961 0.4292 G 24.62 6.98E-07 0.8724 
6 chr6_31240692_A_G 31240692 A 0.423 0.3899 G 24.67 6.82E-07 1.147 
6 chr6_31330066_A_G 31330066 G 0.2644 0.2328 A 28.97 7.36E-08 1.184 
6 rs6457402 31334864 A 0.2507 0.2211 C 26.37 2.82E-07 1.178 
6 chr6_31336100_A_C 31336100 A 0.2643 0.2331 C 28.26 1.06E-07 1.182 
6 rs6936035 31341156 G 0.2294 0.2017 A 24.69 6.74E-07 1.178 
6 rs2844551 31342781 G 0.32 0.288 A 26.4 2.77E-07 1.164 
6 rs4959071 31346436 G 0.1722 0.1451 A 29.88 4.59E-08 1.226 
6 rs2844529 31353593 A 0.354 0.323 G 23.32 1.37E-06 1.148 
6 rs2428486 31354104 G 0.354 0.323 A 23.28 1.40E-06 1.148 
6 rs6911024 31368451 G 0.1394 0.1164 A 25.52 4.37E-07 1.229 
6 rs6910087 31377047 A 0.1403 0.1183 G 23.35 1.35E-06 1.216 
8 rs11992223 4089132 A 0.4394 0.4034 C 28.92 7.56E-08 1.159 
8 rs7822226 4091132 G 0.4864 0.4472 A 33.4 7.50E-09 1.171 
9 chr9_74065947_C_T 74065947 A 0.07308 0.09148 G 24.55 7.23E-07 0.783 
9 rs3924215 1.35E+08 G 0.1193 0.1439 A 28.99 7.27E-08 0.8058 
10 rs6602225 7124442 A 0.1873 0.1593 C 29.61 5.28E-08 1.216 
10 rs9703900 58994564 G 0.3853 0.3533 A 24 9.65E-07 1.148 
10 rs4313504 1.01E+08 A 0.1491 0.1732 G 23.55 1.22E-06 0.8362 
11 rs10736499 1.19E+08 G 0.3019 0.2709 A 25.61 4.19E-07 1.164 
11 rs10790316 1.19E+08 A 0.3596 0.3279 G 24.3 8.26E-07 1.151 
11 rs7950231 1.19E+08 G 0.3632 0.3309 A 25.12 5.38E-07 1.154 
12 rs2216470 46101115 A 0.4675 0.4347 G 23.68 1.14E-06 1.142 
12 rs247930 46239012 G 0.5094 0.4766 A 23.43 1.30E-06 1.14 
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17 rs8066706 1692140 G 0.03181 0.02091 A 25.02 5.69E-07 1.539 
18 rs17330266 73695934 A 0.269 0.2338 G 35.84 2.14E-09 1.206 
18 rs9958743 73697477 A 0.2691 0.2338 G 35.92 2.06E-09 1.206 
18 rs11876265 73706661 G 0.2803 0.2476 A 30.05 4.20E-08 1.184 
19 rs7246472 29389111 A 0.09928 0.0795 C 26.08 3.27E-07 1.276 
20 rs6011609 61727307 A 0.009231 0.01781 G 30.2 3.90E-08 0.5139 
22 rs12170250 29538730 A 0.01823 0.01036 G 23.67 1.15E-06 1.774 
 
CASE 3 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR 
1 chr1_120124218_C_T 1.2E+08 G 0.00884 0.01772 A 33.06 8.93E-09 0.4943 
2 rs859767 1.35E+08 G 0.3967 0.3596 A 31.84 1.67E-08 1.171 
2 rs6430538 1.36E+08 A 0.4567 0.4182 G 32.85 9.96E-09 1.17 
2 rs3814354 1.36E+08 A 0.4831 0.4468 G 28.87 7.74E-08 1.157 
3 chr3_119792288_A_G 1.2E+08 A 0.02366 0.01371 G 29.05 7.04E-08 1.743 
4 rs4602520 61360284 G 0.09108 0.06984 A 32.8 1.02E-08 1.334 
6 chr6_31330066_A_G 31330066 G 0.2644 0.2328 A 28.97 7.36E-08 1.184 
6 chr6_31336100_A_C 31336100 A 0.2643 0.2331 C 28.26 1.06E-07 1.182 
6 rs4959071 31346436 G 0.1722 0.1451 A 29.88 4.59E-08 1.226 
8 rs11992223 4089132 A 0.4394 0.4034 C 28.92 7.56E-08 1.159 
8 rs7822226 4091132 G 0.4864 0.4472 A 33.4 7.50E-09 1.171 
9 rs3924215 1.35E+08 G 0.1193 0.1439 A 28.99 7.27E-08 0.8058 
10 rs6602225 7124442 A 0.1873 0.1593 C 29.61 5.28E-08 1.216 
18 rs17330266 73695934 A 0.269 0.2338 G 35.84 2.14E-09 1.206 
18 rs9958743 73697477 A 0.2691 0.2338 G 35.92 2.06E-09 1.206 
18 rs11876265 73706661 G 0.2803 0.2476 A 30.05 4.20E-08 1.184 
20 rs6011609 61727307 A 0.009231 0.01781 G 30.2 3.90E-08 0.5139 
 
CASE 4 
CHR SNP BP A1 F_A F_U A2 CHISQ P OR 
1 chr1_120124218_C_T 1.2E+08 G 0.00884 0.01772 A 33.06 8.93E-09 0.4943 
1 chr1_214950361_A_G 2.15E+08 G 0.07362 0.09216 A 24.74 6.56E-07 0.7829 
2 chr2_121527169_A_G 1.22E+08 A 0.02629 0.03834 G 25.35 4.78E-07 0.6774 
2 rs859767 1.35E+08 G 0.3967 0.3596 A 31.84 1.67E-08 1.171 
2 rs6750788 1.35E+08 A 0.3933 0.3596 G 26.28 2.95E-07 1.154 
2 rs6759065 1.35E+08 A 0.3945 0.3607 G 26.52 2.61E-07 1.155 
2 rs6705916 1.35E+08 G 0.4691 0.4357 A 24.41 7.79E-07 1.144 
2 rs6430538 1.36E+08 A 0.4567 0.4182 G 32.85 9.96E-09 1.17 
2 rs3769027 1.36E+08 G 0.2764 0.2466 A 24.91 6.01E-07 1.167 
2 rs3814354 1.36E+08 A 0.4831 0.4468 G 28.87 7.74E-08 1.157 
2 chr2_216887593_A_G 2.17E+08 A 0.3378 0.3697 G 24.24 8.51E-07 0.8698 
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3 chr3_119792288_A_G 1.2E+08 A 0.02366 0.01371 G 29.05 7.04E-08 1.743 
4 rs6842825 57125176 A 0.02007 0.01141 G 26.03 3.36E-07 1.774 
4 rs4602520 61360284 G 0.09108 0.06984 A 32.8 1.02E-08 1.334 
5 rs11994 1.5E+08 A 0.3961 0.4292 G 24.62 6.98E-07 0.8724 
6 chr6_31240692_A_G 31240692 A 0.423 0.3899 G 24.67 6.82E-07 1.147 
6 chr6_31330066_A_G 31330066 G 0.2644 0.2328 A 28.97 7.36E-08 1.184 
6 rs6457402 31334864 A 0.2507 0.2211 C 26.37 2.82E-07 1.178 
6 chr6_31336100_A_C 31336100 A 0.2643 0.2331 C 28.26 1.06E-07 1.182 
6 rs6936035 31341156 G 0.2294 0.2017 A 24.69 6.74E-07 1.178 
6 rs2844551 31342781 G 0.32 0.288 A 26.4 2.77E-07 1.164 
6 rs4959071 31346436 G 0.1722 0.1451 A 29.88 4.59E-08 1.226 
6 rs6911024 31368451 G 0.1394 0.1164 A 25.52 4.37E-07 1.229 
8 rs11992223 4089132 A 0.4394 0.4034 C 28.92 7.56E-08 1.159 
8 rs7822226 4091132 G 0.4864 0.4472 A 33.4 7.50E-09 1.171 
9 chr9_74065947_C_T 74065947 A 0.07308 0.09148 G 24.55 7.23E-07 0.783 
9 rs3924215 1.35E+08 G 0.1193 0.1439 A 28.99 7.27E-08 0.8058 
10 rs6602225 7124442 A 0.1873 0.1593 C 29.61 5.28E-08 1.216 
11 rs10736499 1.19E+08 G 0.3019 0.2709 A 25.61 4.19E-07 1.164 
11 rs10790316 1.19E+08 A 0.3596 0.3279 G 24.3 8.26E-07 1.151 
11 rs7950231 1.19E+08 G 0.3632 0.3309 A 25.12 5.38E-07 1.154 
17 rs8066706 1692140 G 0.03181 0.02091 A 25.02 5.69E-07 1.539 
18 rs17330266 73695934 A 0.269 0.2338 G 35.84 2.14E-09 1.206 
18 rs9958743 73697477 A 0.2691 0.2338 G 35.92 2.06E-09 1.206 
18 rs11876265 73706661 G 0.2803 0.2476 A 30.05 4.20E-08 1.184 
19 rs7246472 29389111 A 0.09928 0.0795 C 26.08 3.27E-07 1.276 
20 rs6011609 61727307 A 0.009231 0.01781 G 30.2 3.90E-08 0.5139 
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APPENDIX B  
LAMPlink combinations output based on features selected for each case. 
CASE 1 
COMBID RAW_P Adjusted_P COMB 
1 4.7615e-09 1.3856e-06 chr1_120124218_C_T 
2 7.6298e-09 2.2203e-06 rs4602520 
3 1.8594e-08 5.4108e-06 rs6011609 
4 2.0857e-08 6.0693e-06 rs3924215 
5 1.2047e-07 3.5057e-05 chr3_119792288_A_G 
6 4.9655e-07 0.0001445 rs6842825 
7 5.1652e-07 0.00015031 chr2_121527169_A_G 
8 6.1626e-07 0.00017933 rs6911024 
10 9.666e-07 0.00028128 rs8066706 
11 1.4024e-06 0.00040811 chr9_74065947_C_T 
12 1.4654e-06 0.00042642 chr2_47786807_A_C 
13 1.8291e-06 0.00053227 rs4602520, rs6910087,rs7246472 
14 2.1604e-06 0.00062868 rs7246472 
15 2.4134e-06 0.00070229 chr9_74065947_C_T, chr9_74076686_A_C 
17 2.8572e-06 0.00083143 rs787025 
18 3.2627e-06 0.00094946 chr9_74076686_A_C 
19 4.9796e-06 0.0014491 rs6910087 
20 1.0127e-05 0.0029469 rs4144827 
21 1.0708e-05 0.0031159 rs4144827, rs4602520 
 
CASE 2 
COMBID RAW_P Adjusted_P COMB 
1 4.7615e-09 1.2856e-06 chr1_120124218_C_T 
2 7.6298e-09      2.06e-06 rs4602520 
3 1.8594e-08    5.0204e-06 rs6011609 
4 2.0857e-08    5.6313e-06 rs3924215 
5 1.2047e-07    3.2527e-05 chr3_119792288_A_G 
6 1.4659e-07     3.958e-05 chr1_214950361_A_G, rs3924215 
7 1.9913e-07 5.3764e-05 rs6911024, rs12170250 
9 3.3143e-07 8.9486e-05 rs6852865, rs4602520 
10 4.9655e-07 0.00013407 rs6842825 
11 5.1652e-07 0.00013946 chr2_121527169_A_G 
12 5.3133e-07 0.00014346 rs6852865 
13 6.1626e-07 0.00016639 rs6911024 
15 9.666e-07 0.00026098 rs8066706 
16 1.0708e-06 0.00028911 chr1_214950361_A_G 
17 1.0939e-06 0.00029536 rs12170250 
18 1.4024e-06 0.00037866 chr9_74065947_C_T 
19 1.8291e-06 0.00049385 rs4602520, rs6910087,rs7246472 
20 2.1604e-06 0.00058331 rs7246472 
22 3.1746e-06 0.00085714 rs6852865, rs4602520,rs6910087,rs7246472 
23 3.9059e-06 0.0010546 rs6852865, rs6910087,rs7246472 
25 4.9796e-06 0.0013445 rs6910087 
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CASE 3 
COMBID RAW_P Adjusted_P COMB 
1 7.0224e-12 1.1938e-10 chr1_120124218_C_T 
2 1.6752e-08 2.8478e-07 rs6011609 
3 3.4216e-08 5.8167e-07 rs3924215 
4 8.0663e-08 1.3713e-06 rs4602520 
5 1.4145e-07 2.4046e-06 chr3_119792288_A_G 
6 5.473e-05 0.00093042 rs3924215, rs6011609 
7 8.6376e-05 0.0014684 chr1_120124218_C_T, rs6011609 
 
CASE 4 
COMBID RAW_P Adjusted_P COMB 
1 7.0224e-12 1.1657e-09 chr1_120124218_C_T 
2 1.6752e-08 2.7808e-06 rs6011609 
3 3.4216e-08 5.6799e-06 rs3924215 
4 3.7644e-08 6.2488e-06 rs6911024 
5 8.0663e-08 1.339e-05 rs4602520 
6 1.4145e-07 2.348e-05 chr3_119792288_A_G 
7 2.6106e-07 4.3336e-05 rs7246472 
8 2.9374e-07 4.8761e-05 chr1_214950361_A_G, rs3924215 
9 4.1186e-07 6.8369e-05 rs4602520, rs6911024,rs7246472 
10 1.0484e-06 0.00017404 rs6842825 
11 1.5974e-06 0.00026516 rs8066706 
12 2.4179e-06 0.00040137 chr1_214950361_A_G 
13 3.1453e-06 0.00052212 chr9_74065947_C_T 
14 3.8726e-06 0.00064285 rs6911024, rs7246472 
15 5.1619e-06 0.00085688 rs4602520, rs7246472 
16 8.0748e-06 0.0013404 rs4602520, rs6911024 
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APPENDIX C  
PPP Confidence Scores 
Combination C1 C2 C3 C4 
rs4602520; rs6910087; rs7246472 O O   
9q21.13; 9q21.13 O    
rs4602520; rs4144827 O    
1q41; rs3924215  O  O 
rs6911024; rs12170250  O   
rs6852865; rs4602520  O   
rs6852865; rs4602520; rs6910087; 
rs7246472 
 O   
rs6852865; rs6910087; rs7246472  O   
rs3924215; rs6011609   O  
1p12; rs6011609   O  
rs4602520; rs6911024; rs7246472    O 
rs6911024; rs7246472    O 
rs4602520; rs7246472 O O  O 
rs4602520; rs6911024    O 
 
 
Variant/s Adjusted p-value CHR 
rs4602520; rs6910087; rs7246472 0.00053227  
rs4602520 2.2203e-06 4 
rs6910087 0.0014491 6 
rs7246472 0.00062868 19 
Petals 2 0 
PPPConf = (2/3(.5))+((3-0)/3(.5)) = 0.83333 
 
Variant/s Adjusted p-value CHR 
chr9_74065947_C_T,chr9_74076686_A_C 0.00070229  
chr9_74065947_C_T 0.00040811 9 
chr9_74076686_A_C 0.00094946 9 
Petals 1 2 
PPPConf = (1/2(.5))+((2-2)/2(.5)) = 0.25 
 
Variant/s Adjusted p-value CHR 
rs4602520; rs4144827 0.0031159  
chr9_74065947_C_T 2.2203e-06 4 
chr9_74076686_A_C 0.0029469 2 
Petals 0 0 
PPPConf = (0/2(.5))+((2-2)/2(.5)) = 0.75 
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Variant/s Adjusted p-value CHR 
chr1_214950361_A_G,rs3924215 3.958e-05  
chr1_214950361_A_G 0.00028911 1 
rs3924215 5.6313e-06 9 
Petals 1 0 
PPPConf = (1/2(.5))+((2-0)/2(.5)) = 0.75 
 
Variant/s Adjusted p-value CHR 
rs6911024,rs12170250 5.3764e-05  
rs6911024 0.00016639 6 
rs12170250 0.00029536 22 
Petals 1 0 
PPPConf = (2/2(.5))+((2-0)/2(.5)) = 1 
 
Variant/s Adjusted p-value CHR 
rs6852865; rs4602520; rs6910087; rs7246472 0.00085714  
rs6852865 0.00014346 4 
rs4602520 2.06e-06 4 
rs6910087 0.0013445 6 
rs7246472 0.00058331 19 
Petals 1 2 
PPPConf = (1/4(.5))+((4-2)/4(.5)) = 0.375 
 
Variant/s Adjusted p-value CHR 
rs6852865; rs4602520; rs6910087; rs7246472 0.0010546  
rs6852865 0.00014346 4 
rs6910087 0.0013445 6 
rs7246472 0.00058331 19 
Petals 1 0 
PPPConf = (1/3(.5))+((3-3)/3(.5)) = 0.667 
 
Variant/s Adjusted p-value CHR 
rs3924215,rs6011609 0.00093042  
rs3924215 5.8167e-07 9 
rs6011609 2.8478e-07 20 
Petals 0 0 
PPPConf = (0/2(.5))+((2-0)/2(.5)) = 0.5 
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Variant/s Adjusted p-value CHR  
chr1_120124218_C_T,rs6011609 0.0014684  
chr1_120124218_C_T 1.1938e-10 1 
rs6011609 2.8478e-07 20 
Petals 0 0 
PPPConf = (0/2(.5))+((2-0)/2(.5)) = 0.5 
 
Variant/s Adjusted p-value CHR 
rs4602520,rs6911024,rs7246472 6.8369e-05  
rs4602520 1.339e-05 4 
rs6911024 6.2488e-06 6 
rs7246472 4.3336e-05 19 
Petals 0 0 
PPPConf = (0/3(.5))+((3-0)/3(.5)) = 0.5 
 
Variant/s Adjusted p-value CHR 
rs6911024,rs7246472 0.00064285  
rs6911024 6.2488e-06 6 
rs7246472 4.3336e-05 19 
Petals 0 0 
PPPConf = (0/2(.5))+((2-0)/2(.5)) = 0.5 
 
Variant/s Adjusted p-value CHR 
rs4602520,rs7246472 0.00085688  
rs4602520 1.339e-05 4 
rs7246472 4.3336e-05 19 
Petals 0 0 
PPPConf = (0/2(.5))+((2-0)/2(.5)) = 0.5 
 
Variant/s Adjusted p-value CHR 
rs4602520,rs6911024,rs7246472 0.0013404  
rs4602520 1.339e-05 4 
rs6911024 6.2488e-06 6 
Petals 0 0 
PPPConf = (0/2(.5))+((2-0)/2(.5)) = 0.5 
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APPENDIX D  
Interaction ID combinations 
ID Combination 
1 rs4602520, rs6910087, rs7246472 
2 9q21.13, 9q21.13 
3 rs4144827, rs4602520 
4 1q44, rs3924215 
5 rs6911024, rs12170250 
6 rs6852865, rs4602520 
7 rs6852865, rs4602520, rs6910087, rs7246472 
8 rs6852865, rs6910087, rs7246472 
9 rs3924215, rs6011609 
10 1p12, rs6011609 
11 rs4602520, rs6911024, rs7246472 
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APPENDIX E  
Inference Analysis extended training results 
EXTENDED VERSION OF TABLE 6.8 
Combination Variant/s Model/ 
Comb 
Results 
   F X2 CI < OR > CI  OR P 
1 rs4602520 Dominant 5.51e-09 6.32e-09 1.253399 1.370042 1.497540 5.889e-09 
Additive 3.63e-08 4.017e-08     
Recessive 0.264 0.2768 0.9099653 1.276314 1.7901530 0.2356 
rs6910087 Dominant 1.895e-06 2.14e-06 1.151754 1.241021 1.337206 1.955e-06 
Additive 5.189e-06 5.407e-06     
Recessive 0.01464 0.01573 1.117309 1.393698 1.738458 0.0135 
rs7246472 Dominant 1.317e-06 1.503e-06 1.177445 1.281104 1.393890 1.371e-06 
Additive 6.017e-07 6.844e-07     
Recessive 0.001678 0.002388 1.396208 2.046763 3.000439 0.002069 
rs4602520, rs6910087 Dominant 2.216e-05 2.815e-05 1.296391 1.531307 1.808791 2.568e-05 
Recessive NA NA NA NA NA NA 
AAAA   1.090952 1.388031 1.766008 0.02513 
AAAG   1.035472 1.124566 1.221325 0.01931 
AAGG   0.7074017 0.756109 0.8081700 4.984e-12 
GAAG   1.272643 1.52535 1.828236 0.0001259 
GAAA   0.7790973 1.375466 2.4283307 0.3563 
GGAG   0.8988065 1.667903 3.0951043 0.1735 
GGGG   0.7310389 1.106232 1.6739878 0.6885 
GAGG   1.159623 1.285759 1.425616 6.228e-05 
rs4602520, rs7246472 Dominant 0.0005296 0.0005853 1.256756 1.543559 1.895812 0.0005136 
Recessive NA NA NA NA NA NA 
AAAA   1.254384 1.87664 2.807575 0.01016 
AAAC   1.080824 1.184612 1.298368 0.002373 
AACC   0.6836437 0.7328811 0.7856647 1.981e-13 
GAAC   1.195404 1.48089 1.834557 0.002564 
GACC   1.187408 1.310497 1.446347 6.502e-06 
GGCC   0.850018 1.223292 1.760484 0.3625 
rs6910087, rs7246472 Dominant 2.033e-06 2.15e-06 1.173655 1.27729 1.390076 1.961e-06 
Recessive NA NA NA NA NA NA 
AAAC   1.137773 1.977866 3.438256 0.04248 
AACC   1.029704 1.311648 1.670791 0.06521 
AGAC   1.180675 1.399776 1.659537 0.001155 
AGCC   1.040629 1.130713 1.228596 0.01494 
GGAA   1.135758 1.723343 2.614916 0.03179 
GGAC   1.047497 1.153669 1.270603 0.01487 
GGCC   0.7298925 0.7795632 0.8326141 4.923e-10 
rs4602520, rs6910087, 
rs7246472 
Dominant 1.227e-06 2.977e-06 2.149330 3.334774 5.174038 6.479e-06 
Recessive NA NA NA NA NA NA 
AAGGAA   1.107386 1.712342 2.647782 0.04238 
AAGGAC   1.036098 1.148786 1.273730 0.02712 
AAGGCC   0.6808518 0.7256118 0.7733145 2.22e-16 
GAAGAC   1.971355 3.195814 5.180815 7.632e-05 
GAAGCC   1.041139 1.269444 1.547812 0.04778 
GAGGCC   1.165563 1.303446 1.457641 9.671e-05 
2 9q21.13 Dominant 1.543e-06 1.566e-06 0.7106870 0.7751917 0.8455511 1.427e-06 
Additive 5.081e-06 5.19e-06     
Recessive 0.05874 0.06384 0.4455113 0.6450179 0.9338667 0.0513 
9q21.13 Dominant 3.322e-06 3.69e-06 0.6918528 0.7617881 0.8387926 3.358e-06 
Additive 1.346e-05 1.392e-05     
Recessive 0.1094 0.1386 0.3790459 0.6186729 1.0097885 0.1069 
9q21.13,  
9q21.13 
Dominant 2.546e-06 2.736e-06 0.6880050 0.7579426 0.8349895 2.492e-06 
Recessive 0.1094 0.1386 0.3790459 0.6186729 1.0097885 0.1069 
AACA   0.2783766 0.5365995 1.0343506 0.1187 
AACC   0.3790459 0.6186729 1.0097885 0.1069 
AGAA   0.7374653 0.8762802 1.0412245 0.2078 
AGCA   0.7008870 0.7739858 0.8547084 2.158e-05 
GGAA   1.17869 1.285239 1.40142 1.846e-06 
3 rs4144827 Dominant 9.028e-06 1.04e-05 1.153841 1.296139 1.456627 9.028e-06 
Additive 3.068e-05 3.353e-05     
Recessive 0.1103 0.1149 1.017672 1.673539 2.752098 0.08861 
rs4144827, 
rs4602520 
Dominant 8.961e-06 1.328e-05 1.442503 1.800931 2.248420 1.298e-05 
Recessive NA NA NA NA NA NA 
AAAA   0.6917603 0.7442101 0.8006367 2.949e-11 
AAGA   1.150461 1.267872 1.397265 5.887e-05 
AAGG   0.9329632 1.376581 2.0311349 0.1766 
GAAA   1.052304 1.170382 1.301711 0.01496 
GAGG   0.438461 0.9155752 1.911864 0.8438 
GGAA   0.9034239 1.57224 2.7361880 0.1792 
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GAGA   1.501587 1.906013 2.419364 8.643e-06 
4 1q:44 Dominant 1.19e-06 1.217e-06 0.7102 0.7743 0.8441 1.11e-06 
Additive 3.822e-06 3.946e-06     
Recessive 0.05692 0.07004 0.4223340 0.6290329 0.9368946 0.05562 
rs3924215 Dominant 2.007e-08 2.073e-08 0.7235 0.7785 0.8377 1.893e-08 
Additive 1.33e-07 1.322e-07     
Recessive 0.2272 0.2558 0.6492069 0.8326492 1.0679257 0.2261 
1q:44, rs3924215 Dominant 1.513e-07 1.92e-07 0.4953 0.5863 0.6942 1.973e-07 
Recessive NA NA NA NA NA NA 
AAAA   1.2201 1.3027 1.3908 3.11e-11 
AAGA   0.7841644 0.849142 0.9195039 0.000728 
AAGG   0.676286 0.8879441 1.165845 0.4728 
GAAA   0.8010246 0.8838137 0.9751593 0.03887 
GAGG   0.3462324 0.6442479 1.1987765 0.2442 
GGAA   0.3875557 0.6175804 0.9841312 0.08888 
GAGA   0.4854 0.5807 0.6949 6.284e-07 
 
EXTENDED VERSION OF TABLE 6.9 
Combination Variant/s Model/ 
Comb 
Results      
   F X2 CI < OR > CI  OR P 
8  Dominant 1.355e-06 3.148e-06 2.180334 3.421732 5.369932 7.129e-06 
Recessive NA NA NA NA NA NA 
AAGGCC   0.4823589 0.823883 1.4072159 0.5517 
AGAACC   0.6963769 1.244028 2.2223662 0.5359 
AGAGAC   2.268098 3.938433 6.838879 4.392e-05 
AGAGCC   1.004063 1.22784 1.501492 0.09335 
AGGGAC   0.8959171 1.150594 1.4776663 0.3564 
AGGGCC   1.096949 1.229665 1.378439 0.002906 
GGAACC   1.003834 1.309822 1.709081 0.09521 
GGAGAC   1.000959 1.201448 1.442094 0.09823 
GGAGCC   1.007230 1.100851 1.203175 0.07537 
GGGGAA   0.9725669 1.491969 2.2887600 0.1241 
GGGGAC   1.031120 1.142969 1.266952 0.03282 
GGGGCC   0.6984741 0.7444199 0.7933880 2.531e-14 
9 rs3924215 Dominant 2.357e-08 2.458e-08 0.7227262 0.7780847 0.8376835 2.243e-08 
Additive 1.532e-07 1.562e-07     
Recessive 0.2236 0.2302 0.6412022 0.8236716 1.0580669 0.2026 
rs6011609 Dominant 2.643e-08 3.415e-08 0.4104905 0.5041824 0.6192589 2.643e-08 
Additive 3.201e-08 1.607e-07     
Recessive NA NA NA NA NA NA 
rs3924215, 
rs6011609 
Dominant 4.233e-05 6.43e-05 0.2292273 0.3537798 0.5460090 8.201e-05 
Recessive NA NA NA NA NA NA 
AAAG   0.4477369 0.5661758 0.7159451 6.7e-05 
GAAG   0.2376908 0.3721416 0.5826450 0.000287 
GAGG   0.7455804 0.8046655 0.8684329 2.768e-06 
GGGG   0.6672929 0.8606741 1.1100971 0.3322 
AAGG   1.248754 1.341981 1.442168 1.82e-11 
10 1p12 Dominant 1.697e-08 2.451e-08 0.4018188 0.4952112 0.6103102 3.178e-08 
Additive 2.428e-08 1.052e-07     
Recessive NA NA NA NA NA NA 
1p12, 
rs6011609 
Dominant 0.0005024 0.001227 0.0335983 0.1154139 0.3964597 0.004002 
Recessive NA NA NA NA NA NA 
AAAG   0.4378091 0.5407107 0.6677981 1.66e-06 
AAGG   1.689720 1.963191 2.280922 1.397e-13 
GAGG   0.4266089 0.5292943 0.6566962 1.222e-06 
11 rs6911024 Dominant 4.66e-07 5.331e-07 1.167226 1.258262 1.356397 4.865e-07 
Additive 1.688e-06 1.751e-06     
Recessive 0.01747 0.0205 1.103029 1.376314 1.717308 0.01762 
rs6911024, 
rs7246472 
Dominant 1.6e-05 2.151e-05 1.294671 1.5222 1.789717 1.967e-05 
Recessive NA NA NA NA NA NA 
AAAA   0.3480120 0.5344931 0.8208995 0.01633 
AAAC   0.7941352 0.8744423 0.9628705 0.02197 
AACC   1.210169 1.292758 1.380983 1.577e-10 
GAAC   0.5920245 0.7028669 0.8344619 0.0007267 
GGAC   0.3022718 0.5271586 0.9193585 0.05829 
GGCC   0.6016892 0.7664424 0.9763079 0.07064 
GACC   0.8012848 0.8711706 0.9471516 0.00667 
Dominant 1.541e-05 1.918e-05 1.310632 1.550424 1.834087 1.762e-05 
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rs4602520, 
rs6911024 
Recessive NA NA NA NA NA NA 
AAAA   1.250170 1.336547 1.428893 9.204e-13 
AAGA   0.8054270 0.8752244 0.9510704 0.008346 
AAGG   0.5739463 0.7305342 0.9298433 0.03229 
GAAA   0.7015318 0.7778493 0.8624692 6.293e-05 
GAGG   0.4139599 0.7308316 1.2902573 0.3642 
GGAA   0.6005097 0.9087141 1.3751007 0.7039 
GGGA   0.2894733 0.5477948 1.0366385 0.1206 
GAGA   0.5417441 0.6503037 0.7806174 0.0001065 
5 rs6911024 Dominant 1.286e-06 1.39e-06 1.1567 1.2465 1.3434 1.269e-06 
Additive 4.521e-06 4.614e-06     
Recessive 0.02489 0.02596 1.089573 1.35857 1.693978 0.02235 
rs12170250 Dominant 1.245e-06 1.806e-06 1.4585 1.7789 2.1697 1.839e-06 
Additive 2.122e-06 8.532e-06     
Recessive NA NA NA NA NA NA 
rs6911024, 
rs12170250 
Dominant 1.595e-07 3.728e-07 2.0276 2.8836 4.1010 7.567e-07 
Recessive NA NA NA NA NA NA 
AAAG   1.046805 1.335801 1.704580 0.05076 
AAGG   0.7334 0.7889 0.8487 9.29e-08 
GAGG   1.076066 1.164065 1.259261 0.001478 
GGGG   1.002669 1.257392 1.576825 0.09607 
GAAG   1.8680 2.7163 3.9500 1.135e-05 
6 rs6852865 Dominant 7.401e-07 8.642e-07 1.1994 1.3135 1.4383 7.897e-07 
Additive 3.848e-06 4.365e-06     
Recessive 0.641 0.662 0.7740845 1.138723 1.6751274 0.5799 
rs6852865, 
rs4602520 
Dominant 2.782e-07 3.072e-07 1.2304 1.3567 1.4959 2.826e-07 
Recessive 0.3825 0.4377 0.827657 1.256559 1.907722 0.3683 
AAGG   0.827657 1.256559 1.907722 0.3683 
AGAA   0.8449817 1.048816 1.3018211 0.7168 
AGGA   1.2360 1.3677 0.5135 3.638e-07 
AGGG   0.6530297 1.198081 2.1980581 0.6242 
GGGA   1.076322 1.298829 1.567334 0.0221 
GGAA   0.6890 0.7494 0.8151 1.653e-08 
7  Dominant 1.753e-06 5.453e-06 2.303162 3.832153 6.376189 1.424e-05 
Recessive NA NA NA NA NA NA 
AAGGGGCC   0.4855043 0.861772 1.5296485 0.6698 
AGAAAGCC   0.7311888 1.222341 2.0434073 0.5204 
AGAAGGAC   0.6097411 1.127805 2.0860405 0.7477 
AGAAGGCC   0.6838781 0.9020966 1.1899465 0.5406 
AGGAAACC   0.7020486 1.375066 2.6932718 0.4358 
AGGAAGCC   0.9834412 1.226686 1.5300950 0.1284 
AGGAGGAC   0.8923749 1.176241 1.5504048 0.3337 
AGGAGGCC   1.140013 1.292075 1.464419 0.0007618 
GGAAAACC   1.021367 1.336666 1.749299 0.07604 
GGAAAGAC   0.977733 1.178044 1.419393 0.1481 
GGAAAGCC   0.9918097 1.085478 1.1879919 0.1349 
GGAAGGAA   1.019739 1.586202 2.467334 0.08586 
GGAAGGAC   1.034578 1.14845 1.274856 0.02923 
GGAAGGCC   0.6849178 0.7298533 0.7777368 4.441e-16 
GGGAAGCC   0.8969771 1.396439 2.1740138 0.2147 
GGGAGGAC   0.5555386 0.9698373 1.6931037 0.928 
GGGAGGCC   1.051960 1.328002 1.676479 0.04524 
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APPENDIX F  
CONTINGENCY TABLE VALUES FOR EXTENDED TABLE 6.8 
ID Variant/s Model/ Comb Results    
   Control|Exposed Case|Exposed Control|NotExposed Case|NotExposed 
1 rs4602520 Dominant 4500 4684 683 974 
Recessive 41 57 5142 5601 
rs6910087 Dominant 4055 4206 1128 1452 
Recessive 94 142 5089 5516 
rs7246472 Dominant 4384 4587 799 1071 
Recessive 27 60 5156 5598 
rs4602520 
rs6910087 
Dominant 5020 5390 163 268 
Recessive 5182 5656 1 2 
AAAA 79 119 5104 5539 
AAAG 886 1065 4297 4593 
AAGG 3535 3500 1648 2158 
GAAG 137 225 5046 5433 
GAAA 14 21 5169 5637 
GGAG 11 20 5172 5638 
GGGG 29 35 5154 5623 
GAGG 491 671 4692 4987 
rs4602520 
rs7246472 
Dominant 5078 5483 105 175 
Recessive 0 0 5183 5658 
AAAA 25 51 5158 5607 
AAAC 669 845 4514 4813 
AACC 3806 3788 1377 1870 
GAAC 98 157 5085 5501 
GACC 542 751 4641 4907 
GGCC 36 48 5147 5610 
rs6910087 
rs7246472 
Dominant 4389 4596 794 1062 
Recessive 1 0 5182 565813 
AAAC 13 28 5170 5630 
AACC 80 114 5103 5544 
AGAC 161 243 5022 5415 
AGCC 871 1052 4312 4606 
GGAA 24 45 5159 5613 
GGAC 598 740 4585 4918 
GGCC 3433 3421 1750 2237 
rs4602520 
rs691008 
rs7246472 
Dominant 18 64 5165 5593 
Recessive 0 0 5183 5658 
AAAAAC 10 22 5173 5636 
AAAACC 68 97 5115 5561 
AAAGAC 146 189 5037 5469 
AAAGCC 738 866 4445 4792 
AAGGAA 22 41 5161 5617 
AAGGAC 513 634 4670 5024 
AAGGCC 3000 2825 2183 2833 
GAAACC 12 16 5171 5642 
GAAGAC 15 52 5168 5606 
GAAGCC 122 168 5061 5490 
GAGGAC 81 100 5102 5558 
GGAGCC 11 18 5172 5640 
GGGGCC 25 29 5158 5629 
GAGGCC 408 567 4775 5091 
2 9q21.13 Dominant 4307 4906 906 800 
Recessive 48 34 5165 5672 
9q21.13 Dominant 4495 5087 718 619 
Recessive 28 19 5185 5687 
9q21.13 
9q21.13 
Dominant 4502 5096 711 610 
Recessive 28 19 5185 5687 
AACA 17 10 5196 5696 
AACC 28 19 5185 5687 
AGAA 192 185 5021 5521 
AGCA 666 581 4547 5125 
GGAA 4300 4897 913 809 
3 rs4144827 Dominant 4608 4872 575 788 
Recessive 17 31 5166 5629 
rs4144827 
rs4602520 
Dominant 5098 5495 85 165 
Recessive 1 2 5182 5658 
AAAA 4010 4063 1173 1597 
AAGA 568 764 4615 4896 
AAGG 30 45 5153 5615 
GAAA 476 599 4707 5061 
GAGG 10 10 5173 5650 
GGAA 14 24 5169 5636 
GAGA 72 148 5111 5512 
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4 1q:44 Dominant 4293 4893 919 811 
Recessive 42 29 5170 5675 
rs3924215 Dominant 1407 1275 3805 4429 
Recessive 93 85 5119 5619 
1q:44 
rs3924215 
Dominant 4963 5541 249 163 
Recessive 1 0 5211 5704 
AAAA 3135 3781 2077 1923 
AAGA 1083 1039 4129 4665 
AAGG 75 73 5137 5631 
GAAA 639 627 4573 5077 
GAGG 17 12 5195 5692 
GGAA 31 21 5181 5683 
GAGA 221 143 4991 5561 
 
CONTINGENCY TABLE VALUES FOR EXTENDED TABLE 6.9 
Combination Variant/s Model/ Comb Results    
   Control|Exposed Case|Exposed Control|NotExposed Case|NotExposed 
5 rs6911024 Dominant 4075 4256 1113 1449 
 Recessive 95 141 5093 5564 
rs12170250 Dominant 5081 5499 107 206 
 Recessive 1 2 5187 5703 
rs6911024 
rs12170250 
Dominant 5159 5614 29 91 
Recessive 0 0 5188 5705 
AAAG 78 114 5110 5591 
AAGG 3997 4141 1191 1564 
GAGG 991 1230 4197 4475 
GGGG 93 128 5095 5577 
GAAG 26 77 5162 5628 
6 rs6852865 Dominant 4524 4751 659 909 
 Recessive 33 41 5150 5619 
rs6852865 
rs4602520 
Dominant 4636 4879 547 781 
Recessive 27 37 5156 5623 
AAGG 27 37 5156 5623 
AGAA 111 127 5072 5533 
AGGA 502 724 4681 4936 
AGGG 13 17 5170 5643 
GGGA 135 190 5048 5470 
GGAA 4388 4558 795 1102 
7 rs6852865 
rs4602520 
rs6910087 
rs7246472 
Dominant 5170 5604 13 54 
Recessive 0 0 5183 5658 
AAGGGGCC 17 16 5166 5642 
AGAAAGCC 18 24 5165 5634 
AGAAGGAC 13 16 5170 5642 
AGAAGGCC 72 71 5111 5587 
AGGAAACC 10 15 5173 5643 
AGGAAGCC 99 132 5084 5526 
AGGAGGAC 64 82 5119 5576 
AGGAGGCC 319 442 4864 5216 
GGAAAACC 64 93 5119 5565 
GGAAAGAC 143 183 5040 5475 
GGAAAGCC 719 842 4464 4816 
GGAAGGAA 22 38 5161 5620 
GGAAGGAC 500 618 4683 5040 
GGAAGGCC 2928 2753 2255 2905 
GGGAAGCC 23 35 5160 5623 
GGGAGGAC 17 18 5166 5640 
GGGAGGCC 86 124 5097 5534 
8 Dominant 5166 5595 17 63 
Recessive 0 0 5183 5658 
AAGGCC 20 18 5163 5640 
AGAACC 14 19 5169 5639 
AGAGAC 11 47 5172 5611 
AGAGCC 120 160 5063 5498 
AGGGAC 79 99 5104 5559 
AGGGCC 398 525 4785 5133 
GGAACC 66 94 5117 5564 
GGAGAC 148 193 5035 5465 
GGAGCC 742 879 4441 4779 
GGGGAA 24 39 5159 5619 
GGGGAC 517 636 4666 5022 
GGGGCC 3015 2878 2168 2780 
9 rs3924215 Dominant 3773 4335 1396 1248 
Recessive 93 83 5076 5500 
rs6011609 Dominant 184 102 4985 5481 
Recessive 1 1 5168 5582 
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rs3924215 
rs6011609 
Dominant 52 20 5117 5563 
Recessive 0 0 5169 5583 
AAAG 131 81 5038 5502 
GAAG 47 19 5122 5564 
GAGG 1256 1146 3913 4437 
GGGG 88 82 5081 5501 
AAGG 3641 4253 1528 1330 
10 1p12 Dominant 180 98 4989 5485 
Recessive 2 2 5167 5581 
1p12 
rs6011609 
Dominant 16 2 5153 5581 
Recessive 0 0 5169 5583 
AAAG 167 99 5002 5484 
AAGG 4821 5385 348 198 
GAGG 162 94 5007 5489 
11 rs6911024 Dominant 4055 4217 1102 1442 
Recessive 94 141 5063 5518 
rs6911024 
rs7246472 
Dominant 173 284 4984 5375 
Recessive 1 0 5156 5659 
AAAA 22 45 5135 5614 
AAAC 602 743 4555 4916 
AACC 1726 2230 3431 3429 
GAAC 157 242 5000 5417 
GGAC 13 27 5144 5632 
GGCC 80 114 5077 5545 
GACC 849 1044 4308 4615 
12 rs4602520 
rs6911024 
Dominant 4998 5393 159 266 
Recessive 1 2 5156 5657 
AAAA 3536 3509 1621 2150 
AAGA 864 1058 4293 4601 
AAGG 79 118 5078 5541 
GAAA 490 673 4667 490 
GAGG 14 21 5143 5638 
GGAA 29 35 5128 5624 
GGGA 10 20 5147 5639 
GAGA 134 223 5023 5436 
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APPENDIX G 
Decision Trees Full Extension for all combinations that yielded significant results. 
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